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Abstract 
 
Polysubstituted aromatics are highly desirable in medicinal chemistry for library 
generation and the tetrasubstituted aryl motif appears in many pharmaceuticals. Current 
methods to access 1,2,4,5- and 1,2,3,4- tetrasubstituted aromatics are problematic. 
Therefore new routes giving defined regiochemical outcomes with four different 
orthogonal functionalities were sought.  
This work took two directions; 1) the bromination and nitration of trisubstituted aryl 
MIDA boronates, and 2) the nitration of trisubstituted aryl bromides, both leading to the 
desired tetrasubstituted aromatics.  
MIDA boronates are boronic acids masked with N-methyliminodiacetic acid (MIDA). 
This allows for iterative palladium cross-coupling reactions. The first step in the work 
was developing a new rapid microwave-mediated method (5-15 min) towards MIDA 
boronates using ether poly-ethylene glycol 300, acetonitrile or dimethylformamide as a 
solvent. This methodology gave a library of over 20, mainly aryl or heteroaryl 
MIDAboronates.1,2 
Trisubstituted aryl-MIDAboronates were then brominated or nitrated giving 6 novel 
tetrasubstituted aromatic compounds. The 3 new tetrasubstituted aryl-MIDAboronates 
bromides were then used in a selection of iterative Suzuki–Miyaura cross coupling 
reactions (SM) to show the potential uses of the compound in library generation.  
Three different bromo-fluorobenzaldehyde regioisomers were nitrated giving 3 different 
tetrasubstituted aromatics. These 3 compounds were then subjected to several different 
conditions to modify them i.e. nitro reduction, Sonogashira couplings, reductive 
aminations, Clauson-Kaas pyrrole synthesis. A number of tetrasubstituted anilines were 
reacted with 4-chloro-6,7-dimethoxyquinazoline to afford novel, potential kinase 
inhibitors.  
Publications: 
(1)  Close, A. J.; Kemmitt, P.; Emmerson, M. K.; Spencer, J. Tetrahedron 2014, 70, 
9125–9131. 
(2)  Close, A. J.; Corden, V.; Spencer, J. Use of a camera to monitor reaction stirring 
and reagent dissolution during a reaction; a MIDA boronate library generation case 
study. http://www.cemmicrowave.co.uk/assets/cameramida-boronate---app-
note.pdf (accessed Nov 15, 2015). 
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1. Introduction 
Importance of tetrasubstituted aromatic compounds   
Polyfunctional aromatic compounds containing orthogonal functionality, allowing for 
independent group transformations, are desirable scaffolds for exploration in medicinal 
chemistry. The reactivity of the different functional groups allows for efficient library 
generation and consequently development of new small molecule therapeutics. Often the 
seemingly simple, desired tetrasubstituted scaffolds are not commercially available and 
are highly expensive, thus new methodology towards these molecules is required.1 For 
these reasons AstraZeneca funded this CASE award with the outlined objectives: 
1. Synthesised tetrasubstituted aromatics must contain 4 different orthogonal groups. 
2. Synthesised tetrasubstituted aromatics must have either a 1,2,3,4 or a 1,2,4,5-
substitution pattern. 
3. Methods of preparation must be scalable.  
Tetrasubstituted aromatics in drugs and natural products 
Tetrasubstituted arenes appear in different formats within drugs as highlighted in Figure 
1.1 below.  
 
Figure 1.1. Example of pharmaceuticals with tetrasubstituted 
framework (1,2,3,4-substitution pattern, green) (1,2,4,5-substitution 
pattern, red) 
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Oxycodone is an example of a synthetic opioid and is used in the treatment of pain.2 
Oxycodone and other opioids such as morphine or codeine contain a phenanthrene type 
ring with one 1,2,3,4-functionalised aromatic ring, as highlighted in red.3 The HCl salt of 
oxycodone is under licence by Pfizer and Acura Pharmaceuticals and is sold as Oxecta™. 
This is an abuse-deterrent formulation that only allows oral consumption of the product.4  
A plethora of thiazide diuretics were discovered in the late 50s and early 60s. These 
compounds typically contain a 1,2,4,5-functionalised aromatic i.e. hydrochlorothiazide 
or furosemide (Figure 1.1).5,6 In the case of furosemide there are four different functional 
groups that link to one aromatic core, showing the importance of polysubstituted aromatic 
cores in bioactive molecules. Oxycodone and furosemide are both drugs of high value 
and are required to run a basic healthcare system, as outlined on the 2015 list of essential 
medicines from the World Health Organisation (WHO).7  
Ziprasidone is a antipsychotic treatment for schizophrenia and has a 1,2,3,4- 
functionalised aromatic ring as part of a heterocyclic core.8,9 It was first synthesized in 
1989 as one of a series of compounds in a patent, which involved joining two pre-made 
heterocyclic cores together by a SN2 reaction.
10 A later synthesis built the molecule up 
from 1,4-dichloro-2-methyl-5-nitrobenzene. This outlines the potential of tetrasubstituted 
aromatics as a starting material for on-the-market pharmaceuticals.11 
The tetrasubstituted motif also appears in Nature, as shown in the natural products in 
Figure 1.2. This exemplar of molecules show either the 1,2,3,4- or 1,2,4,5-substitution 
Figure 1.2. Natural products with tetrasubstituted frameworks 
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framework and they also exhibited some pharmacological activity. Selaginellin D was 
extracted using ethyl acetate from Selaginella pollinate; this plant has been used 
historically in Chinese medicine. It has activity as an anti-microbial and an anti-fungal 
chemical.12  
The Amathaspiramide compounds were extracted from a New Zealand marine bryozoans 
called Amathia Wilsoni, by Prinsep et al in 1999.13 They also found that amathaspiramide 
E (Figure 1.2) has activity against poliovirus as well as antimicrobial activity.  Due to the 
interest around this group a total synthesis has been accomplished to allow further 
investigations into these compounds.14  
Lasalocid A was first isolated from Streptomyces. Within this first publication it was 
noted as an antibiotic.15 It was later recognised that this molecule was part of the polyether 
antibiotics group. These compounds are veterinary medicines of high value, and often 
mixed with animal feeds to prevent and control coccidiaes.3  
The natural product and pharmaceutical examples above illustrate the importance of 
tetrasubstituted scaffolds and highlights the need for new methodology towards them, 
which will allow drug discovery groups to take advantage of these complex motifs.  
Kinase inhibitors  
Normal cell growth is typically governed by external signals, in the form of growth factor 
ligands, which instruct the cell when to grow and divide. The growth factors bind to the 
extracellular domain of a growth receptor and a signal is passed to the intercellular 
domain. This allows phosphorylation of a tyrosine, threonine or serine on a protein at the 
intercellular domain, starting an intercellular cascade of pathways that, result in cell 
growth and or cell division.16  
Uncontrolled cell division, known as proliferation, is a quintessential cancer 
characteristic. Cancer cells can produce their own growth factors and transport them in to 
the extracellular domain, which allows them to divide with reduced external stimulation. 
This is known as autocrine stimulation. Cancer cells also, often exhibit a mutation in a 
gene encoding for the regulation of growth receptors. The lack of regulation leads to the 
over production of growth receptors, and this over expression gives an increased potential 
for a tumour to be triggered into its growth stage. Growth factor receptor over expression 
can also lead to ligand independent signalling. These factors all lead to uncontrolled 
tumour growth.17 
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Existing therapeutics can be made that target different aspects of the signalling pathway. 
The key areas are shown in Figure 1.3(a,b,c): 
 
 
a) Antibodies can be employed to intercept the ligand before it is able to bind to the 
receptor. Bevacizumab is a monoclonal antibody that binds vascular endothelial 
growth factor (VEGF). Bevacizumab, alongside chemotherapy gives a significantly 
improved response compared to chemotherapy alone in the treatment of colorectal 
cancer.18 
b) The extracellular part of the receptor can be targeted by antibodies, which bind to 
the ligand-binding site, thereby inhibiting the receptor. Cetuximab is used to treat 
advanced-stage colorectal cancer, expressing epidermal growth factor receptors 
(EGFR).19 
c) Small molecule inhibitors can also be used to block receptor function, via an 
interaction at the intercellular domain. These compounds competitively inhibit the 
binding of adenosine triphosphate (ATP) (Figure 1.4.) to the growth receptor. This 
prevents the phosphorylation of a tyrosine, threonine or serine on a downstream 
protein, and thereby arrests the following signalling pathway.20 Gefitinib (Figure 
1.5) (marketed as Iressa®) is an orally-available EGFR kinase inhibitor that 
improves disease-related symptoms and shows induced tumour regressions in non-
small cell lung cancer (NSCLC).21,22 
 
Figure 1.3. Representation of a growth factor receptor, showing three therapeutic targeting areas 
labelled a, b and c. 
Figure 1.4. Adenosine triphosphate (ATP) with 
the adenine heterocycle in blue 
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Small molecule kinase inhibitors are of interest in this project as they commonly 
incorporate polysubstituted aromatics, as shown in Figure 1.5. For example vemurafenib, 
which is used for the treatment of metastatic melanoma, contains a 1,2,3,4-substituted 
aromatic core.23 
 Protein kinases have a cleft, which forms the ATP binding site. Within this cleft there is 
the hinge, which interacts with the adenine heterocycle (Figure 1.4). This acts as the target 
for the majority of inhibitors. Most kinase inhibitors do not utilise the ribose or the 
triphosphate binding sites. Small molecule kinase inhibitors can be placed into four 
different types.24  
1. Type one. Protein kinases exist in equilibrium between active and inactive 
conformations, with the active conformer responsible for protein phosphorylation. 
Type one inhibitors bind to the active conformation of the protein, by mimicking 
ATP. These competitive inhibitors interact with the purine-binding site at the 
hinge, forming 1-3 hydrogen bonds. The molecules comprise of a heterocyclic core 
to mimic the adenine, with complementary functionalities to target the subtle 
environmental differences within the protein cleft, to give selectivity and potency.  
Figure 1.5. Small molecule kinase inhibitors with highlighted polysubstituted aromatics (tetrasubstituted 
in red, trisubstituted in blue and disubstituted in green) 
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2. Type two. These inhibitors bind to the ATP binding site of the inactive conformer. 
Upon binding, the inhibitor will stabilise the inactive conformer of the protein 
kinase therefore denaturing it.  
3. Allosteric inhibitors. Allosteric inhibitors interact with the protein kinases outside 
the ATP binding site, causing a change in the shape of the active site, which prevents 
ATP binding. These inhibitors are the most selective as the allosteric sites targeted 
are unique to the protein kinase. An example of this type of inhibitor is CI-1040 
shown Figure 1.5, which inhibits MEK1 and MEK2.25 MEK1 and MEK2 are found in 
the mitogen-activated protein kinase (MAPK) signalling pathway. This pathway is 
exhibited in 30 % of all human cancers, resulting in undesirable cellular 
transformations.26 
4. Covalent inhibitors. Covalent inhibitors irreversibly bind to the ATP pocket by 
means of a covalent bond. This is typically achieved by the incorporation of a Michel 
acceptor that is susceptible to nucleophilic attack, normally by a cysteine thiol 
moiety. 
Three out of the four types of kinase inhibitors rely on binding to the ATP binding site, 
emphasising the importance of good selectivity, as there are over 500 different protein 
kinases in the human body.21 This selectivity is achieved by rational drug design with the 
aid of structural data and computational modelling and assessed by counter screening the 
new analogues against an array of protein kinases, evaluating at each step to develop new 
inhibitors with high potency.29 
The EGFR type one inhibitor gefitinib is an excellent example of successful drug 
discovery.23 The first lead compound was N-(3-bromophenyl)-6,7-dimethoxyquinazolin-
4-amine, compound 1 (Figure 1.6) which has an IC50 = 15 nM, was found via a high 
throughput screening approach. This compound was synthesised from 3-bromoaniline 
and the 4-chloro-6,7-dimethoxyquinazoline to form the secondary amine. This approach 
allowed for quick modification of the quinazoline and aniline, followed by the linking of 
the two units to make new analogues.  
 7 
Modification of the quinazoline unit in the 5,6,7 or 8 positions showed that electron-
donating units were required in the 6 and 7 positions. This increases the pKa of the 
nitrogen atoms in quinazoline, making them better hydrogen bond acceptors. 
Modifications of the aniline moiety showed that a small lipophilic group in the 3 (meta) 
position improved activity. This produced a new lead compound with an IC50 = 5 nM , 7-
dimethoxy-N-(m-tolyl)quinazolin-4-amine, compound 2 (Figure 1.6).   
Compound 2 suffers with a short half-life of approximately 1 h due to metabolism by the 
P450 enzyme to the two metabolites 2a and 2b, which reduced the in vivo activity. This 
problem was navigated by the installation of a chloro group in the meta position and a 
fluoro substituent in the para position (compound 3). Compound 3 had better activity in 
vivo due to its resistance to P450, but it was less active in vitro, IC50 = 9 nM.
24  
 Figure 1.7. Left; co-crystal 3D image of the EGFRs ATP binding cleft with Gefitinib binding. Right; 
2D cleft representation of Gefitinib bound to EGFRs. PDB 4WKQ155 
 
Figure 1.6. Analogues explored in synthesis towards Gefitinib 
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Whilst the activity of the lead had been improved, the lipophilicity remained unacceptably 
high, and therefore further modifications were required to reduce this. It was found that 
adding a morpholine moiety at the 6 position was found to solve the solubility issue, due 
to the basic nitrogen allowing the formation of water-soluble salts. Gefitinib, is such that 
the chloro fits into a hydrophobic pocket. The nitrogen atoms in the quinazoline act as 
hydrogen bond acceptors for the methionine amide bond in Figure 1.7, and bridging water 
molecules enable a bond with a threonine residue. The morpholine sits outside of the 
binding site in the aqueous environment and does not desolvate when the drug binds, 
therefore there is no associated energy penalty. 
Chronic myeloind leukemia (CML) is a rare life-threatening cancer that is responsible for 
around 1 in 100,000 cases of leukemia. It is caused by a specific chromosomal 
translocation, referred to as the Philadelphia chromosome. This creates a new hybrid 
protein BCR-Abl from Abelson murine leukemia viral oncogene homolog 1 (ABL1) from 
chromosome 9 and breakpoint cluster region protein (BCR) from gene on chromosome 
22. This fusion protein BCR-Abl has oncogenic properties due to tyrosine kinase activity 
leading to cellular proliferation. Given that BCR-Abl appears essential for cell survival, 
it was identified as a promising drug target, and the subsequent investigation led to the 
discovery of Gleevec, Figure 1.5.31 This was the first orally available compound for the 
treatment of CML. 
A screening based approach found the original lead, N-phenylpyrimidin-2-amine (Figure 
1.8, compound 4), eventually afforded Gleevec, which has improved selectivity 
Figure 1.8. Analogues explored in synthesis towards Gleevec. 
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Compound 4 became the first lead of interest via a high throughput-screening program, 
and provoked a study involving over 300 molecules. Compound 5 became the next 
compound of interest following early studies; the improvement came from the addition 
of a 3-pyridyl group on the 3 position of the pyrimidine ring Table 1.1. 
Table 1.1. Compound activity of Gleevec analogues. 
Activity IC50 (μm) Abl PKCα PKCβ 
5 
6 
7 
Gleevec 
>10 
0.4 
0.4 
0.038 
- 
1.2 
72 
>100 
- 
23 
>500 
>100 
 
After this a benzamide group was added (compound 7), which decreased the IC50 to 0.4 
μM, but unfortunately following SAR studies showed that the selectivity was low as 
compound 5 also inhibited protein kinase C (PKC). The addition of a methyl group to the 
diamino moiety (compound 7) increased potency without loss of activity, as the 
conformation was locked in to a shape complimentary to BCR-Alb binding site, Figure 
1.9. This compound exhibited solubility issues and it was found that the addition of a 
benzyl N-methylpiperazine solved this problem. Benzyl amine moieties are prefered over 
Figure 1.9. 2D pocket representation of Imatinib (Gleevec) bound to ABL. PDB 2HYY156 
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aniline derivatives due to their lower genotoxicity. The resulting compound, Imatinib is 
sold as the mesylate salt under the brand name Gleevec.32 
Gleevec also has therapeutic use in gastrointestinal stromal tumours (GIST).33 It has been 
shown that it can halt or reverse GIST with an acceptable safety profile and has made it 
onto the WHO’s list of essential medicines.7 
Unfortunately, despite continuing efforts to develop effective protein kinase inhibitors 
there remains a vast amount of work to be done. Tumours can develop resistance to kinase 
inhibitors, because the drugs enforce selective pressures on the cell, which induce the 
tumour to evolve coping mechanisms. This happens in several ways e.g. increased 
function and expression of transporters involved in drug efflux, evolution of a drug 
resistant alternative of the target protein, mutation of the ATP binding pocket and 
upregulation of alternate pathways which are able to compensate for the loss of protein 
function. Indeed, resistance of CML to Gleevec treatment follows these trends.34  
Gleevec is a type 2 inhibitor and still the most selective treatment for CML due to its 
binding mode, which relies upon the dynamic equilibrium between conformations of 
BCR-Abl.29 The ATP binding site in BCR-Abl is only accessible in the inactive 
conformation and therefore Gleevec stabilizes this conformation, inactivating BCR-Abl. 
The high selectivity of Gleevec allows small mutations in the binding domain of BCR-
Abl to reduce its activity, such that ATP is able to bind. Some new inhibitors have 
necessarily been created to target these mutants. In other cases poorly selective inhibitors 
from other protein kinase targets can be utilized, although these must often be given in a 
poly-therapeutic dose i.e. multiple therapy treament.35 Nilotinib and Dasatinib have been 
shown to be active against Gleevec resistant CML. Sunitinib has been used in the 
treatment of GIST and has shown activity in Gleevec resistance tumors.36–38  
It is likely that over time NSCLC can become resistant to treatment with gefitinib as 
mutations can develop on EGFR.39 However, Neratinib (Figure 1.5), a new pipeline 
treatment is a covalent inhibitor and therefore includes a Michael acceptor and forms a 
bond irreversibly with a cysteine upon binding.40 This cysteine in EGFR arises from a 
mutation, making this a useful technique to combat resistant tumours. 
This selection of kinase inhibitors demonstrates the necessary requirement for new 
tetrasubstituted aromatic starting materials. These will supplement the synthesis of new 
inhibitors with improved affinity and selectivity and help to overcome the problem with 
drug resistance.  
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Fluorine in drugs 
Approximately 25% of pipeline pharmaceuticals include at least one or more fluorine, 
demonstrating the high importance of organofluorine compounds in medicinal chemistry. 
Fluorine being the most electronegative atom, can be used to modulate the pKa of 
compounds.41 This approach has improved the bioavailability of a series of 3-
piperidinylindole antipsychotic drugs by decreasing the basicity of the amines (Table 
1.2).42 Lowering the pKa reduces the amount of protonated amine (ammonium species), 
which in turn affects the absorption process since unionised drug can pass through cell 
membranes. 
Table 1.2. Basicity and bioavailability (F) of a series of 3-piperidinylindole  
Indole 5-HT2A (nM) pKa F (%) 
 
0.99 10.4 Poor 
 
0.43 8.5 18 
 
0.06 - 80 
 
The 5-HT2 receptors normally bind to the neurotransmitter 5-hydroxytryptamine (5-HT). 
This series binds selectively to the 5-HT2 receptors over the dopamine D2 receptor. The 
first addition of the fluorine to the piperidine moiety improved the bioavailability by 
reducing the pKa by 1.9 units. This compound was metabolised by hydroxylation in the 6 
position of the indole; this was blocked by the addition of fluorine. The resulting 
molecule’s bioavailability was vastly improved further and enhanced the binding affinity 
by an order of magnitude. 
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Drugs are commonly metabolized typically by oxidation by P450 enzymes prior to 
elimination. Oxidation decreases the lipophilicity, allowing rapid clearance from the 
body. Fluorine substituents have been used to block metabolism at labile sites on 
compounds.43 
log 𝑝 𝑜𝑐𝑡/𝑤𝑎𝑡 = 𝑙𝑜𝑔 (
[𝑠𝑜𝑙𝑢𝑡𝑒]
  𝑢𝑛𝑖𝑛𝑜𝑖𝑠𝑒𝑑 
𝑜𝑐𝑡𝑎𝑛𝑜𝑙
[𝑠𝑜𝑙𝑢𝑡𝑒] 
  𝑢𝑛𝑖𝑛𝑜𝑖𝑠𝑒𝑑 
𝑤𝑎𝑡𝑒𝑟
) 
Equation 1 
Lipophilicity can be regulated by fluorine functionalities. Lipophilicity (log p) is usually 
measured as a partition-coefficient between water and octanol as shown in Equation 1. 
Selective fluorination of alkyl groups (e.g. mono, di or trifluoromethyl) typically 
decreases lipophilicity due to the strong electron withdrawing effect of fluorine. In 
contrast, fluorination adjacent to π-bonds i.e. aromatic fluorine, increases lipophilicity 
due to the C–F bond being highly non-polarisable, as the 2p orbitals overlap with the 
corresponding orbitals on carbon; the exception to this is when α to a carbonyl.44  
Atorvastatin, which is marketed under the name Lipitor, is part of the statin drug class, 
which are used in the treatment of hypercholesterolemia (Figure 1.10). Atorvastatin’s 
fluorophenyl group is involved in the binding to its target, as it forms a bond to the 
guanidinium group of an arginine.45 This is a polar interaction between the nitrogens.    
Fluorine incorporation brings a wide range of positive properties as outlined above. For 
this reason fluorine or fluorine containing substituents have been incorporated within the 
tetrasubstituted molecules that we will present later in this work. 
 
 
 
Figure 1.10. Showing left Atorvastatin (Lipitor) and right arginine (blue highlights the 
guanidinium group). 
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Boron in medicinal chemistry46  
Phenyl boronic acids were noted for their antibacterial properties for over 100 years,47 
and aromatic boronic acids have also been used in the application of carbohydrate 
recognition.48,49 This is due to boron having a vacant p-orbital (see section 0, Figure 1.14. 
Boron sp3 vs. sp2) this allows it to make dative covalent bonds to nucleophilic moieties 
within a targeted binding site. These dative covalent bonds are stronger than typical non-
covalent hydrophobic interactions that are utilised in the bulk of pharmaceuticals.50 
Dative covalent bonds are also reversible, unlike standard covalent inhibitors (section 0., 
the 4th type of kinase inhibitor).  
The first boronic acid containing pharmaceutical was Bortezomib (marketed at Velcade, 
Figure 1.11).51 Bortezomib was approved by the FDA in 2003 for the treatment of 
relapsed multiple myeloma (a bone marrow cancer) and mantle cell lymphoma.52 
Bortezomib’s method of action involves the boronic acid functionality forming a complex 
with the threonine hydroxyl group of the enzyme inside the active site.  
Neratinib (Figure 1.5), is a new pipeline treatment for NSCLC resistant to treatment with 
Gefitinib (section 0). It is a covalent inhibitor and therefore includes a Michael acceptor 
which forms an irreversible bond with a cysteine residue in EGFR upon binding (section 
0).40 Nakamura et al tested boron to pick up the same residue using a dative covalent 
bond, Figure 1.12.53 Docking studies showed an O-B dative covalent bond to an aspartic 
acid residue within this same region and formed hydrogen bonds to a cysteine. This shows 
Figure 1.11. Bortezomib.  
Figure 1.12, Kinase inhibitors containing boronic acids. 
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the potential of boronic acids to be used for prolonged inhibition through covalent bond 
formation.  
Boric acid is considered not to be very toxic, as it has a similar LD50 to that of table salt.
54 
This, linked with the properties above show that boron has potential to be utilised in 
medicinal chemistry but is often overlooked.  
Synthesis of tetrasubstituted aromatics  
Electrophilic aromatic substitution55  
Electrophilic aromatic substitution is one of the most common ways of functionalizing 
aromatic compounds. The aromaticity of benzene, by virtue of its 6π electrons, gives it 
higher levels of stability, thus the reactions require much stronger electrophiles than for 
the electrophilic addition of alkenes. The first step of the mechanism requires the 
formation of a σ-complex (arenium ion). The formation of this sp3 carbon atom interrupts 
the aromaticity, usually making the nature of this step highly endothermic. The 
aromaticity is restored via reversal of the first step, or loss of the proton from the sp3 
carbon giving the product (Scheme 1.1). 
Scheme 1.1. Mechanism of Electrophilic Aromatic Substitution. 
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Effects of alkyl groups  
Toluene, while undergoing electrophilic aromatic substitution, reacts around 25 times 
faster than benzene under the same reaction conditions. All alkyl groups cause a similar 
increase in reactivity and are considered activating groups, due to the alkyl groups 
donating electron density back though the σ bond via hyperconjugation. This electron 
density facilitates stabilization of the rate-determining step, the formation of the σ 
complex; this is known as inductive stabilization. 
Scheme 1.2. σ complexes for, ortho, para and meta substitution respectively. 
Alkyl groups also have an ortho-para directing effect. The canonical forms in Scheme 
1.2 show the positive charge is stabilized by the alkyl group making these forms more 
favourable, therefore the transition state energy required to form the intermediate is lower 
when the alkyl group is ortho or para with respect to the substitution site. This is 
summarized by substitution ratios shown in Scheme 1.3 for the nitration of toluene. 
 
Scheme 1.3. Nitration of toluene.claydon56 
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It is noteworthy that, for the electrophilic aromatic substitution at the meta position of 
toluene, the intermediate has a lower energy transition state than that of the electrophilic 
aromatic substitution of benzene, Figure 1.13. This shows that the inductive effect still 
causes a small amount of stabilization at the meta position.55  
Figure 1.13. Hammond postulate comparing reactivity of toluene to benzene.   
Electron donating substituents  
Aryls substituted with groups that contain non-bonding electrons e.g. oxygen and 
nitrogen, increase the rate of electrophilic aromatic substitution, even though these groups 
are more electronegative than carbon.  A lone, non-bonding pair of electrons from the 
substituent can stabilize the carbocation, formed in the intermediate by donating electron 
density through the formation of a π bond as one of the canonical forms. Electron 
donating groups (EDG) are ortho, para-directing, resulting from especially stable 
intermediates formed by the π-donating effect (Scheme 1.4). 
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Scheme 1.4. σ complexes of, ortho, para and meta substitution respectively with EDGs. 
 
In the case of anisole the π-donation stabilising effect, described above result in nitration 
400 times faster than toluene, and 10,000 times faster than benzene.  
 
The effect of halogen substituents  
Halogen substituents are strongly electronegative and due to the negative inductive effect 
react slower with electrophiles than benzene. However they do have non-bonding 
electrons and do form a halonium ion as their intermediate and this in turn stabilises this 
rate-determining step by π donation. The mechanism for this is similar to that shown in 
Scheme 1.4 (the rate of reaction is slower) leading to halogen substituents having an 
ortho, para-directing effect.  
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Effects of electron withdrawing substituents 
Electron withdrawing groups (EWG) slow down the rates of reaction of electrophilic 
aromatic substitutions. In the case of nitrobenzene it is around 100,000 times less reactive 
than benzene. EWGs are known as deactivating groups and remove electron density 
predominantly from the ortho and para positions. The strongest deactivating group is the 
nitro group due to the positive charge on the nitrogen atom, but with different EWGs a 
δ+ can placed on the adjoining atom.  
 
Scheme 1.5. σ complexes of, ortho, para and meta substitution respectively with EWGs. 
The canonical forms in Scheme 1.5 demonstrate how only the substitution at the meta 
position proceeds thought an intermediate which is not destabilized adjacent positives or 
δ-positives.   
Effect of multiple substituents  
When combining different functional groups, several factors need to be considered before 
making a prediction regarding the outcome of the reaction; the strength of the directing 
group, whether it is para or ortho directing and the steric fatctors involved. The balance 
of the three factors governs the outcome of these reactions. In some cases all directing 
groups direct to the same position making prediction of the site of substitution simpler, 
but sometimes mixtures cannot be avoided. The relative strength of the directing group 
has the greatest effect on the overall reaction outcome. This information is summarized 
in Table 1.3 below. 
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Table 1.3. Summary of directing groups and their relative strengths of activation effecting electrophilic 
aromatic substitution.  
 
The formation of the electrophile is a key step in the reaction, as this needs to be formed 
in situ. The formation of the nitronium ion (NO2+) requires the use of strong acids, 
normally concentrated sulphuric acid and concentrated nitric acid (Scheme 1.6). A 
selection of arylboronic acids were synthesised using these strong conditions (Scheme 
1.7).57,58 These results show the stability of the boronic acid under these strong acid 
conditions (Scheme 1.7).  
HO NO2 NO2H2O NO2H2O
H
Scheme 1.6 Formation of nitronium electrophile. 
a fuming nitric acid in sulphuric acid, rt, 30 min. b fuming nitric acid, -30 °C, 45 
min.  
Scheme 1.7. Compound made via nitration. 
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Seaman and Johnson showed that phenylboronic acid could be nitrated selectively, giving 
mainly meta or ortho product depending on the reaction conditions used (Scheme 1.8, top 
and middle).47 They found that using nitric acid alone gave 85% meta substitution with 
a total reaction yield of 80%. Whereas, when acetic anhydride was used with catalytic 
urea, 95% ortho substitution with a total reaction yield of 65% were observed. Van Der 
Eycken et al later used this methodology, and found that the catalytic urea was crucial to 
the ortho selectivity.59 In this case they found that the para substituted product was the 
predominant product, 64%, with an overall yield of 58% (Scheme 1.8, bottom reaction). 
This shows how the boronic acid can be manipulated to direct nitration of the phenyl ring. 
Van Der Eycken et al hypothesised that this control is due to formation of a boronate 
species between the boronic acid and urea facilitating ortho substitutions, but no evidence 
has been found.  
Different nitronium sources can be used, such as nitronium tetrafluoroborate (NO2BF4), 
which has been studied in depth.60,61 Raitio et al synthesized 3-hydroxy-4-methoxy-2-
nitrobenzaldehyde (8) as an intermediate towards a series of CB2 cannabinoid receptor 
ligands (Scheme 1.9).62 This series of compounds showed anti-inflammatory properties 
in vivo; the R group was changed throughout the study. They used NO2BF4 as it improved 
regioselectivity, as using standard nitric acid in sulphuric acid gave 8 in only a 10% yield. 
Scheme 1.8. Nitration of phenylboronic acid under different conditions.  
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Halogenation typically requires the formation of an electrophilic complex with a Lewis 
acid, to form the reactive electrophile in the reaction. Harvey et al used this in the 
synthesis of 2-bromo-1,4-dimethylnaphthalene, from which they made a variety of 
polyaromatic hydrocarbons for biological testing of carcinogenic affects (Scheme 1.10).63 
They used a catalytic amount of iron powder to form the Lewis acid iron (III) bromide in 
situ. The formation of this catalyst in situ is standard procedure due to the reactivity of 
iron (III) bromide to moisture and air. Different Lewis acids can be used with bromine to 
produce similar Lewis acid complexes such as BF3.
64 
Hall et al produced a wide array of ortho halogenated tetrasubstituted aromatic boronic 
acids using stoichiometric silver sulphate at room temperature (Scheme 1.11).65 Within 
this work there are no examples of deactivated aromatics being halogenated.  
N-Bromosuccinimide (NBS) is used more often as a brominating agent in modern times 
due to its ease of handling and since it produces succinimide as a relatively inert side 
Scheme 1.10 Bromination with iron catalyst. 
Scheme 1.9 Nitration forming 3-hydroxy-4-methoxy-2-nitrobenzaldehyde, as an intermediate towards a 
series of CB2 cannabinoid receptor ligands. 
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product.66 Saiganesh et al showed that bromination on highly deactivated substrates can 
be achieved using NBS in sulphuric acid.67  
Benzynes 
Treatment of bromobenzene in a sodium hydroxide melt would appear to give a 
nucleophilic substitution reaction to afford phenol, but this pathway for aromatic rings is 
highly unlikely. In a SN2 process, the carbon bromine bond is in plane with the aromatic 
ring, and the nucleophile would need to attack the σ* orbital from the back of the C-Br 
bond; this would require the nucleophile to be inside the ring to attack, this attack would 
lose the ring’s planar shape. If this were to go via an SN1 it would require the unaided 
loss of the bromine making an unstable phenyl cation with an empty sp2 orbital.
56 This 
reaction proceeds via a benzyne intermediate, formed via the deprotonation using a strong 
base ortho to the bromine. Elimination of the bromine is the next step of the reaction 
forming the benzyne (Scheme 1.12).  
 
Scheme 1.12 Mechanisms for benzyne formation. 
aAgNO3 1 eq, was used. 
bBr2 2 eq was used.  
Scheme 1.11 Ortho halogenated aromatic boronic acids. 
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Then benzyne is not a true alkyne, it only has one normal π bond, which is part of the 
aromatic system. The newly formed π bond is made from two sp2 orbitals that sit outside 
the ring, making it very weak and unstable. This weak bond allows the attack of 
nucleophiles.  
Benzynes can be synthesised in several different ways as shown above in Scheme 1.13 
aside from a sodium hydroxide melt. Strong bases can be used to deprotonate, ortho to 
the halogen (Scheme 1.13, 12). Similarly ortho dihalide arenes can be used to prepare a 
Grignard or a lithium halogen exchange (Scheme 1.13, 9). Both these processes lead to 
metalation ortho to the halogen, allowing for the elimination step to occur.68  
Benzynes can be made via methods that generate gas, thus are entropically driven. The 
first example of this was using arenediazonium-2-carboxylate (Scheme 1.13, 11), which 
was produced in situ from the corresponding aniline. Compound 11 was heated to give 
off nitrogen and carbon dioxide gas, forming the benzyne.69 1-Aminobenzotriazole 
(Scheme 1.13, 10) amino-protons can be oxidatively removed with lead (IV) acetate, this 
then fragments to give the benzyne and two nitrogen gas molecules.70 
Milder, more modern methods been developed e.g. silyl triflates have become a milder 
way to form benzynes, without use of pyrophoric bases, shock-sensitive materials or toxic 
oxidants. Benzynes can be synthesised from 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate (Scheme 1.13, 13), at room temperature using 
tetrabutylammonium fluoride. 
Scheme 1.13 Methods to generate benzynes. 
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Benzynes are used regularly in the production of natural products such as in the synthesis 
of (+)-Liphagal, Scheme 1.14. This molecule has shown activity as a selective kinase 
inhibitor against phosphatidylinositol 3-kinase.71 
Diazonium salts 
Aromatic diazonium salts, considering their structure, are surprising stable at 
temperatures below 5 °C, in the presence of water. This is due to the lack of stability of 
the carbocation formed on the loss of nitrogen, making nitrogen loss slower, allowing for 
controlled reactivity in SN1 reactions. The diazonium salts can be installed from an 
aniline, using nitric acid, sodium nitrite in HCl, or an alkyl nitrite in HCl; the mechanism 
is shown below, Scheme 1.15.56 
Scheme 1.14 Synthesis of (+)-Liphagal. 
Scheme 1.15 Mechanisms for the formation of diazonium salt. 
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 The diazonium salt’s anion is usually the conjugate base of the acid used in the 
preparation. Typically these salts are used in-situ, due to instability at room temperature, 
but room temperature stable analogues can be isolated via anion exchange to make the 
tetrafluoroborate salt.
56  
  
In Scheme 1.16 the reactions outlined in blue are known as Sandmeyer reactions, and 
typically use copper salts, with the exception of iodination. Iodo groups are useful in 
aromatic compounds as they can be used in a large array of organometallic chemistry. 
Unfortunately iodine is not a good electrophile, unlike chlorine and bromine. This makes 
the Sandmeyer reaction a powerful method of group inter-conversion since iodine cannot 
be introduced via nucleophilic iodide. Krasnokutskaya et al have recently published a 
paper on these iodinations, using an efficient one-pot method. Starting from variety of 
different anilines, reactions took between 20 min and 2 h.72 
The example highlighted in red is an example of the Balz-Schiemann Reaction. This 
reaction forms the tetrafluoroborate aryl diazonium salt and is then heated to cause 
decomposition of the salts to nitrogen and boron trifluoride producing the desired 
arylfluoride. This reaction has been used in the synthesis of 4-fluoro-1H-
Scheme 1.16 Reactions that can be performed with diazonium salts.55 
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pyrrolo[2,3]pyridine (Scheme 1.17, 14), the compound was formed via spontaneous 
decomposition from the tetrafluoroborate, on heating from 0 °C to r.t.73 As highlighted in 
section 0 fluorine is highly desirable in medicinal chemistry, showing the importance of 
these methods.  
Nakata et al used the Sandmeyer reaction to iodinate an intermediate in the synthesis of 
(±)-A80915G, which is a natural product with antibiotic properties, Scheme 1.18.74 The 
iodine gave selectivity over the bromine in two subsequent Stille cross-coupling 
reactions.  
The use of diazonium salts goes hand in hand with electrophilic aromatic substitution, as 
it allows for selective use of these two methods to give the desired compound. When 
taking into account that the nitro group is meta directing, this can be reduced to the 
corresponding aniline, which is ortho, para directing. This aniline can be transformed 
into a wide range of functionalities using diazonium salts, including the use of 
hypophosphorous acid reducing back to an aromatic proton, Scheme 1.16. Using these 
with foresight, can lead to selective functionalization of an aromatic ring.  
Directed Ortho Metalation (DoM)  
Butyllithium can deprotonate sp2 hybridized carbons even in the presence of sp3 carbons, 
because sp2 protons are more acidic shown in Scheme 1.19. The independent research 
groups of Wittig and Gilman discovered this methodology of ortho lithiation of 
anisole.75,76 The aryllithium can then be quenched with a plethora of electrophiles, leading 
Scheme 1.18 Sandmeyer step in the synthesis of (±)-A80915G. 
O O
Lin-BuLi
O O
OH
diethyl ether, -78 oC
CO2
Scheme 1.19 Directed ortho lithiation. 
Scheme 1.17 Example of Balz-Schiemann reaction. 
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to different functionalities regioselectively at the ortho position e.g. DMF to make the 
corresponding aldehyde, methyl iodide to make the corresponding methyl group or 
bromine to make corresponding bromide.  
The mechanism of lithiation requires the directing group to complex to the lithium before 
the deprotonation occurs, shown in Scheme 1.20.  
  
This is known as the complex-induced proximity effect (CIPE).77 The directing groups 
can be ordered in strength of their relative directive effect shown in Scheme 1.21. These 
are based on competition studies and rankings can change due to reaction temperature 
and the solvent used.78 
Scheme 1.20 Mechanism for direct ortho metalation. 
C H
LiR
C H
LiR
C H
Li
R -RH
C Li
E
C E
FG FGFG FGFG
Scheme 1.21 Strength of directing effect. 
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Snieckus et al used this methodology to prepare an array of ortho-boropinacolato aryl 
and heteroaryl sulfonamides, some aromatic examples of which are shown in Scheme 
1.22.79 Within this publication they also showed its use as the first part of a two stage, 
one pot synthesis. The second stage was a Suzuki reaction following the DOM borylation; 
this was achieved by adding an aryl halide, base and a palladium catalyst to the same 
reaction mixture, Scheme 1.23. The yields were good considering that this methodology 
removed an aqueous work up / purification procedure.  
The Iwao group used DOM in the first total synthesis of veiutamine.80 This marine 
alkaloid was of particular interest due to its antitumor activity. The aryl lithium was 
reacted with a para substituted benzaldehyde forming the alcohol (14), which was later 
cyclised as part of a larger synthetic route, Scheme 1.24. 
Scheme 1.23 Suzuki reaction following the borylation. 
SO2NEt2
R1
1) n-BuLi 1.3 eq, THF, -78 oC, 1 h
2) MeOBpin  3 eq, -78oC - r.t., 12 h
SO2NEt2
R1
R2
SO2NEt2
F
NO2
SO2NEt2
OMe
OMe
TMS
SO2NEt2
3) Pd(DtBPF)Cl2 8 mol %, Na2CO3 4eq, 
    DME/ H2O (4/1), Ar-X 1.4eq
    80 oC, 12 h
N
MOM
60%69%60%
Scheme 1.22 Ortho-boropinacolatoaryls prepared via DOM. 
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C-H activation  
C-H activation is often transition metal-catalysed functionalization of a carbon-hydrogen 
bond forming a large variety of different, carbon-carbon,81,82 or carbon-heteroatom bonds, 
improving the atom economy of the reaction. These can be split into two groups, 1) 
without directing group functionalities,83 2) with directing groups functionalities.84   
Palladium is used in a large variety of different C-H transformations and in most cases 
they are directed by functionalities attached to the starting material. For this body of work, 
only aromatic examples will be given.  
  One of the first examples of palladium C-H activation was acetoxylation with 
(diacetoxyiodo)benzene (PhI(OAc)2).
85,86 These reactions use a palladium (II) / palladium 
(IV) catalytic cycle, Scheme 1.25. The C-H activation does not change the oxidation state 
of the palladium centre and the selectivity of this step is driven by the directing effect of 
the ligand. In acetoxylation, PhI(OAc)2 is the oxidant used in the catalytic cycle, which 
allows the product to reductively eliminate, but other oxidants can be used.  
 
Scheme 1.24 A crucial DOM step in the synthesis of veiutamine. 
Scheme 1.25 General catalytic cycle for palladium-mediated C-H activation. 
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This methodology was used to prepare a variety of different examples, some are shown 
in Scheme 1.26. In this scheme the directing groups shown are pyridine derivatives and 
2-pyrrolidinone moieties, but other examples include e.g. diazenes, pyrazole.  
Table 1.4 Showing different parameters and isolated yields.85 
 
 
In the first acetoxylation publication, the authors demonstrated that different solvents and 
different oxidants changed the reaction outcome, shown in Table 1.4.87 When an alcoholic 
solvent was used it was incorporated into the product. It also highlighted that the addition 
of excess lithium halide (Cl or Br) gave the corresponding halogenated species. 
 
Oxidant Solvent Product (X) Time (h) Yield (%) 
(PhI(OAc)2) MeCN OAc/OH 11:1 12 86 
(PhI(OAc)2) MeOH OMe 12 95 
(PhI(OAc)2) EtOH OEt 12 80 
(PhI(OAc)2) i-PrOH/AcOH OiPr 12 72 
(PhI(OAc)2) CF3CH2OH OCH2CF3 12 71 
NCS MeCN Cl 24-72 95 
NBS MeCN Br 24-72 93 
a, Pd(OAc)2 5 mol%, PhI(OAc)2, benzene/AcOH or benzene/Ac2O, 100 °C, 0.5- 4 h. 
b, Pd(OAc)2 5 mol%, PhI(OAc)2, 
AcOH or Ac2O, 100 °C, 3-12 h 
Scheme 1.26 Products formed via acetoxylation with PhI(OAc)2. 
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Halogenation did require optimisation; this was done by changing the oxidant to the N-
bromosuccinimide (NBS) or N-chlorosuccinimide. 
The Bedford group later used this approach in the C-H halogenation of anilides.87 A 
selection of these halogenations is shown in Scheme 1.27, note that when pivaloyl (Piv) 
is used the reaction conditions required modification.  
 Fu et al achieved ortho borylation via a palladium C-H activation route using 1,4-
benzoquinone as an oxidant.88 With their results they attained seven different 
tetrasubstituted aromatics all of which contain four different orthogonal groups Scheme 
1.28. Scheme 1.28 highlights this technique, as being highly functional group tolerant.  
Yu’s lab recently advanced the scope of C-H activation by the addition of meta directing 
ligands.89,90 In order to achieve this, they developed the meta directing ligand, shown in 
Scheme 1.29. which also enables a diverse array of olefinations. This ligand gave the 
highest selectivity, as highlighted in the schemes ortho: meta: para ratios, but not absolute 
Scheme 1.27 Showing examples of  C-H halogenation of anilides. 
Scheme 1.28 Tetrasubstituted aromatics prepared via ortho borylation. 
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selectivity. They also synthesized a tetrasubstituted aromatic, giving a 1,2,3,4-
substitution pattern when the starting material is di-ortho substituted.  
Yu’s lab have also published a procedure for transforming an ortho directing group C-H 
activation into a meta C-H activation using norbornene as a transient mediator, shown in 
Scheme 1.30.91 They had optimised against pitfalls such as mono ortho functionalization, 
ortho-meta difunctionalization and reductive elimination forming an ortho-meta 
norbornene adduct. On testing of a wide range of ligands they found the pyridine based 
group shown in Scheme 1.30, gave the best results. This highlights a powerful technique 
for synthesising meta substituted compounds without the need to form unique internal 
directing ligands.  
 
 
Scheme 1.29 Meta selective C–H olefination. 
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Ackermann et al have used rhodium complexes and Gaunt et al have used copper to 
achive C-H activations in the meta postion without the need for internal directing 
ligands.92,93 Larrosa et al have used salicylic acids in the presence of a palladium-catalyst 
undergo protodecarboxylation and can be transformed giving the corresponding meta-
arylphenols.94 
aPd(OAc)2 15 mol%, L 30 mol%, RX 3 eq, DCE, 16 h. 
bPd(OAc)2 10 mol%, L 20 mol%, RX 6 eq, DCE, 16 h. 
cPd(OAc)2 15 mol%, 
L 30 mol%, ArI 3 eq, TBME, 12 h 
Scheme 1.30 C-H activation into a meta using norbornene as a transient mediator, including represenative 
results. 
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Iridium can be used to achieve catalytic C-H borylation of aromatic compounds.95 
Ishiyama and Miyaura’s group developed the original undirected methodology in 
collaboration with the Hartwig group. This reaction can be performed via a directed route 
or an undirected route. The mechanisms are shown in Scheme 1.31.96,97 Note that the 4,4′-
di-tert-butyl-2,2′-dipyridine (dtbpy) is the ligand throughout the catalytic cycle. The 
selectivity of the reactions are governed by the sterics of the starting material, electronics 
only playing a small role. This was shown in an in-depth study of para substituted 
compounds, and the products that were synthesised.98  
Scheme 1.32 shows examples of products formed by this technique; the top example is 
the non-directed route,99 the bottom shows some silyl-directed examples.97 Clark et al 
also showed that benzylic amines could be used to ortho direct borylation.100,101 
Scheme 1.31 Catalytic cycles for iridium-catalysed borylation of arenes, left nondirected method, right 
directed method. 
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Hartwig later published methodology towards tetrasubstituted aromatic compounds 
shown in Scheme 1.32.102 Within this publication a method for a one pot Suzuki was 
incorporated into the reactions, allowing for borylation, followed by cross-coupling with 
no work up.  
Li et al borylated a series of MIDA boronate containing aromatic and heteroaromatic 
compounds, Scheme 1.52. These were able undergo iterative coupling, elaborated further 
in section 0.103 
The reaction times have been improved by the use of microwave-assisted synthesis by 
Steel et el.104 This development reduced reaction times to under an hour and in some cases 
as fast as five minutes. They also applied the one pot cross-coupling technique, achieving 
cross-couplings in 5 minutes, with yields above 90%.  
Scheme 1.32 Iridium borylation; top, non-directed method; middle, directed method; bottom, non-
directed method forming tetrasubstituted motifs.  
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These examples show the high functional group tolerances, yields and selectivity of these 
reactions.  
Palladium cross-coupling reactions 
 
 Palladium-catalysed coupling reactions have become one of the most used synthetic tools 
in the organic chemist’s arsenal. These reactions involve cross-coupling an 
organometallic nucleophilic reagent with an electrophilic organic halogen or pseudo-
halogen reagent. These types of reactions are typically used for the formation of carbon-
carbon bonds but are also used in carbon-nitrogen bond construction (Scheme 1.33). The 
scope of the organometallic reagent has been expanded to include Mg, Zn, B, Sn, or Si, 
over the 50 years since the first use of palladium in cross-coupling reactions.105 
All palladium cross couplings follow a similar general mechanism, with three key steps, 
shown in Scheme 1.34:106  
1. Oxidative addition of the organic electrophile, oxidising the palladium(0) to the 
palladium(II) species.  
Scheme 1.33 Showing different palladium cross-coupling reactions. 
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2. Transmetalation of the nucleophilic organometallic component. 
3. Reductive elimination, releasing the coupled product, regenerating the 
palladium(0) species, thus restarting the catalytic cycle. 
 
The Heck reaction follows a slightly different pathway, of migratory insertion followed 
by β-hydride elimination.  
Palladium cross-couplings are used regularly because of high functional group tolerance, 
low catalytic loading (on optimized systems) and the development of new ligands and co-
catalysts allowing for the control of reactivity. These reactions are used on gram scale in 
academic and medicinal research labs, to ton-scale in the pharmaceutical and fine 
chemical industries.107 The fathers of this chemistry Heck, Negishi and Suzuki received 
a combined Nobel Prize in 2010 for their work in founding this area of chemistry.108 
During this project Suzuki and Sonogashira reactions were the only palladium cross-
coupling reactions used; these will be discussed in greater detail in section 0 and 0 
 
 
Scheme 1.34 Palladium cross-coupling general mechanism. 
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Suzuki cross coupling  
The first palladium cross-coupling of alkenylboranes with alkenyl or aryl halides was 
performed by Suzuki, Miyaura and Yamada in 1979.109,110 This is known as the Suzuki 
or Suzuki-Miyaura coupling. The Suzuki reaction is the most common synthesis of the 
biphenyl motif, which is considered a privileged structure in medicinal chemistry and 
appeared in 4.3 % of drugs in 2000.111 Biphenyls have shown diversity in receptor 
selectivity, as they can be functionalised with substitution patterns that enable 
complementary binding to aromatic and or hydrophobic sites with a protein.112 Biphenyls 
have various applications, for example in the synthesis of dialkylbiaryl phosphine 
ligands,113 chiral biaryl compounds,114 liquid crystals,115–117 and natural products e.g. 
selaginellin D (Figure 1.2). These all demonstrate the importance of the Suzuki coupling. 
The Suzuki reaction is the favoured method due to the mild reaction conditions, high 
functional group tolerance, the commercial availability of starting materials, also the 
reaction by-products are much less toxic than other reactions (e.g. tin in the Stille 
coupling) and the reactions are high yielding when optimised. For these reasons 
highlighted above, the number of publications and patents using this reactions between 
the years 2001-2010 out numbers any other palladium cross-coupling by almost 3000.105   
There are differing proposals for the Suzuki coupling catalytic cycle. Earlier proposals 
are represented in Scheme 1.37 general cycle 2.118 This cycle involves the negatively 
charged boronate in situ e.g. R2B(OR)2OH
-, formed from the base, and facilitates 
transmetalation. 
Scheme 1.35. General Suzuki cross-coupling 
conditions. 
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One of the modifications which defines cycle 2 was the addition of the metathesis step, 
whereby the ligand exchanges in the palladium coordination sphere. The halogen or 
pseudo-halogen from oxidative addition, exchanges to a hydroxyl, which is shown as the 
metathesis step. This enables the transmetalation; evidence for this came from Suzuki et 
al, Scheme 1.36. These works show the chloro-compound to be unreactive, whereas the 
methoxy compound resulted in the production of palladium black and was complete 
within one hour. This highlights a role of the base in enabling transmetallation.119  
Amatore and Jutand et al, did selective reaction probing, showing detailed evidence for 
the role of the base in the transmetallation step.120 They showed that the boronate was not 
the reactive species in transmetallation, as the rate of reaction became very slow at high 
–OH concentrations, as shown in Scheme 1.38 pathway 4. At these concentrations the 
boronate (PhB(OH)3
-) and the [Pd(Ar)(PPh)2(OH)] both exist together, as they 
demonstrated the shift in equilibrium at high –OH concentrations shown in 11B and 31P 
Scheme 1.37. Different general catalytic cycles for Suzuki couplings. 1) modern, 2) general. 
Scheme 1.36. Differences in reactivity between chloro compound vs methoxy compound. 
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NMR spectroscopic experiments respectively. This showed that the boronate was 
unfavourably disposed towards transmetallation. In this series of experiments the starting 
material was the premade product of stoichiometric oxidative addition i.e. [(p-NC-
C6H4)Pd(PPh)2Br]. This removed the oxidative addition step from the rate mechanistic 
investigation. The introduction of this species into a system with no hydroxide ions 
present exhibited no reaction, thus discounting pathway 1 as the likely mechanism. This 
was conducive with the example described in Scheme 1.36. Experiments to explore the 
role of  pathway 2 required the preformed boronate species to be added to a reaction 
system with excess halogen concentration, thus ensuring the Pd-halogen bond remained 
intact. Pathway 2 was ruled out as no reaction was observed, in that case.   
These obsevations showed that pathway 3 was the most favoured and they postulated a 
four-centred transition state, which was supported by DFT calculations.121 
This body of work supports that cycle 1 from Scheme 1.37 is the more likely mechanism 
for Suzuki reactions.  
Several examples of Suzuki couplings appear throughout sections 0 and 0.   
 Sonogashira cross-coupling  
Castro and Stephens, in 1963, showed that cuprous acetylides could be coupled with aryl 
iodides to effectively prepare arylated alkynes.122 This seminal work was improved with 
the use of catalytic palladium with alkynes and aryl iodides. These sp-sp2 C bond-forming 
reactions led to independent publications by the groups of Heck and Cassar.123,124 
Scheme 1.38. Mechanism of the transmetallation through different pathways. 
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Sonogashira et al improved reaction conditions furthered by the addition of catalytic 
amounts of copper (I) iodide, Scheme 1.39.125 This enabled a room temperature reaction 
as it formed copper acetylides in situ. This methodology has become the standard for the 
preparation of arylated alkynes.126 
The generally accepted mechanism of the Sonogashira coupling has changed little from 
the original publication. There are two simultaneous catalytic cycles as shown in Scheme 
1.40.  
The palladium catalytic cycle is typical of most palladium cross coupling reactions, 
oxidative addition of an aryl halide, with a transmetallation of a copper acetylide. The 
copper catalytic cycle is less understood, but the most accepted hypothesis is the presence 
of a copper (I) salt allows for the deprotonation of the terminal alkyne.127 
Scheme 1.39. General Sonogashira coupling reaction. 
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Scheme 1.40. General mechanism of Sonogashira cross couplings. 
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Table 1.5. pKa of typical compounds used in Sonogashira cross couplings. 
Compound pKa 
Phenyl acetylene 23 
Triethylamine 11 
Potassium carbonate 10 
 
Phenyl acetylene cannot be deprotonated directly by the traditional base used in the 
reaction e.g. triethylamine, potassium carbonate, as they are not strong enough bases see 
(Table 1.5). It is assumed that the copper forms a π-complex with the alkyne, in a similar 
manner to the formation of silver acetylides.128 This enables the deprotonation of the 
alkyne by enhancing the acidity of the terminal hydrogen.  Transmetallation can then 
occur followed by reductive elimination, forming the product and the palladium(0) 
species.  
This methodology has been used in the total synthesis of (-)-heliannuol E as show in 
Scheme 1.41.129 This was a quantitative yielding reaction and this highlights the use of a 
tetrasubstituted starting material in total synthesis.  
Aryl chlorides have also been used in Sonogashira reactions; Buchwald et al performed 
a selection of copper-free reactions using [PdCl2(CH3CN)2] and XPhos (2-
dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl) as ligands (Scheme 1.42).127 Yi et 
al showed that similar chlorides could be coupled using the PdCl2(PCy3)2 as the catalyst 
Scheme 1.42. Copper-free Sonogashira reaction, XPhos ligand shown in blue. 
Scheme 1.41. Outlining Sonogashira coupling in the total synthesis of (-)-Heliannuol E. 
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at high temperatures (150 °C) in DMSO.130 Lipshutz et al used the PTS surfactant to 
achieve copper-free Sonogashira of aryl bromides at room temperature, therefore 
removing organic solvents from these alkyne couplings.131 
N-methyliminodiacetic acid (MIDA) boronates 
sp3 vs. sp2 
When boronic acids are protected with N-methyliminodiacetic acid the boron atom 
becomes sp3 hybridized via a dative covalent bond. Transmetallation requires a Lewis 
acidic, vacant p-orbital, making MIDA boronates poor coupling partners in palladium 
cross coupling reactions as shown in Figure 1.14.132 
Different protecting groups can form an sp3 centre i.e. N-methyldiethanolamine boronates 
but the strength of the dative covalent bond differs. Burke et al showed this via 
comparison of variable temperature (VT) NMR studies (Figure 1.15).133  
Burke showed that there were no major differences in the X-ray crystallography between 
the structures of both boronates. The methylenes in the backbone of both boronates have 
protons that are diastereotopic; on heating these coalescence due to an equilibrium 
between the two states (Figure 1.15). The MIDA boronate showed no coalescence on 
heating to 150 °C, whereas N-methyldiethanolamine boronate showed coalescence 
Figure 1.15. Variable temperatures comparison of two different boronates 
conformational rigidity, at NMR time scale. 
Figure 1.14. Boron sp3 vs. sp2. 
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between 23 °C - 60 °C.  This shows that at room temperature the p-orbital of the N-
methyldiethanolamine boronate is accessible due to the dynamic dative covalent bond, 
whereas the p-orbital of the MIDA boronate is not kinetically accessible at less than 150 
°C. 
The boron reagent tends to be the most nucleophilic part in the SM coupling, and 
comparisons have been made between reactions with the same electrophile to give them 
a rating of nucleophilicity.134 The MIDA boronate was the least nucleophilic of the 
common reagents including the aforementioned N-methyldiethanolamine boronate. This 
is due to the electron withdrawing effect from the carbonyls, even with the quaternization 
of the nitrogen. As in the case of the N-methyldiethanolamine boronate the electron 
density given via the dative covalent bond increases its nucleophilicity. 
Use of MIDA boronates in iterative couplings  
The MIDA boronate functionality is cleaved to give unmasked boronic acid under 
aqueous basic conditions.135 The inertness of the MIDA boronate functionality allows for 
it to be used in iterative anhydrous palladium cross coupling reactions. This chemistry 
allows for protection, anhydrous coupling, deprotection and secondary coupling 
cycles.136 Within this publication this methodology was applied to several simple 
molecules as shown in Scheme 1.43.  
They also applied this to the preparation of Ratanhine, which is a complex natural 
product. This was made up from 3 coupling / deprotection cycles of different units. These 
Scheme 1.43. Reaction showing simple cross-coupling and deprotection cycle. Ratanhine natural product 
formed by iterative cross couplings, with dashed lines showing new bonds.    
 45 
units and the bonds formed are shown in Scheme 1.43 highlighted by the dashed lines. 
This, including the two MOMO group deprotections (giving the phenols) was the first 
synthesis of Ratanhine. 
MIDA boronates can be used as a protecting group in different types of palladium cross-
couplings. Grob et al have made use of this in a selection of one-pot Buchwald-Hartwig 
couplings, followed by in situ release of the masked boronic acid for Suzuki coupling as 
shown in Scheme 1.44. This uses the same catalyst throughout, one work up and one 
purification, thus cutting down on solvent and reagent, making a greener telescopic 
reaction.137 
The Negishi coupling reaction has also been achieved using this methodology shown in 
Scheme 1.45. A MIDA boronate improved the synthesis of the amino acid derivative, as 
they found that aryl pinacol boronates were problematic to purify and maintain 
stereoselectivity.138  
Many examples of this type iterative chemistry have been done on a wide variety of 
different palladium cross-coupling reactions i.e. Sonogashira (with ethynyl MIDA 
boronate), Heck and Stille.139–142 
Automation is a powerful tool in increasing production speed in iterative chemical 
synthesis. For instance, the use of a peptide synthesiser in peptide synthesis allows for 
Scheme 1.44. One-pot Bucheald-Hartwig followed by Suzuki coupling. 
Scheme 1.45. Negishi reaction followed by a Suzuki coupling. 
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the user to work more productively, as the machine will perform reactions, cleavages and 
cleaning cycles to the “recipe” the user instructed. This has long been awaited for in small 
molecule synthesis as outlined by Glorius and Wang.143 Burke published a paper in 2015, 
that outlines a machine that has synthesised 14 distinct classes of small molecules in a 
fully automated process.144 This uses a catch and release method of purification, 
absorbing the crude MIDA boronate by passing it over silica gel, immobilising it onto the 
gel with 1.5 % methanol in diethyl ether; this solution is used to elute the remaining 
organic impurities. THF is then used to elute the now purified MIDA boronate, which is 
then used in the next step of the automated synthesis. 
This shows the potential for MIDA boronates to enable quick library generation. Current 
stumbling blocks involve low availability of interesting MIDA boronate starting 
materials. This outlines the importance to make new, scalable methodologies towards 
aromatic MIDA boronate cores.  
MIDA boronate use for slow release cross-coupling.  
 2-Heterocyclic boronic acids have limited bench stability, due to protodeboronation, 
oxidation, or polymerization, and this instability has a tendency to increase under reaction 
conditions. It has been found that making the corresponding MIDA boronate analogues 
vastly increases the shelf-life of these compounds. It has also improved the yields under 
Suzuki conditions compared to free boronic acid analogues. This is due to the MIDA 
group cleavage being slow under the reaction conditions, thus having a syringe pump 
affect.145 In effect the catalysis is in excess of the reagent, thus the reaction can take place 
before reagent decomposition. Representative yields are shown in Scheme 1.46. The 
purity of the boronic acid in Scheme 1.46 drops to 7% after 15 days, under bench 
conditions. The MIDA boronate shows higher stability, as its purity remains >95 % after 
60 days under bench conditions. Within this paper similar results were observed in a large 
number of examples, showing how MIDA boronate chemistry can improve the coupling 
and storage of many 2-heterocyclic, alkyl and vinyl boronic acids. 
Scheme 1.46.  Difference in yield between slow release BMIDA and B(OH)2 
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Lipshutz et al have improved on this work by demostrationg slow release couplings at 
room temperature, in water with the commercially available surfactant TPGS-750-M.146 
Within this system they used Pd(dtbpf)Cl2 (Pd118) as the catalyst and triethylamine as a 
base (Scheme 1.47). They found that adding water caused precipitation of pure product, 
making a green synthetic process.  
The 2-pyridyl subunit is found in a wide range of pharmaceuticals and natural products. 
The incorporation of this unit via cross-coupling methodologies is often difficult because 
of a lack of air stable building blocks and inefficient couplings.  Burke et al used the slow 
release methodology and also optimised coupling conditions to enable incorporation of 
this motif. The addition of copper acetate and  diethylamine (DEA) as a ligand improved 
yields. The role of the DEA is unclear and they suggested two different pathways for 
DEA incorporation. Firstly, DEA could chelate to the copper aiding the transmetallation 
of the MIDA boronate to the copper, before it entered the palladium catalytic cycle. 
Secondly, DEA could displace the MIDA making the DEA boronate, which would allow 
transmetallation on to the copper. Selective reaction probing the different reagents found 
that the first suggested pathway was the most likely, but could not prove this 
systematically.  
These slow release reactions of the 2-pyridyl MIDA boronate couple difficult coupling 
partners, in good yields. This shows that more electron-rich chlorides do cause a reduction 
Scheme 1.47. Slow release couplings at room temperature in water. 
Scheme 1.48. 2-Pyridyl MIDA boronate coupling with chloro aromatics. 
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in the yield, as shown by the 2,4-dimethoxy groups in 16 in Scheme 1.48. Sterics factors 
would also seem not to pose a major problem as demonstrated by the 2,5-dimethyl groups 
of 15. 
This process has been applied to sp2-sp3 couplings, allowing the additions of alkanes via 
a Suzuki coupling.147 Scheme 1.49 shows the use of the technique in the synthesis of a 
long aliphatic chain. Within the paper there are over 30 examples using different chain 
length MIDAs and different haloaryls and heteroaryl groups.  
Scheme 1.50 shows the addition of trans-2-(trifluoromethyl)cyclopropane groups, with a 
variety of different haloaryl and heteroaryl substituents. The example given shows two 
different tetrasubstituted aromatic compounds each with four orthogonal groups. This 
vastly improves the scope of C-C bond formation, allowing for “the clipping” of building 
blocks in a more efficient process.  
 
 
 
 
Scheme 1.50. sp2-sp3 couplings149 
Scheme 1.49. sp2-sp3 couplings.  
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Functionalization in the presence of MIDA boronates. 
Burke et al outlined a plethora of intergroup conversions, showing the compatibility of 
the MIDA boronate functionality, Scheme 1.51.133 Oxidation of the p-
hydroxymethylphenyl MIDA boronate (17) to the corresponding aldehyde (18) was 
performed using Swern conditions.  However, they found that other oxidants were also 
tolerated i.e. Dess-Martin periodinane, tetrapropylammonium perruthenate (TPAP) with 
N-methylmorpholine N-oxide (NMO) as a co-oxidant. They also found that direct 
oxidation to the corresponding carboxylix acid (19) could be achieved under harsh Jones 
conditions. Jones conditions lead to the decomposition of the corresponding, pinacol 
boronic acid ester, trifluoroborate salt, N-methyldiethanolamine boronate, and the 1,8-
diaminonaphthalene adduct. This shows the impressive relative stability of the MIDA 
boronate group. 
Reduction of the aldehyde 18 back to 17 was achieved using sodium borohydride. 
Reductive amination of this aldehyde was also enabled with morpholine and sodium 
triacetoxyborohydride as the reductant.  
The protection of 17 shows the tolerance against stronger acids, as 
trifluoromethanesulfonic acid (TfOH) facilitates acid-catalysed p-methoxybenzylation 
Scheme 1.51. Hydroxyl group transformations. 
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(OPMB) protection forming compound 20. Cleavage was achieved with 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ). The cleavage of the tert-butyldiphenylsilyl ether (21) 
was enabled with hydrogen fluoride pyridine, as the MIDA boronate was found to be 
incompatible with tetrabutylammonium fluoride (TBAF). Other incompatibilities include 
lithium aluminium hydride, diisobutylaluminium hydride (DIBAL) and metal alkoxide 
bases. 
As mentioned above, reductive aminations are tolerated and Grob et al continued this 
work to prepare a library of compounds,148 by reductive amination on formyl MIDA 
boronate cores, followed by a one pot iterative Suzuki coupling. 
 A fantastic piece of work by Xu and co-workers used iridium C-H borylations of 
aromatic MIDA boronates to make a library of molecules able to do iterative Suzuki 
couplings, Scheme 1.52.103 This methodology made an array of poly-functional aromatics 
containing two orthogonal boron species. 
The trans-2-(trifluoromethyl)cyclopropyl MIDA boronate, shown in Section 0 was made 
from vinyl MIDA boronate, Scheme 1.53.149 
Scheme 1.52. Compounds prepared by borylation. 
Scheme 1.53. Trans-2-(trifluoromethyl)cyclopropyl MIDA 
boronate synthesis. 
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In this synthesis they found the vinyl MIDA boronate to be a far superior starting material 
as it was solid, bench stable and the product could be purified safely via column 
chromatography. MIDA has the bonus of being a bulky rigid conformer and this promotes 
the trans isomer because it only allows for a single faced attack, unlike the problematic  
dibuty-l-2-(trifluoromethyl)-cyclopropylboronate which was synthesised in a 2:3 ratio of 
the cis and trans isomers because of a lack of steric constraints in the starting material 
Scheme 1.53.  
This section demonstrates the use of MIDA boronates underlining their usefulness in 
modern synthesis, as they increase efficiency and allow for the construction of more 
complex building blocks.  
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Microwave-Assisted Organic Synthesis (MAOS)  
Microwave-assisted organic synthesis has been used since the mid-1980s and has 
increased in popularity since then. Microwaves are electromagnetic radiation that has a 
frequency range between 0.3-300 GHz. They consist of two components, an electric field 
and a magnetic field and the heating effect is caused by the electric component. There are 
two main mechanisms for microwave heating, dipolar polarisation and ionic 
conduction.150 Dipolar polarisation is when a molecule that contains a dipole aligns itself 
to an applied electrical field. Oscillation of the applied field causes friction between the 
molecules, generating heat. A frequency of 2.45 GHz is used in commercial microwave 
systems, as it gives the best time profile to allow dipoles to produce heat.  Ionic 
conduction is where dissolved ionic particles are oscillated due to the applied field, 
causing collisions, leading to heating.151 
The nature of heating the reaction matrix rather than heating the outside of the reaction 
vessel (as with traditional reaction heating) reverses the heating profile of a reaction 
(Figure 1.16). This leads to far shorter ramping times in reaction heating. Modern-day 
purpose built microwave reactors use a closed vessel system allowing for the safe, 
controlled heating of solvents above their boiling point and elevated reaction pressures. 
Figure 1.16. Heating after 60 seconds (right) effected by microwave heating (left) compared to oil bath.157 
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These combined advantages give quicker reactions times and higher yield due to a 
reduction in side product formation owing to homogenous controlled heating.152 
Leadbeater et al showed an example of a microwave Suzuki coupling using water as a 
sole solvent with palladium(II) acetate and tetrabutylammonium bromide (TBAB) as a 
phase-transfer catalyst.153 This work is considered greener than a typical Suzuki reaction 
as the procedure avoids the use of unfavourable organic solvents. The Spencer group used 
this procedure in rapid synthesis of biaryls (Scheme 1.54) used in a larger library 
generation project.154 Steel et al also achieved a series of iridium borylations using 
microwave heating to speed up reaction times, as mentioned in Section 0.104  
 
  
 
 
 
 
Scheme 1.54. Biaryl compounds by Suzuki reaction. 
aPd(PPh3)4 used, Na2CO3,toluene/EtOH/H2O (1:1:1), 150 °C 
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Synthetic design and consideration  
Commercially available trisubstituted starting materials will be used to elaborated the 
desired aryl scaffolds; this will be mainly achieved by electrophilic aromatic substitution. 
This methodology will be used to enable simple, cost-effective, and scalable reactions to 
be discussed hereafter.  
Fluorinated, and boronated aromatics are highly desirable due to their medicinal 
chemistry applications and their added synthetic potential. Structural diversity will be 
added to the aryl template demonstrating their chemical potential for making drug-like 
small molecules. Scheme 1.55 is a rough retrosynthetic plan showing the synthetic 
potential of some of the desired scaffolds.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.55. Rough retrosynthetic plan. 
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2. MIDA boronate synthesis  
2.1. Overview  
The aim of this Chapter is to produce new rapid synthetic methodologies towards MIDA 
protected aromatic boronic acids, as these compounds were key starting materials for 
work discussed later in Chapters 3 and 4. The hypothesis was that microwave heating 
could reduce reactions times, making a more efficient synthesis. The use of DMSO with 
the addition of benzene to aid azeotropic removal of water was unattractive; we postulated 
that alternative solvents could be used making a “greener,” safer process.   
2.2. Introduction  
As elaborated in the large review in Chapter 1 (0) Burke’s group has produced 
pioneering work into MIDA boronate chemistry. This work shows that MIDA 
boronates are orthogonal to boronic acids in Suzuki reactions, by virtue of the sp3 
hybridized boron in MIDA boronates (Figure 1.14).1 This electron rich boronate is 
less prone to transmetallation, exemplified by the competitive Suzuki cross-coupling 
reaction, shown in Scheme 2.1.2  
 
The series of experiments illustrated in Scheme 2.1, demonstrate that the MIDA 
protecting group slows the transmetalation step, exhibited in the significant differences 
in the ratios of the final products. This effect could only be due to the sp3 hybridisation 
Scheme 2.1. Competitive Suzuki cross-coupling experiments showing ratios of products. 
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at boron of the compound 24 or 27, as it was the only variable changed throughout, 
these experiments. Compounds 24 and 26 have been shown to have a stronger dative 
covalent bond compared to that of the N-methyldiethanolamine derivative shown in 
compound 27.3 This explains why there was no observed difference in the destitution of 
compound 22 and 23 in this case.  
This selective reactivity under anhydrous conditions has enabled iterative palladium 
cross-couplings. The MIDA boronate can be demasked after an initial cross-coupling to 
give its parent boronic acid under basic aqueous conditions to enable a second cross-
coupling. In situ cleavage of the MIDA boronates allows for a greener, multistep one-
pot process reducing time taken, work-up time and solvent usage. The scope to which 
this has been applied is highlighted in-depth in Chapter 1 e.g. Negishi, Heck, 
Sonogashira, Stille and Buchwald–Hartwig amination,4–8 and in various functional 
group interconversions on arenes. Examples of the latter include oxidations under 
Swern or Jones conditions, and cycloisomerization of arylethynyl MIDA 
boronates.3,9 These telescopic reactions are desirable in medicinal chemistry as 
modern industry favours processes with reduced reaction times, fewer reaction steps 
and lower solvent volumes.10 Additionally, MIDA boronates are also crystalline 
solids, stable and silica-gel column-compatible.11 These attributes have been 
employed to improve the shelf life and stability of otherwise unstable boronic acids, 
which tend to protodeboronate.12–15  
Due to their many advantageous attributes numerous MIDA boronates are now, not 
unsurprisingly, commercially available.16 However, more complex MIDA boronates 
still require individual syntheses. 
 Mancilla et. al. in 1986 were the first to syntheses MIDA boronates (Scheme 2.2).17 
Their synthesis involved the esterification of a boronic acid with MIDA in DMSO, 
with the addition of ether benzene or toluene to aid the azeotropic removal of water 
with a Dean-Stark apparatus. This method remains as one of the core methods of 
MIDA boronate synthesis. 
Scheme 2.2. Synthesis of MIDA boronates using Dean-Stark trap. 
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Burke et al later introduced an alternate method of MIDA boronate synthesis by 
means of intercepting a trialkylboronate, synthesised in situ via metalation, with 
MIDA in DMSO (Scheme 2.3).18 The trialkylboronate species was synthesised from 
an aromatic halide via lithium halogen exchange using an organolithium reagent, 
alternately Grignard reagents have been used. This metalated species under went 
borylation, typically using either trimethyl- or triisopropyl borate. To avoid an 
unnecessary work-up and purification at this point, the reaction mixture was added 
directly to a heated mixture of MIDA in DMSO.  
Burke also outlined within this publication, the MIDA esterification of boronic acids 
with 4-methylmorpholine-2,6-dione (MIDA anhydride) at reflux in THF (Scheme 
2.4). Advantageously this method avoids azeotropic removal of water, or high boiling 
point solvents i.e. DMSO or DMF.  
Ingleson et al developed a method of electrophilic arene borylation.19 The borylation 
typically utilises the BCl2 or the boron catecholate adduct, which are then reacted to 
form a MIDA boronate. The MIDA esterification is achieved in most cases using the 
bis-trimethylsilyl ester of MIDA, however some examples also employ the disodium 
salt of MIDA or MIDA alone.  
Grob el al synthesized a wide array of aryl MIDA boronates from their parent boronic 
acids.20 The esterification was achieved via heating a mixture of the aryl boronic acid 
with MIDA in DMF at 85 oC for 18 h. In a similar procedure, Cheon et al. found that 
Scheme 2.3. Formation of MIDA boronates via in situ  
Scheme 2.4. MIDA esterification of a boronic acid using MIDA anhydride.
Scheme 2.5.  
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MIDA boronates can be prepared from unstable 2-hydroxyphenylboronic acids.21 
The MIDA boronates were synthesised by heating MIDA in DMF at 120 oC for 3 h, 
in the presence of  molecular sieves.  
Due to the orthogonal functional group requirements in this project the MIDA 
boronate group became a desirable group to incorporate into tetrasubstituted aromatic 
compounds being synthesised. Many of the synthetic methods outlined towards 
MIDA boronates require a multistep process, large solvent volume and/or extensive 
period of heating. In addition to scalability being a key project objective, there was 
need for generation of a large amount of examples for later experiments, and this 
required the development of new, faster methodology. To shorten reaction times it 
was proposed to perform this chemistry using microwave heating, which has been 
shown to enable quick, more efficient reactions and was anticipated to be 
advantageous in MIDA boronate synthesis.22–24 
This work was also performed with particular emphasis on removing the requirement 
of unattractive solvents e.g. with high boiling point, or high toxicity, from the MIDA 
esterification, described in examples above.   
Discussion 
Large amounts of the MIDA ester of 4-fluoro-3-formyl boronic acid 29 was required for 
the chemistry described in Chapter 3. A rapid screen of solvents and potential additives 
was performed under microwave conditions to ascertain the optimum conditions. Small 
volumes of deuterated solvents were employed in the screening process to facilitate yield 
calculation via 1H-NMR spectroscopy. This was achieved via taking a small aliquot of 
the reaction mixture after cooling and diluting it in an NMR tube prior to inspection. 
Results from this survey are summarised in Table 2.1. 
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Table 2.1. Solvent screen optimisation.  
 
Entry Solvent / Additive % 
1 Acetonitrile-d3 95a 
2 Acetonitrile-d3 + 3Å molecular sieves 93a 
3 Water 5b 
4 DMSO-d6 60a 
5 DMSO-d6  + 4Å molecular sieves 0a 
6 DMF dry 97a,c 
7 DMF reagent grade 72a,c 
8 PEG 300 69b 
a% conversion calculated from 1H-NMR spectroscopy analysis of crude mixture. bisolated yield, 
cexperiments performed by Matthew Emerson.  
 
Table 2.1 entries 4 and 5 shows that, DMSO gave the poorest results out of the solvents 
trialled, with the exception of water, entry 3. These reaction mixtures using DMSO tended 
to blacken and the odour of dimethylsulphide was detectable. This was particularly 
apparent when molecular sieves were employed. The observed increase in decomposition 
present visually and by the large amounts of impurities in the crude 1H-NMR spectrum, 
could be due to the Lewis acidic nature of the molecular sieves.25 DMF (entry 6) was 
notable as it gave the highest conversion of all solvents trialled. Entry 7 gave a lower 
conversion than dry DMF, the proposed cause of this was the decomposition of DMF at 
high temperatures, generating dimethylamine. These basic conditions can induce the in 
situ MIDA boronate cleavage, due to the small amounts of water present in reagent grade 
DMF.26 Employing acetonitrile (entry 1) gave comparable conversions to that of entry 6, 
but entry 1 was deemed to be the most encouraging, due to the favourable properties of 
this solvent e.g. reduced toxicity, lower boiling point.27,28 In entry 2 the use of molecular 
sieves with acetonitrile did not cause the reaction to completion. PEG 300 (entry 8) was 
considered as a worthy choice of candidate solvent in this study as it has similar solvent 
properties to DMSO. As highlighted by Jessop, in terms of polarity and hydrogen bond 
acceptability PEG 300 appears in a similar sector in two Kamlet–Taft plots of common 
solvents.29 PEG 300 also has desirable green solvent properties e.g. low flammability, 
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negligible vapour pressure, reduced environmental damage and a complete toxicity report 
which outlines its approval by the FDA for human consumption.30 These factors led to its 
inclusion in this study, and to our delight a good yield was obtained, shown in entry 8 
Table 2.1. 
Whilst caring out the solvent screen it was observed that the starting materials had poor 
solubility at room temperature, leading to an investigation of these reactions employing 
an in situ microwave camera. This enabled the observation of the solubility of each 
reaction component at different temperatures. These experiments involved heating MIDA 
alone in each of acetonitrile, dimethylformamide or PEG 300, to find it’s solubility in 
each solvent under the reactions conditions. The observations of these test reactions after 
4 minutes of heating are shown in Figure 2.1. 
 
As shown in Figure 2.1 MIDA did not dissolve fully in any of the solvents used at the 
reaction concentration. It was also observed that initiation of stirring proved difficult in 
these studies due to the flocculation of the MIDA. Stirring of microwave reactions is of 
high importance, as it enables uniform heating of the reaction mixture. It has been shown 
that heating in microwave assisted processes can differ up to 30 °C between the middle 
and the edge of the reaction vessel in the absence of adequate stirring.31  
In this body of work we have only monitored reactions via an IR thermometer that 
measures the temperature of the external surface of the vial; this makes effective stirring 
key to reporting reproducible results. The use of the camera to monitor the reaction allows 
observations in real time of the effectiveness of stirring and gives a qualitative measure 
of heat distribution in the microwave vial, without the need for internal optical fibre 
temperature probes.  
Figure 2.1. From left to right, (a) neat MIDA (1 mmol) in MeCN (1 mL) heated at 130 OC for 4 min. 
(b) neat MIDA (1 mmol) in DMF (dry 1 mL) heated at 130 OC for 4 min. (c) neat MIDA (1 mmol) in 
PEG 300 (1 mL) heated at 130 OC for 4 min. Note: the small rings are reflections from lighting LEDs. 
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Real time observation also enabled the visual monitoring of the reaction progress. On 
heating the reaction, shown in Table 2.1 (entry 1), to 130 OC it initially appeared cloudy. 
After maintaining heating for a further 3 minutes the reaction became clear. This showed 
that the reaction had gone to completion as the MIDA, which was insoluble in its 
unreacted form, had been consumed forming the protected boronate product, which was 
soluble in hot MeCN (Figure 2.2).   
Similar observations were noted when the reactions were performed in DMF (Table 2.1 
entry 6). This reaction progressed much faster than in MeCN as the disappearance of the 
cloudy suspension was seen after 1 minute.  
The reaction in PEG 300 (Table 2.1 entry 8) did not follow this pattern as at no point did 
the reaction mixture fully dissolve (Figure 2.4). This is potentially why there was a 
noticeable difference between the conversions in MeCN and DMF (95% and 97%) 
compared to that of the isolated yield of PEG (69 %). 
Figure 2.2. (a) initial reaction mixture; heating to 130 OC in MeCN. 
(b)Mixture after a further 3 minutes of heating. 
Figure 2.3(a) initial reaction heating 130 OC in DMF. (b) reaction 
after a further 1 minute of heating. 
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The low solubility of MIDA in the reaction mixture can lead to sedimentation at the 
bottom of the microwave vial making it difficult to initiate stirring. When the reaction 
was performed in MeCN its low boiling point caused agitation of the sedimented MIDA, 
which freed the magnetic stirrer thus initiating stirring. When the reaction is performed 
in PEG 300, the viscosity in the reaction medium was higher than in MeCN, and this has 
been shown to limit the stirring rate in the microwave vial.32,33 This, along with the 
sedimentation of the MIDA, causes difficulties in initiating stirring in the reaction vial. 
Due to the high boiling point of PEG 300, heating to 130 °C did not cause agitation and 
initiation of stirring, unlike with the more volatile MeCN. We found that using the hot 
keys to start and stop the stirring and the use of cross-shaped stirrer bars during the heating 
phase of the reaction helped dislodge the stirrer at the low speed setting. At elevated 
temperatures the stirrer could be turned up to a faster setting. A consequence of low speed 
stirring during the heating phase of PEG 300 was overheating. Upon increasing the stirrer 
speed, this caused the heat to rapidly transfer from the centre to the outer surface of the 
vial, making the reaction temperature overheat by up to 40 °C in some cases. We found 
that reducing the maximum power from 200 W to 40 W increased the duration of the 
heating phase; this allowed for uniform heating at the low stirring rate and removed the 
problem of overshooting. 
Due to the nature of the solvents that were used in this early optimisation study (i.e. DMF, 
PEG 300 and MeCN), no lengthy work up was required. The simple addition of water 
caused precipitation of the product; this then could the filtered and washed with water to 
remove any residual reaction solvent. The high stability of the MIDA boronates enabled 
fast efficient drying of product in an oven.    
 
Figure 2.4 Reaction mixture after 
4 minutes of heating in PEG 300. 
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2.3. Results  
From the optimisation study, a library of MIDA boronates was synthesised. This fast 
methodology has led to 3 general methods using MeCN, DMF or PEG 300; the results 
are shown in Table 2.2. 
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Table 2.2 Isolated yields (%) for MIDA boronates using general method A, B or C. 
 
 
a1 mmol scale, b3.5 mmol scale, c5 mmol scale, d10 mmol scale, e experiments performed by Matthew 
Emerson. 
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The initial solvent tested was acetonitrile shown in Table 2.2 (general method A, orange 
highlight), these reactions were done employing a 5 minute time hold microwave method. 
In general, the reaction showed good functional group tolerance and yields were good to 
exceptional, e.g. 30, 31, 37. A close to quantitative yield was achieved in the preparation 
of 41, a simple alkyl MIDA boronate. However, for unknown reasons 38 was formed in 
a low yield and 44 was a notable exception, which was unable to be synthesised. In the 
case of 44, the presence of two ortho substituents flanking the boronic acid functionality 
was hypothesised to have caused the low yield. This led to the use of higher boiling point 
solvent and/or extended reaction times that might facilitate formation of 44. 
31, 32, 36 and 43 were all attempted on a larger scale, and all exhibited similar yields to 
the smaller scale examples. Some technical adjustments were required for the larger scale 
reactions. When attempting 5 mmol scale reactions in a 35 mL CEM microwave vial 
increased pressurisation was observed, resulting from reduction in relative head space in 
the closed system. This was resolved by adopting a like-for-like mmol mL-1 ratio to that 
used original 1 mmol conditions, enabling the same relative head space, regardless of vial 
size. Therefore a 3.5 mmol scale reactions were performed in a 35 mL vial. This was the 
limit of scale for using MeCN as its lower boiling point did not facilitate open vessel 
reactions.  
The use of DMF as solvent required increasing the reaction time to 10 min, as a rapid 
screen showed incomplete reactions after a 5 min heating period. This led to 44 being 
prepared in yield of 62% and series heteroaryl MIDA and 2-substituted aryl boronates 
were now included in the library (Table 2.2) mostly in reasonable to good yields. Poor 
yields were recorded for the 2-phenol derivative 50 the chloropyridine 48, and 
additionally 53 was unproductive. An acceptable 44% yield was achieved for the 
benzaldehyde derivative 45, which Grob et al reported a yield of 0% in their 18 hour 
DMF heating methodology.20 Due to the higher boiling point of DMF increasing the scale 
of the reactions was less problematic than those carried out in MeCN. 5 mmol scale 
reactions, as could be achieved using a 35 mL reaction vial and yields were comparable 
to the smaller scale reactions shown with 44 and 51. Open vessel reactions were also 
achievable with DMF as the solvent, allowing for the 10 mmol scale synthesis of 47 
yielding over 2 g of product. 
Yields in PEG 300 were generally good, as shown in Table 2.2 (general method C, green 
highlight). Synthesis of 2-substituted MIDA boronates in PEG 300 tended to be lower 
yielding than those obtained using DMF, for example, 47 (51% vs 97%), 49 (60% vs 
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83%) and 44 (14% vs 62%) showing that DMF would be a solvent of choice. Although, 
PEG 300 showed comparable yields in the synthesis of 36 on a range of scales, and a 
yield of 82% was observed in the preparation of 48. As with DMF increasing the scale of 
reactions was done with ease due to PEG 300’s low vapour pressure and enabled open 
vessel MW reaction on a 10 mmol scale for example 57. The work up procedure using 
PEG 300 proved easy: precipitation of the pure MIDA boronate product, after cooling, 
was achieved using water.  
 
2.4. Conclusion   
The rapid microwave-mediated synthesis in either acetonitrile, DMF or PEG 300 was 
developed in this Chapter, facilitating the generation of a library of MIDA boronates. 
This reaction in most cases gave high yields, using minimal solvent, with reduced reaction 
times. A range of different functional groups were tolerated at a variety of positions on 
the aromatic ring with respect to the boronic acid, although the isolated yields varied 
depending on the solvent used. Generally DMF gave higher yields than either acetonitrile 
or PEG 300, with substrates that had functional groups on the aromatic ring ortho to the 
boronic acid. This rapid synthesis could be performed on larger scales giving yields 
comparable to the 1 mmol reactions. The higher boiling point solvents, DMF and PEG 
300, facilitated open vessel microwave reactions at 130 °C, this enabled much larger 
multigram scale reactions.   
The work led to the first publications from this thesis, with the aid of Matthew Emmerson, 
a Spencer lab MChem student, who, under my supervision achieved some of the results 
using DMF.34 The observations using the microwave camera were of interest to CEM and 
published as a CEM applications note on their website.35 
This work enables the synthesis of key compounds that are used in Chapter 3 for the 
examination of polysubstituted arene synthesis via bromination and nitration reactions. 
This work also meets the aims outlined by AstraZeneca, as methods are scalable, utilising 
cheap starting materials.  
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2.5. Experimental   
Solvents and reagents were purchased from commercial suppliers and used without 
further purification. Reactions were heated using a CEM Discovery microwave fitted 
with an Explorer unit; ensure a ventilated fumehood with the sash lowered is used as these 
reactions are under high pressure and temperature.  NMR spectra were recorded on a 
Varian 500 MHz or 400 MHz spectrometer. Chemical shifts are reported in ppm and are 
referenced to the residual solvent peak or to TMS used as an internal standard; note that 
in some cases the carbon bonded to the boron is not detectable in the 13C NMR23. LCMSs 
were ran on a Shimadzu LCMS-2020 equipped with a Gemini® 5 µm C18 110 Å column. 
Percentage purities were performed using a 30 minutes method in water/acetonitrile with 
0.1% Formic acid (5min at 5%, 5%-95% over 20 min, 5min at 95%) with the UV set to 
254 nm. High resolution mass spectrometry (HRMS) was done ether internally or by the 
National Mass Spectrometry Facility, Swansea. A number of the products described 
below are commercially available or known, e.g. in patents. In these cases, 1H, 13C, 
HRMS and % purity data are presented since in many cases these data are not published. 
For compounds that appear to be novel, more analytical data are presented including 11B 
NMR. 
 
General procedure for MIDA boronate formation with acetonitrile (General 
Method A) 
 
The boronic acid (1 mmol) was added to a 10 mL microwave vial equipped with a 
magnetic stirrer, and then acetonitrile (1 mL) was added, followed by 
methyliminodiacetic acid (MIDA) (147 mg, 1 mmol). The Teflon cap was added and the 
reaction was heated using the dynamic heating method, with the maximum power set to 
300 W, max pressure 250 psi, max temperature 130 oC, high stirring throughout and 
power max turned off. This method was used to hold the reaction mixture at 130 oC for 5 
min. After cooling, the magnetic stirrer was retrieved and the acetonitrile was removed 
under reduced pressure giving a crude white powder. This crude material was first 
triturated via sonication with deionised water (5 mL), cooled in an ice bath, collected by 
filtration and washed with cold water (5 mL). This solid was then further triturated with 
diethyl ether (5 mL), cooled in an ice bath, collected by filtration and washed with diethyl 
ether (5 mL) giving pure product as a white precipitate (if not otherwise quoted) which 
was air dried.  
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Note: The 3.5 mmol scale reaction was done using a 35 mL microwave vial, with the 
same heating profile. 
 
General procedure for MIDA boronate formation with DMF (General Method B) 
 
The boronic acid (1 mmol) was added to a 10 mL microwave vial equipped with a 
magnetic stirrer, followed by methyliminodiacetic acid (MIDA) (1 mmol) and dry DMF 
(1 mL) was added to the vial. The Teflon cap was added and the reaction was heated 
using the dynamic heating method, with max power set to 300 W, max pressure 300 psi, 
max temperature 130 oC, high stirring throughout and power max turned off. This method 
was used to hold the reaction mixture at 130 oC for 10 min. 
After cooling, the DMF was removed under reduced pressure giving crude yellow oil. 
The latter was triturated via sonication with deionised water (5 mL), cooled in an ice bath 
collected by filtration and washed with cold water (5 mL). This solid was then further 
triturated with diethyl ether (5 mL), cooled in an ice bath, collected by filtration and 
washed with diethyl ether (5 mL) then air dried giving pure product as a white precipitate.  
 
General procedure for MIDA boronate formation with PEG 300 (General Method 
C) 
 
The boronic acid (1 mmol) was added to a 10 mL microwave vial equipped with a 
magnetic stirrer, and then PEG 300 (1 mL) was added followed by methyliminodiacetic 
acid (MIDA) (147 mg, 1 mmol). The Teflon cap was added and the reaction was heated 
using the dynamic heating method, with max power set to 40 W, max pressure 250 psi, 
max temperature 130 oC, high stirring throughout and power max turned off. This method 
was used to hold the reaction mixture at 130 oC for 5 min. 
After cooling, the mixture was added to water (9 mL). This mixture was stirred forming 
a white precipitate, then cooled in an ice bath allowing flocculation, then collected by 
filtration and washed with cold water (5 mL). The precipitate was allowed to dry in an 
oven set to 100oC, giving pure product as a white precipitate (if not otherwise quoted). 
Notes: The 5 mmol scale reaction was performed using a 35 mL microwave vial and the 
10 mmol scale was carried out using a 100 mL round bottomed flask with a small air 
condenser attached with the open vessel attenuator installed.  The heating parameters 
 77 
were kept the same but the hold time was changed to 7.5 min for the 5 mmol scale and 
10 min for the 10 mmol scale reactions. 
 
4-Fluoro-3-formylphenyl MIDA boronate, 29.20 
  
Made following General Method A. 
Yield: 226 mg (81%) as a white precipitate. 
Made following General Method C. 
Yield: 193 mg (69%) as a white precipitate. 
HRMS-ESI (m/z) found 302.0607, calcd for [C12H11
10BNO5Na]
+ 302.0607. 
1H NMR (500 MHz, Acetonitrile-D3) δ 10.30 (s, 1H), 7.96 (dd, 4JFH = 7.5, 4JHH = 2.0 Hz, 
1H), 7.82 (ddd, 3JHH = 8.5, 
4JFH = 5.5, 
4JHH = 2.0 Hz, 1H), 7.27 (dd, 
3JFH = 11.5,
 3JHH = 
8.5 Hz, 1H), 4.10 (d, J = 17.0 Hz, 2H), 3.93 (d, J = 17.0 Hz, 2H), 2.54 (s, 3H).  
13C NMR (126 MHz, Acetonitrile-D3) δ 187.9 (d, 3JFC = 6.0 Hz), 168.3, 165.0 (d, 1JFC = 
260.0 Hz), 140.9 (d, 3JFC = 9.0 Hz), 134.0 (d, 
3JFC = 2.0 Hz), 123.7 (d, 
2JFC = 8.0 Hz), 
116.1 (d, 2JFC = 20.0 Hz), 62.1, 47.7.  
19F NMR (376 MHz, Acetonitrile-D3) δ -110.85 (ddd, J = 11.5, 7.5, 5.5 Hz).  
11B NMR (128 MHz, Acetonitrile-D3) δ 10.6.  
LCMS purity UV = 96%, Ret. time = 14.10 min.  
 
3-Fluoro-4-formylphenyl MIDA boronate, 30.20 
 
Made following General Method A. 
Yield: 235 mg (84%) as a white precipitate. 
Made following General Method C. 
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Yield: 204 mg (73%) as a white precipitate.  
HRMS-ESI (m/z) found 302.0605, calcd for [C12H11
10BFNO5Na]
+ 302.0607 
1H NMR (500 MHz, Acetonitrile-D3) δ 10.34 (s, 1H), 7.87 (appt, 3JHH,4JFH J = 7.5 Hz, 
1H), 7.49 (d, 3JHH = 7.5 Hz, 1H), 7.43 (d, 
3JFH = 11.5 Hz, 1H), 4.15 (d, J = 17.0 Hz, 2H), 
3.98 (d, J = 17.0 Hz, 2H), 2.59 (s, 3H).  
13C NMR (126 MHz, Acetonitrile-D3) δ 188.7 (d, 3JFC = 6.0 Hz), 169.2, 164.9 (d, 1JFC = 
258.0 Hz), 129.8, (d, 3JFC = 4.0. Hz), 129.4, 125.7 (d, 
2JFC = 9.0 Hz), 121.3 (d, 
2JFC = 19.0 
Hz), 63.2, 48.7.  
19F NMR (376 MHz, Acetonitrile-D3) δ -112.46 (dd, J = 11.7, 7.3 Hz).  
11B NMR (128 MHz, Acetonitrile-D3) δ 10.6. 
LCMS purity UV 94%, Ret. time = 14.24 min. 
 
3-Acetamidophenyl MIDA boronate, 31. 
 
Made following General Method A  
Yield: 230 mg (1 mmol scale, 79%), 861 mg (3.5 mmol scale, 85%) as a pink precipitate. 
Made following General Method C. 
Yield: 223 mg (77%) as a pink precipitate. 
HRMS-FTMS (m/z) found 290.1180, calcd for [C13H15
10BN2O5H]
+ 290.1183. 
1H NMR (500 MHz, DMSO-D6) δ 9.87 (s, 1H), 7.79 – 7.74 (m, 1H), 7.46 (s, 1H), 7.31 – 
7.24 (m, 1H), 7.12 – 7.06 (m, 1H), 4.33 (d, J = 17.0 Hz, 2H), 4.09 (d, J = 17.0 Hz, 2H), 
2.49 (s, 3H), 2.02 (s, 3H).  
13C NMR (126 MHz, DMSO-D6) δ 169.2, 168.1, 138.7, 128.0, 127.0, 122.9, 119.7, 61.6, 
47.5, 23.9.  
11B NMR (128 MHz, DMSO-D6) δ 11.3.  
LCMS purity >99% (UV), Ret. time = 11.76 min.  
 
B
O
N
O
O
O
HN
O
 79 
4-Acetamidophenyl MIDA boronate, 32. 
 
Made following General Method A. 
Yield:  232 mg (80%), 768 mg (3.5 mmol scale, 76%) as a brown crystalline solid. 
Made following General Method C. 
Yield:  252 mg (1 mmol scale, 87%) as a brown crystalline solid.  
HRMS-FTMS (m/z) found 290.1181, calcd for [C13H15
10BN2O5H]
+ 290.1183. 
1H NMR (500 MHz, DMSO-D6) δ 9.90 (s, 1H), 7.55 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 
Hz, 2H), 4.30 (d, J = 17.0 Hz, 2H), 4.08 (d, J = 17.0 Hz, 2H), 2.48 (s, 3H), 2.04 (s, 3H).  
13C NMR (126 MHz, DMSO-D6) δ 169.3, 168.2, 139.9, 132.8, 118.2, 61.7, 47.5, 24.0. 
11B NMR (128 MHz, DMSO-D6) δ 10.4.  
LCMS purity >99% (UV), Ret. time = 11.37 min.  
 
3-Formylphenyl MIDA boronate, 33.20 
 
Made following General Method A. 
Yield: 200 mg (76%) as a white precipitate. 
Made following General Method C. 
Yield: 264 mg (51%) as a white precipitate.   
HRMS-ESI (m/z) found 284.0701, calcd for [C12H12
10BNO5Na]
+ 284.0701. 
1H NMR (500 MHz, DMSO-D6) δ 10.04 (s, 1H), 8.00 (s, 1H), 7.91 (d, J = 7.5 Hz, 1H), 
7.78 (d, J = 7.5 Hz, 1H), 7.60 (appt, J = 7.5 Hz, 1H), 4.37 (d, J = 17.2 Hz, 2H), 4.17 (d, J 
= 17.2 Hz, 2H), 2.53 (s, 3H).  
13C NMR (126 MHz, DMSO-D6) δ 193.5, 169.2, 138.6, 135.5, 133.9, 129.8, 128.4, 62.0, 
47.7. 11B NMR (128 MHz, DMSO-D6) δ 11.3.  
LCMS purity UV = 98%, Ret. time = 13.45 min.  
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4-Formylphenyl MIDA boronate, 34.20 
 
Made following General Method A. 
Yield: 264 mg (99%) as a white precipitate. 
Made following General Method C. 
Yield: 227 mg (87%) as a white precipitate. 
HRMS-ESI (m/z) found 284.0699, calcd for [C12H12
10BNO5Na]
+ 284.0701. 
1H NMR (500 MHz, Acetonitrile-D3) δ 10.04 (s, 1H), 7.89 (d, J = 8.0 Hz, 2H), 7.72 (d, J 
= 8.0 Hz, 2H), 4.10 (d, J = 17.1 Hz, 2H), 3.93 (d, J = 17.1 Hz, 2H), 2.52 (s, 3H).  
13C NMR (126 MHz, DMSO-D6) δ 193.4, 169.2, 136.5, 133.1, 128.5, 62.0, 47.7.  
11B NMR (128 MHz, DMSO-D6) δ 10.8.  
LCMS purity >99% (UV), Ret. time = 11.76 min.  
 
3-Bromophenyl MIDA boronate, 35.2 
 
Made following General Method A. 
Yield: 274 mg (88%) as a white precipitate. 
Made following General Method C. 
Yield: 218 mg (70%) as a white precipitate.   
HRMS-ESI (m/z) found 333.9851, calcd for [C11H11
10B79BrNO4H]
+ 333.9857. 
1H NMR (500 MHz, Acetonitrile-D3) δ 7.65 (s, 1H), 7.63 – 7.59 (m, 1H), 7.53 – 7.48 (m, 
1H), 7.37 – 7.33 (m, 1H), 4.07 (d, J = 17.1 Hz, 2H), 3.91 (d, J = 17.1 Hz, 2H), 2.53 (s, 
3H).  
13C NMR (126 MHz, Acetonitrile-D3) δ 169.3, 136.2, 133.2, 132.3, 131.0, 123.4, 63.0, 
48.7.  
11B NMR (128 MHz, Acetonitrile-D3) δ 11.3.  
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LCMS purity UV >99%, Ret. time = 16.73 min.  
 
4-Bromophenyl MIDA boronate, 36.2 
 
Made following General Method A. 
Yield: 278 mg (1 mmol scale, 89%), 861 mg (3.5 mmol scale, 79 %) as a white 
precipitate. 
Made following General Method C. 
Yield: 259 mg (1 mmol scale, 83%), 1.127 g (5 mmol scale, 72%), 2.551 g (10 mmol 
scale, 82%) as a white precipitate.  
HRMS-ESI (m/z) found 333.9857, calcd for [C11H11
10BBrNO4H]
+ 333.9857. 
1H NMR (500 MHz, Acetonitrile-D3) δ 7.55 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 
4.07 (d, J = 17.0 Hz, 2H), 3.89 (d, J = 17.0 Hz, 2H), 2.51 (s, 3H).  
13C NMR (126 MHz, Acetonitrile-D3) δ 169.4, 135.6, 132.0, 124.4, 62.9, 48.6.  
11B NMR (128 MHz, Acetonitrile-D3) δ 11.2.  
LCMS purity UV >99%, Ret. time = 16.87 min.  
 
 3-Hydroxyphenyl MIDA boronate 37. 
 
Made following General Method A.  
Yield: 199 mg (80%) as a white precipitate.  
HRMS-ESI (m/z) found 250.0878, calcd for [C11H12
10BNO5H]
+ 250.0881. 
1H NMR (500 MHz, DMSO-D6) δ 9.26 (s, 1H), 7.25 (d, J = 8.0 Hz, 1H), 6.96 – 6.90 (m, 
2H), 6.84 (d, J = 8.0 Hz, 1H), 4.40 (d, J = 17.0 Hz, 2H), 4.18 (d, J = 17.0 Hz, 2H), 2.58 
(s, 3H).  
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13C NMR (126 MHz, DMSO-D6) δ 169.3, 156.7, 128.8, 122.9, 119.0, 115.8, 61.7, 47.5.  
11B NMR (128 MHz, DMSO-D6) δ 11.7.  
LCMS purity >99% (UV), Ret. time = 11.61 min.  
 
4-Hydroxyphenyl MIDA boronate, 38. 
 
Made following General Method A. 
Yield: 87 mg (35%) as a white precipitate. 
HRMS-ESI (m/z) found 272.0700, calcd for [C11H12
10BNO5Na]
+ 272.0701. 
1H NMR (500 MHz, Acetonitrile-D3) δ 7.33 (d, J = 8.0 Hz, 2H), 6.93 (s, 1H), 6.82 (d, J 
= 8.0 Hz, 2H), 4.02 (d, J = 17.0 Hz, 2H), 3.84 (d, J = 17.0 Hz, 2H), 2.48 (s, 3H).  
13C NMR (100 MHz, Acetonitrile-D3) δ 169.6, 159.0, 135.0, 115.9, 62.7, 48.4. 11B NMR 
(128 MHz, Acetonitrile-D3) δ 11.6.  
LCMS purity >99% (UV), Ret. time = 11.14 min.  
 
 
2-Fluoropyridine-5 MIDA boronate, 39. 
 
Made following General Method A. 
Yield: 152 mg (60%) as a white precipitate. 
Made following General Method C. 
Yield: 121 mg (48%) as a white precipitate. 
HRMS-ESI (m/z) found 253.0789, calcd for [C10H10
10BN2O4H]
+ 253.0790. 
1H NMR (500 MHz, DMSO-D6) δ 8.26 – 8.23 (m, 1H), 8.03 – 7.97 (m, 1H), 7.17 – 7.13 
(m, 1H), 4.36 (d, J = 17.0 Hz, 2H), 4.16 (d, J = 17.0 Hz, 2H), 2.58 (s, 3H).  
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13C NMR (100 MHz, DMSO-D6) δ 169.0, 164.0 (d, 1JFC = 236.0 Hz), 151.6 (d, 3JFC = 
14.0 Hz), 146.4 (d, 3JFC = 7.5 Hz), 108.7 (d, 
2JFC = 36.0 Hz), 62.0, 47.7.  
19F NMR (376 MHz, DMSO-D6) δ -68.77 (d, J = 9.0 Hz).  
11B NMR (128 MHz, DMSO-D6) δ 11.2.  
LCMS purity UV >99%, Ret. time = 12.13 min. 
 
3-Fluorophenyl MIDA boronate, 40. 
  
Made following General Method A. 
Yield: 231 mg (92%) as a white precipitate. 
Made following General Method C. 
Yield: 171 mg (68%) as a white precipitate. 
HRMS-FTMS (m/z) found 274.0664, calcd for [C11H11O4NBFNa]
+ 274.0664. 
1H NMR (500 MHz, DMSO-D6) δ 7.44 – 7.38 (m, 1H), 7.26 (d, J = 7.3 Hz, 1H), 7.23 – 
7.12 (m, 2H), 4.34 (d, J = 17.0 Hz, 2H), 4.14 (d, J = 17.0 Hz, 2H), 2.53 (s, 3H).  
13C NMR (126 MHz, DMSO-D6) δ 169.2, 162.0 (d, J = 244.0 Hz), 129.8 (d, J = 7.5 Hz), 
128.3 (d, J = 2.5 Hz), 118.6 (d, J = 18.5 Hz), 115.6 (d, J = 21.0 Hz), 61.9 , 47.6.  
19F NMR (376 MHz, DMSO-d6) δ -114.11 (td, J = 9.5, 6.0 Hz).  
11B NMR (128 MHz, DMSO-D6) δ 10.7.  
LCMS purity UV >99%, Ret. time = 15.22 min.  
 
Methyl MIDA boronate, 41. 
 
Made following General Method A. 
Yield: 171 mg (99%) as a white precipitate.  
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Made following General Method C.  
Yield: 87 mg (51%) as a white precipitate.  
HRMS-ESI (m/z) found 194.0594, calcd for [C6H10
10BNO4Na]
+ 194.0595 
1H NMR (500 MHz, Acetonitrile-D3) δ 3.92 (d, J = 17.0 Hz, 2H), 3.78 (d, J = 17.0 Hz, 
2H), 2.84 (s, 3H), 0.10 (s, 3H).  
13C NMR (126 MHz, Acetonitrile-D3) δ 169.1, 62.6, 46.9.  
11B NMR (128 MHz, Acetonitrile-D3) δ 13.4. 
 
Phenyl MIDA boronate, 42.17 
 
Made following General Method A. 
Yield: 123 mg (53%) as a white precipitate. 
Made following General Method C. 
Yield: 128 mg (55%) as a white precipitate. 
HRMS-ESI (m/z) found 256.0750, calcd for [C11H12
10BNO4Na]
+ 256.0752 
1H NMR (500 MHz, Acetonitrile-D3) δ 7.53 – 7.47 (m, 2H), 7.44 – 7.36 (m, 3H), 4.06 (d, 
J = 17.0 Hz, 2H), 3.88 (d, J = 17.0 Hz, 2H), 2.49 (s, 3H).  
13C NMR (100 MHz, Acetonitrile-D3) δ 169.6, 133.4, 130.3, 128.9, 62.8, 48.5.  
LCMS purity UV >99%, Ret. time = 14.38 min.  
 
(E)-Styryl MIDA boronate, 43. 
 
Made following General Method A. 
Yield: 135 mg (52%), 480 mg (3.5 mmol scale, 53%). 
Made following General Method C. 
Yield: 75 mg (29%).  
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HRMS-FTMS (m/z) found 259.1005, calcd for [C13H14BNO4H]
+ 259.1016. 
1H NMR (400 MHz, DMSO-d6) δ 7.52 – 7.47 (m, 2H), 7.39 – 7.32 (m, 2H), 7.29 – 7.24 
(m, 1H), 6.83 (d, J = 18.0 Hz, 1H), 6.28 (d, J = 18.0 Hz, 1H), 4.25 (d, J = 17.0 Hz, 2H), 
4.04 (d, J = 17.0 Hz, 2H), 2.81 (s, 3H).  
13C NMR (101 MHz, DMSO) δ 169.0, 141.0, 137.8, 128.5, 127.8, 126.4, 61.3, 46.7, 39.5.  
11B NMR (128 MHz, DMSO-d6) δ 10.5.  
LCMS purity UV = >99%, Ret. time = 1.75 min.  
 
2-Bromo-6-fluorophenyl MIDA boronate, 44. 
 
Made following General Method B. 
Yield: 205 mg (62%), 924 mg (5 mmol scale, 56%)  
Made following General Method C. 
Yield: 46 mg (14%).  
HRMS-FTMS (m/z) found 328.9971, calcd for [C11H10
10BBrFNO4H]
+ 328.9979. 
1H NMR (500 MHz, DMSO-D6) δ 7.49 (d, 3JHH = 8.0 Hz, 1H), 7.36 (dd, 3JHH  = 8.0, 8.5 
Hz, 1H), 7.19 (dd, 3JFH = 11.0,
 3JHH = 8.5 Hz, 1H), 4.42 (d, J = 17.5 Hz, 2H), 4.16 (d, J = 
17.5 Hz, 2H), 2.72 (s, 3H).  
13C NMR (126 MHz, DMSO-D6) δ 168.6, 166.5 (d, 1JCF = 248.0 Hz), 132.6 (d, 3JFC = 
11.0 Hz), 130.5 (d, 4JFC = 3.0 Hz), 127.8 (d, 
3JFC = 9.0 Hz), 115.2 (d, 
2JFC = 27.0 Hz), 
63.0, 47.9  
19F NMR (376 MHz, DMSO-d6) δ -97.67 (dd, J = 11.0, 6.3 Hz).  
11B NMR (128 MHz, DMSO-D6) δ 10.6.  
LCMS purity UV = >99%, Ret. time = 15.42 min. 
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2-Formylphenyl MIDA boronate, 45. 
Following General Method B 
Yield: 116 mg (44%) as a white precipitate. 
Following General Method C 
Yield: 23 mg (9%) as a white precipitate. 
HRMS-FTMS (m/z) found 262.0880, calcd for [C12H12
10BNO5H]
+ 262.0881. 
1H NMR (500 MHz, Acetonitrile-D3): δ 10.11 (s, 1H), 7.93 (m, 1H), 7.80 (m, 1H), 7.66 
(m, 2H), 4.14 (d, J=18.0, 2H), 4.14 (d, J=18.0, 2H), 2.68 (s, 3H).  
13C NMR (126 MHz, Acetonitrile-D3):
 196.8, 169.9, 142.1, 136.8, 135.2, 134.0, 130.7, 
65.7, 50.0.  
11B NMR (128 MHz, Acetonitrile-D3): 11.8.  
LCMS purity UV = >99%, Ret. time = 12.94 min.  
 
2-Bromophenyl MIDA boronate, 46.2 
 
Made following General Method B 
Yield: 224 mg (72%) as a white precipitate.  
Made following General Method C 
Yield: 218 mg (70%) as a white precipitate. 
HRMS-FTMS (m/z) found 333.9862, calcd for [C11H11
10B79BrNO4Na]
+ 333.9857. 
1H NMR (500 MHz, Acetonitrile-D3): δ 7.67 (d, J=7.4, 1H), 7.62 (d, J = 7.8 Hz, 1H), 
7.39 (dd, J = 7.4, 7.5 Hz, 1H), 7.30 (dd, J = 7.8, 7.5 Hz, 1H), 4.13 (d, J = 17.0 Hz, 2H), 
4.03 (d, J = 17.0 Hz, 2H), 2.71 (s, 3H).  
13C NMR (126 MHz, Acetonitrile-D3):
 169.5, 137.4, 134.6, 132.4, 128.7, 128.0, 65.3, 
49.6. 
11B NMR (128 MHz, Acetonitrile-D3): 11.6. 
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LCMS purity UV = >99%, Ret. time = 15.44 min.  
 
2-Methoxyphenyl MIDA boronate, 47. 
 
Made following General Method B 
Yield: 254 mg (97%), 1144 mg (5 mmol scale, 87%), 2420 mg (10 mmol scale, 92%) as 
a white precipitate. 
 Made following General Method C 
Yield: 134 mg (51%) as a white precipitate.  
HRMS-FTMS (m/z) found 286.0860, calcd for [C12H14
10BNO5Na]
+ 286.0857. 
1H NMR (500 MHz, Acetonitrile-D3): δ 7.56 (dd, J = 7.0, 2.0 Hz, 1H), 7.39 (ddd, J = 8.0, 
7.0, 2.0 Hz, 1H), 6.97 (m, 2H), 4.06 (d, J = 17.0 Hz, 2H), 3.95 (d, J = 17.0 Hz, 2H), 3.77 
(s, 3H), 2.61 (s, 3H).  
13C NMR (126 MHz, DMSO-D6): 169.2, 162.0, 133.9, 130.7, 120.2, 110.3, 63.2, 54.8, 
47.2.  
11B NMR (128 MHz, Acetonitrile-D3): 7.7.  
LCMS purity UV = >99%, Ret. time = 14.76 min.  
 
2-Chloro-3-pyridyl MIDA boronate, 48. 
 
Made following General Method B 
Yield: 67 mg (25%) as a white precipitate. 
Made following General Method C 
Yield: 220 mg (82%) as a white precipitate.  
HRMS-FTMS (m/z) found 269.0429, calcd for [C10H10
10BClN2O4H]
+ 269.0495. 
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1H NMR (500 MHz, Acetonitrile-D3): δ 8.39 (dd, J = 5.0, 2.0 Hz, 1H), 8.11 (dd, J=2.0, 
7.5 Hz, 1H), 7.35 (dd, J = 7.5, 5.0 Hz, 1H), 4.16 (d, J = 17.5 Hz, 2H), 4.05 (d, J = 17.5 
Hz, 2H), 2.75 (s, 3H).  
13C NMR (126 MHz, Acetonitrile-D3):
 169.3, 151.6, 146.6, 123.5, 111.0, 65.2, 49.3.  
11B NMR (128 MHz, Acetonitrile-D3): 11.0.  
LCMS purity UV = >99%, Ret. time = 11.43 min.  
 
2,4-Dimethoxypyrimidine-5-MIDA boronate, 49. 
Made following General Method B 
Yield: 245 mg (83%) as a white precipitate. 
Made following General Method C 
Yield: 177 mg (60%) as a white precipitate.  
HRMS-FTMS (m/z) found 296.1046, calcd for [C11H14
10BN3O6H]
+ 296.1048. 
1H NMR (500 MHz, Acetonitrile-D3): δ 8.38 (s, 1H), 4.08 (d, J = 17.0 Hz, 2H), 3.95 (s, 
3H), 3.94 (d, J = 17.0 Hz, 2H), 3.91 (s, 3H), 2.66 (s, 3H).  
13C NMR (126 MHz, Acetonitrile-D3): δ 174.8, 169.3, 167.9, 164.9, 111.0, 64.0, 55.2, 
54.3, 48.2.  
11B NMR (128 MHz, Acetonitrile-D3); δ 11.2 (s). 
LCMS purity UV = 97%, Ret. time = 10.34 min.  
 
2-Hydroxyphenyl MIDA boronate, 50. 
 
Made following General Method B 
Yield: 105 mg (42%) as a white precipitate. 
Following General Method B 
Yield: 105 mg (42%) as a white precipitate. 
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HRMS-FTMS (m/z) found 272.0702, calcd for [C11H12
10BNO5Na]
+ 272.0701. 
1H NMR (500 MHz, DMSO-D6): δ 9.53 (s, 1H), 7.38 (dd, J = 7.5, 1.5 Hz, 1H), 7.17 (ddd, 
J = 8.0, 7.5, 1.5 Hz, 1H), 6.80-6.73 (m, 2H), 4.32 (d, J = 17.0 Hz, 2H), 4.03 (d, J = 17.0 
Hz, 2H), 2.63 (s, 3H).  
13C NMR (126 MHz, DMSO-D6): 169.3, 160.0, 134.0, 130.2, 118.7, 114.6, 63.1, 47.1.  
11B NMR (128 MHz, DMSO-D6): 11.8.  
LCMS purity UV = >99%, Ret. time = 12.76 min.  
 
2-Fluorophenyl MIDA boronate, 51. 
 
Following General Method B 
Yield: 208 mg (83%), 991 mg (5 mmol scale, 79%) as a white precipitate. 
HRMS-FTMS (m/z) found 274.0661, calcd for [C11H11
10BFNO4Na]
+ 274.0657. 
1H NMR (500 MHz, Acetonitrile-D3): 7.59 (dd, J = 7.5 Hz, 1H), 7.49-7.41 (m, 1H), 7.22 
(dd, J = 7.5 Hz, 1H), 7.08 (dd, J = 10.5, 8.5 Hz, 1H), 4.12 (d, J = 17.0 Hz, 2H), 3.95 (d, 
J = 17.0 Hz, 2H), 2.64 (s, 3H).   
13C NMR (126 MHz, DMSO-D6): 168.9, 165.5 (d, J = 241.0 Hz), 134.7 (d, J = 9.0 Hz), 
131.6 (d, J = 8.5 Hz), 124.1 (d, J = 2.5 Hz), 114.9 (d, J = 25.0 Hz), 62.4 (d, J = 2.0 Hz), 
47.5.  
19F NMR (376 MHz, DMSO-D6): -107.5 (m).
  
11B NMR (128 MHz, Acetonitrile-D3): 10.5. 
LCMS purity UV = >99%, Ret. time = 14.72 min.  
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2, 6-Dichlorophenyl MIDA boronate, 52. 
 
Following General Method B 
Yield: 104 mg (35%) as a white precipitate.  
HRMS-FTMS (m/z) found 323.9967, calcd for [C11H10
10BCl2NO4Na]
+ 323.9972. 
1H NMR (500 MHz, Acetonitrile-D3): δ 7.40 (m, 1H), 7.34 – 7.29 (m, 2H), 4.15 (d, J = 
17.5 Hz, 2H), 4.01 (d, J = 17.5 Hz, 2H), 2.83 (s, 3H).  
13C NMR (126 MHz, Acetonitrile-D3): δ 169.2, 142.0, 132.4, 130.9, 65.4, 49.7.  
11B NMR (128 MHz, Acetonitrile-D3); δ 11.4 (s).  
LCMS purity UV = >99%, Ret. Time = 15.56 min.  
 
4-Methoxyphenyl MIDA boronate, 54. 
 
Made following General Method C 
Yield: 184 mg (70%) as a white precipitate.  
HRMS-ESI (m/z) found 286.0869, calcd for [C12H14
10BNO5Na]
+ 286.0857 
1H NMR (500 MHz, Acetonitrile-D3) δ 7.42 (d, J = 8.6 Hz, 2H), 6.94 (d, J = 8.5 Hz, 2H), 
4.03 (d, J = 17.1 Hz, 2H), 3.86 (d, J = 17.1 Hz, 2H), 3.80 (s, 3H), 2.49 (s, 3H).  
13C NMR (126 MHz, Acetonitrile-D3) δ 169.6, 161.8, 134.9, 114.5, 62.7, 55.8, 48.4.  
11B NMR (128 MHz, Acetonitrile-D3) δ 11.6. 
LCMS purity UV >99%, Ret. time = 14.36 min.  
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5-Bromo-2-methoxypheny l MIDA boronate, 55. 
 
Made following General Method B 
Yield: 318 mg (93%) as a white precipitate. 
FTMS APCI MS (m/z) found 344.0118, calcd for [C12H13B
81BrNO5H]
+ 344.0123. 
1H NMR (399 MHz, DMSO-D6) δ 7.50 – 7.45 (m, 2H), 6.91 (d, J = 9.5 Hz, 1H), 4.33 (d, 
J = 17.0 Hz, 2H), 3.99 (d, J = 17.0 Hz, 2H), 3.69 (s, 3H), 2.59 (s, 3H). 
13C NMR (100 MHz, DMSO-d6) δ 169.6, 161.7, 136.6, 133.5, 113.4, 112.8, 63.7, 55.8, 
47.8. 
11B NMR (128 MHz, DMSO-D6) δ 11.1. 
Elemental analysis CHN (%) found C: 42.25, H: 3.88 N: 4.15, calcd for 
C12H13BBrF4NO5: 40.15, H: 3.83, N: 4.10. 
 
2-Fluoro-4-(trifluoromethyl)phenyl MIDA boronate, 56. 
 
Made following General Method C 
Yield: 1.36 g (85%) as a white precipitate. 
FTMS ESI (m/z) found 337.0975, calcd for [C12H10BF4NO4NH4]
+ 337.0977. 
1H NMR (500 MHz, DMSO-D6) δ 7.78 – 7.68 (m, 1H), 7.64 – 7.52 (m, 2H), 4.50 – 4.43 
(m, 2H), 4.19 – 4.10 (m, 2H), 2.67 (d, J = 3.0 Hz, 3H), 4.51 – 4.41 (m, 2H). 
13C NMR (126 MHz, DMSO-D6) δ 169.2, 165.67 (d, 1JCF =  243.5 Hz), 136.7 (d, 3JCF = 
9.5 Hz), 132.5 (qd, 2JCF =  32.5, 
3JCF = 9.0 Hz), 123.6 (qd, 
1JCF =  272.0, 
4JCF = 3.0 Hz), 
121.35 – 121.20 (m), 112.7 (dq, 3JCF  = 29.0, 4JCF = 4.0 Hz), 63.0, 48.0. 
19F NMR (376 MHz, DMSO-D6) δ -61.46 , -103.26 – -103.40 (m). 
11B NMR (128 MHz, DMSO-D6) δ 11.1. 
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LCMS purity UV >99%, Ret. time = 17.38 min.  
 
2-Fluoro-4-methylphenyl MIDA boronate, 57. 
 
 
Made following General Method C 
Yield: 1.90 g (72%) as a white precipitate. 
HRMS-ESI (m/z) found 288.0814, calcd for [C12H13
10BFNO4Na]
+ 288.0814 
1H NMR (500 MHz, DMSO-D6) δ 7.37 (pt, 3JHH, 4JHF = 7.0 Hz, 1H), 7.02 (d, 3JHH = 7.5 
Hz, 1H), 6.95 (d, 3JHF = 11.0 Hz, 1H), 4.40 (d, J = 17.0 Hz, 2H), 4.08 (d, J = 17.0 Hz, 
2H), 2.61 (s, 3H), 2.32 (s, 3H). 
13C NMR (126 MHz, DMSO-D6) δ 169.4, 166.0 (d, , 1JCF = 240.5 Hz), 142.3 (d, 3JCF = 
8.7 Hz), 135.0 (d, 3JCF = 10.0 Hz), 125.3 (d, 
4JCF = 2.5 Hz), 115.8 (d, 
2JCF = 24.5 Hz), 
62.8, 47.9, 21.1. 
19F NMR (376 MHz, DMSO-D6) δ -106.68 (dd, J = 11.0, 7.0 Hz). 
11B NMR (128 MHz, DMSO-D6) δ 11.1. 
LCMS purity UV >99%, Ret. time = 15.90 min.  
 
 
 
 
 
 
 
 
 
 
 
B
O
N
O
O
O
F
Me
 93 
2.6. Bibliography  
 (1)  Lennox, A. J. J.; Lloyd-Jones, G. C. Chem. Soc. Rev. 2014, 43, 412–443. 
(2)  Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2007, 129, 6716–6717. 
(3)  Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2008, 130, 14084–14085. 
(4)  Colgin, N.; Flinn, T.; Cobb, S. L. Org. Biomol. Chem. 2011, 9, 1864–1870. 
(5)  Grob, J. E.; Dechantsreiter, M. A.; Tichkule, R. B.; Connolly, M. K.; Honda, A.; 
Tomlinson, R. C.; Hamann, L. G. Org. Lett. 2012, 14, 5578–5581. 
(6)  Lee, S. J.; Gray, K. C.; Paek, J. S.; Burke, M. D. J. Am. Chem. Soc. 2008, 130, 466–
468. 
(7)  Woerly, E. M.; Struble, J. R.; Palyam, N.; O’Hara, S. P.; Burke, M. D. Tetrahedron 
2011, 67, 4333–4343. 
(8)  Burns, A. R.; McAllister, G. D.; Shanahan, S. E.; Taylor, R. J. K. Angew. Chemie Int. 
Ed. 2010, 49, 5574–5577. 
(9)  Chan, J. M. W.; Amarante, G. W.; Toste, F. D. Tetrahedron 2011, 67, 4306–4312. 
(10)  Bryan, M. C.; Dillon, B.; Hamann, L. G.; Hughes, G. J.; Kopach, M. E.; Peterson, E. 
A.; Pourashraf, M.; Raheem, I.; Richardson, P.; Richter, D.; Sneddon, H. F. J. Med. 
Chem. 2013, 56, 6007–6021. 
(11)  Gillis, E.; Burke, M. Aldrichimica Acta 2009, 42, 17–27. 
(12)  Duncton, M. J.; Singh, R. Org. Lett. 2013, 15, 4284–4287. 
(13)  St Denis, J. D.; Scully, C. C. G.; Lee, C. F.; Yudin, A. K. Org. Lett. 2014, 16, 1338–
1341. 
(14)  Isley, N.; Gallou, F.; Lipshutz, B. H. J. Am. Chem. Soc. 2013, 135, 17707–17710. 
(15)  Knapp, D. M.; Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2009, 131, 6961–6963. 
(16)  Nakhla, J. ChemFiles 2009, 9, 1–10. 
(17)  Mancilla, T.; Contreras, R.; Wrackmeyer, B. J. Organomet. Chem. 1986, 307, 4–
 94 
6. 
(18)  Burke, M.; Dick, G.; Knapp, D. METHODS FOR FORMING PROTECTED 
ORGANOBORONIC ACIDS. US 2011/0201806 A1, 2011. 
(19)  Bagutski, V.; Del Grosso, A.; Carrillo, J. A.; Cade, I. A.; Helm, M. D.; Lawson, J. R.; 
Singleton, P. J.; Solomon, S. A.; Marcelli, T.; Ingleson, M. J. J. Am. Chem. Soc. 
2013, 135, 474–487. 
(20)  Grob, J. E.; Nunez, J.; Dechantsreiter, M. a; Hamann, L. G. J. Org. Chem. 2011, 76, 
4930–4940. 
(21)  Ahn, S.-J.; Lee, C.-Y.; Cheon, C.-H. Adv. Synth. Catal. 2014, 356, 1767–1772. 
(22)  Kappe, C. O. Angew. Chemie Int. Ed. 2004, 43, 6250–6284. 
(23)  Spencer, J.; Baltus, C. B.; Patel, H.; Press, N. J.; Callear, S. K.; Male, L.; Coles, S. J. 
ACS Comb. Sci. 2011, 13, 24–31. 
(24)  Gronnow, M. J.; White, R. J.; Clark, J. H.; Macquarrie, D. J. Org. Process Res. Dev. 
2005, 9, 516–518. 
(25)  Mésangeau, C.; Yous, S.; Pérès, B.; Lesieur, D.; Besson, T. Tetrahedron Lett. 
2005, 46, 2465–2468. 
(26)  Muzart, J. Tetrahedron 2009, 65, 8313–8323. 
(27)  Material Safety Data Sheet, S.-A. Material Safety Data Sheet, 2014, 271004. 
(28)  Material Safety Data Sheet, S.-A. Material Safety Data Sheet, 2014, D4551. 
(29)  Jessop, P. G. Green Chem. 2011, 13, 1391–1398. 
(30)  Chen, J.; Spear, S. K.; Huddleston, J. G.; Rogers, R. D. Green Chem. 2005, 7, 64–
82. 
(31)  Herrero, M. A.; Kremsner, J. M.; Kappe, C. O.; Graz, K. V; Graz, A. J. Org. Chem. 
2008, 73, 36–47. 
(32)  Hayden, S.; Damm, M.; Kappe, C. O. Macromol. Chem. Phys. 2013, 214, 423–
434. 
 95 
(33)  Obermayer, D.; Damm, M.; Kappe, C. O. Org. Biomol. Chem. 2013, 11, 4949–
4956. 
(34)  Close, A. J.; Kemmitt, P.; Emmerson, M. K.; Spencer, J. Tetrahedron 2014, 70, 
9125–9131. 
(35)  Close, A. J.; Corden, V.; Spencer, J. Use of a camera to monitor reaction stirring 
and reagent dissolution during a reaction; a MIDA boronate library 
generation case study. 
http://www.cemmicrowave.co.uk/assets/cameramida-boronate---app-
note.pdf (accessed Nov 15, 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 96 
3 Electrophilic Aromatic Substitution 
3.1 Overview  
The aim of this Chapter is to produce novel tetrasubstituted aromatic compounds using a 
scalable methodology.  The initial study will be based around the nitration of three 
different regioisomers of bromofluorobenzaldehyde. The later studies will involve the 
electrophilic aromatic substitution (nitration and bromination) of tri and di substituted 
phenyl MIDA boronates, with the hypothesis that the MIDA boronates functionality will 
be able to withstand the harsh reaction conditions.  
3.2 Introduction  
Historically, electrophilic aromatic substitution is the principal way of synthesising 
polyfunctionalised aromatic compounds. The review in the introduction (0) highlights the 
different techniques other than electrophilic aromatic substitution used to synthesise 
polyfunctionalised aromatic compounds. Due to the need for high scalability, 
electrophilic aromatic substitution was the focus of this project to achieve bromination 
and nitration, forming tetrasubstituted aromatics.  
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Synthesizing tetrasubstituted aromatics via nitration chemistry has been achieved before 
as outlined in Scheme 3.1. Equations 1 and 2 show two examples from patents on the use 
of nitric acid in sulphuric acid to perform nitration.1,2 Note that equation 1 has a much 
faster reaction time due to the large excess of nitric acid. The use of potassium nitrate in 
sulphuric acid is a standard method for nitration, as used by Gaster et al. in the synthesis 
towards 5-HT1B (5-hydroxytryptamine, serotonin) receptor agonists (Scheme 3.1 
equation 3).3 This method produces the nitric acid in situ from the potassium nitrate. This 
is advantageous as nitric acid is sold in approximate concentration (≈ 69%) and so allows 
for more accurate stoichiometry.  
 Nitronium tetrafluoroborate is also used to perform nitrations, having the advantage of 
being milder and that it can be added stoichiometrically. Raitio et al used nitronium 
tetrafluoroborate to synthesize 3-hydroxy-4-methoxy-2-nitrobenzaldehyde as an 
Scheme 3.2. Nitronium tetrafluoroborate use in nitration.  
Scheme 3.1. Tetrasubstituted aromatics formed via nitration.  
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intermediate towards a series of CB2 cannabinoid receptor ligands (Scheme 3.2 and 
Scheme 1.9).4 They used NO2BF4 as it improved regioselectivity; using standard nitric 
acid in sulphuric acid only gave a 10 % yield of 3-hydroxy-4-methoxy-2-
nitrobenzaldehyde. 
Werner-type transition-metal complexes have been used as catalysts for nitration by 
Abdulla et al, which were performed in DCM using one equivalent of 69 % nitric acid.5 
In this work they showed that stoichiometric Mn(acac)3 gave the best results for 
deactivated arenes, in particular using the conditions as shown in Scheme 3.3.  
Nitration using microwave-assisted synthesis has been achieved using different metal 
nitrates. Bose et al. used calcium nitrate in glacial acetic acid with microwave heating to 
perform nitrations on different phenols (Scheme 3.4).6 In a similar microwave-mediated 
method Ghalsasi et al. nitrated phenol using copper (II) nitrate in acetic acid.7 This work 
gave a mixture of ortho- and para-nitrophenol with low regioselectivity. 
Scheme 3.4. Calcium nitrate nitrations performed in a microwave.  
Scheme 3.3. Mn(acac)3 nitrations.  
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The use of NBS in electrophilic aromatic bromination reactions is standard practice due 
to its ease of handling and the formation of the moderately inert succinimide as by-
product.8 Dolbier et al. published a procedure for the bromination of deactivated 
compounds using NBS in a mixture of trifluoroacetic acid (TFA) with the addition of  a 
catalytic amount of sulphuric acid.9 Saiganesh et al. have used a protocol for bromination 
similar to that of Dolbier’s method where sulphuric acid is used as a solvent, rather than 
an additive (Scheme 3.5).10  
Bovonsombat et al. showed that using NBS in MeCN with p-toluenesulfonic acid (PTSA) 
gave high selectivity in the bromination of phenols.11 It should be noted that in this 
publication they reported similar results using sulphuric acid as the catalyst in place of 
PTSA. This work produced an array of diverse ortho- and para-substituted phenols in 
high yields, some of which some are shown in Scheme 3.6. 
In 2010 Wang et al. published two papers both outlining the use of gold (III) chloride as 
a Lewis acid catalyst in the bromination of aromatic compounds using NBS in 1,2-
dichloroethane. Wang’s first paper showed the bromination of substituted aromatic 
Scheme 3.5. Saiganesh et al.’s protocol for bromination. 
Scheme 3.6. Bromination of phenols with PTSA, NBS. 
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compounds.8 The second publication described the bromination of substituted phenyl 
boronic acid pinacol esters (Scheme 3.7).12  
Hall et al. also in 2010 demonstrated direct bromination and iodination of phenyl boronic 
acids using silver(I) sulphate and one equivalent of respective neat halogen in ethanol 
(Scheme 1.11).13 As with Wang’s research, Hall has only produced results with activated 
systems and showed that the presence of deactivating groups on the aromatic ring lowered 
yields and inhibited the reactions. 
Tanemura et al. combined NBS with iron(III) chloride or ammonium nitrate, in either 
catalytic or stoichiometric quantities, to afford a wide range of brominated products.14 
Their reactions were high yielding on both activated and deactivated aromatics. They 
found that iron(III) chloride gave better results comparatively when deactivated arenes 
were the target substrate (Scheme 3.8).  
   
Scheme 3.7. Bromination with gold (III) chloride.                                        
Reaction conditions: a 1eq NBS, rt, 6 h. b 40 °C, 6 h. c 70 °C, 24 h. d 80 °C, 48 h. 
Scheme 3.8. Bromination with NO3NH4 or FeCl3.                             
Reaction conditions: a NO3NH4 10 mol%, rt, 10 min. b NO3NH4 10 mol%, 
60 °C, 8 h. c FeCl3 1 eq, 150 °C, no solvent, 2 h. d FeCl3 1 eq, 100 °C, 7 h. 
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Bedford et al. synthesised a variety of different ortho-bromophenylanilides via ortho 
directed palladium catalysed C-H halogenation (Scheme 3.9).15 This work employed 
ether acetate or pivaloyl anilide as a directing ligand to afford high selectivity in these 
bromination reactions.   
 
In 2014 Cheon et al. showed that under mild conditions MIDA boronates can be used as 
a para-blocking group affording selective ortho electrophilic substitution, whereas the 
corresponding boronic acid or pinacol ester, quantitatively yields the ipso substituted 
isomer (Scheme 3.10).16 This demonstrates a different way to achieve selectivity with an 
Scheme 3.9. Bromination via palladium ortho C-H activation.        
Reaction conditions: a 50 °C. b 24  h. 
Scheme 3.10. MIDA boronate used as a blocking group. 
Reaction conditions: aNBS 1eq, DCM, rt, 10 min. bNBS 1eq, AgNO3 1 eq, EtCN, reflux, 3 h. ci) NaOH, 
THF, 10 min, ii) wet DMSO 100 °C, 24 h. 
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ortho para directing group. This work was published after the body of work in this 
chapter. 
Using the variety of aromatic electrophilic substitution techniques outlined above 
tetrasubstituted aromatic compounds were synthesised. This work will have particular 
implications in the use of phenyl MIDA boronates in bromination and nitration reactions. 
This is both as a protecting group of the boronic acid moiety, and also as an orthogonal 
group upon bromination, which will enable iterative palladium cross coupling reactions.   
3.3 Results and Discussion: Nitration  
3.3.1 Nitration of bromo-fluoro-benzaldehydes 
The initial aim of this project was to study nitration of three different regioisomers of 
bromo-fluoro-benzaldehydes 58, 60 and 62, focusing on finding a successful method 
amenable to scale. Methods of nitration for compounds 58 and 60 were already known as 
shown in Scheme 3.1 equations 1 and 2, although we wanted to explore milder conditions 
that would be applicable to a wider variety of substrates. This made 58 and 60 ideal 
compounds for testing different methods as 1H-NMR spectroscopic data are known from 
the literature. Several literature methods were trialled on 58, as this was predicted to give 
one regioisomer due to the directing effects (0) of all the functionalities being 
complementary to the same site of substitution.  
When compound 58 was subjected to the nitration procedure of Abdulla et al., using 
Mn(acac)3, poor results were observed (Scheme 3.11). Comparison of 58 to the 
benzaldehyde used in the original publication, showed 58 to be a more deactivated aryl 
due to the presence of the two electron-withdrawing halogen groups. This was speculated 
to be the cause of the poor result.  
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Nitration of 58 employing potassium nitrate was attempted under similar conditions to 
those of Gaster et al. (Scheme 3.11). A crude 1H NMR spectroscopic analysis revealed 
that this reaction had not gone to completion, even after being left overnight. Using an 
excess of potassium nitrate still gave low yielding results, thus different conditions were 
explored.  
Microwave synthesis using copper (II) nitrate in acetic acid was also trialled on 5-bromo-
2-fluorobenzaldehyde (60) giving poor results.7 This method resulted in no nitration of 
60 and formation of the corresponding benzoic acid derivative was observed resulting 
from the oxidation of benzaldehyde functionality (Scheme 3.11). The crude 1H-NMR 
spectrum after an ethyl acetate work up matched with a known spectrum of 5-bromo-2-
fluorobenzoic acid, also by 13C-NMR spectrum and showed the disappearance of the 
aldehyde peak.17 Copper (II) salts are known to oxidize aldehydes - for example 
Benedict’s reagent which is used to detect presence of reducing sugars.18 In the original 
protocol, the use of phenol gave much higher reactivity than compound 60. Therefore, it 
was postulated that the nitronium ion generated in this system was not strong enough to 
nitrate such a deactivated aryl. In Bose et al.’s microwave nitration method using calcium 
(II) nitrate in acetic acid they nitrated p-hydroxybenzaldehyde in 78% yield without 
oxidation of the aldehyde.6 This aryl system is much more electron rich due to π donation 
from the hydroxyl group, thus this chemistry was not attempted due to the previous two 
methods not providing encouraging results. 
Scheme 3.11. Attempted nitrations on compound 1a and 2b. 
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F
O
F
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O OH
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F
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Using nitronium tetrafluoroborate, in a similar method to that of Raitio et al., 58 was 
successfully nitrated in high yield (Table 3.1, entry 1) giving one major product, 4-
bromo-2-fluoro-5-nitrobenzaldehyde (59). We also found that adopting a protocol using 
nitric acid in sulphuric acid, akin to conditions used in Scheme 3.1 equation 1 and 2, gave 
high yielding results.  
Table 3.1. Nitration of 1a. 
a 12 mmol scale, b25 mmol scale, c 99 mmol scale. 
Comparing the nitronium tetrafluoroborate nitration protocol used on 58 (Table 3.1 entry 
1) with the nitration of 3-bromo-4-fluoro-benzaldehyde (59) under similar conditions, no 
reaction was observed after four days via TLC analysis. A crude 1H-NMR spectrum after 
work up showed a mixture of starting material and oxidized starting material to give the 
corresponding 3-bromo-4-fluoro-benzoic acid (Scheme 3.12). 5-Bromo-2-
fluorobenzaldehyde (62, Scheme 3.12) indicated no reaction under these conditions after 
four days via TLC, and this was confirmed by crude 1H-NMR spectrum analysis.  
 
Entry  Nitration Method Product Yield (%) 
1 
NO2BF4 
-20 °C – r.t, 16 h 
 
 
59 
88a 
 
 
2 
H2SO4/HNO3 
0 °C – r.t, 16 h 
59 
 
84b 
 
94c 
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5-Bromo-4-fluoro-2-nitrobenzaldehyde (61) and 3-bromo-6-fluoro-2-nitrobenzaldehyde 
(63) were successfully prepared employing the same nitric acid, nitration conditions used 
in the synthesis of compound 59 (Table 3.2, entry 1 and 2).  
Table 3.2. Bromofluoronitrobenzaldehydes formed by nitration 
a30 mm scale, b 99 mmol scale 
 
Recrystallization was found to be the most efficient purification method of crude material 
in this series of bromofluoronitrobenzaldehydes in Table 3.1 and Table 3.2. Side products 
usually consisted of small amounts of regioisomers, and were found to be inseparable via 
column chromatography. Recrystallization was achieved by dissolving the 
bromofluoronitrobenzaldehyde in the minimum amount hot of diethyl ether, with hexane. 
 
Entry Starting 
material 
Nitration Method Product Yield (%) 
1 
60 
H2SO4/HNO3 
0 °C – RT, 16 h 
61 
 
61a 
 
74b 
2 
62 
H2SO4/HNO3 
0 °C – RT, 16 h 
63 
 
30a 
 
27b 
Scheme 3.12. Attempted NO2BF4 nitration on 2a and 3a. 
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60
62
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This purification method is more applicable on a large scale than flash column 
chromatography (used in one the original patents) as it requires less solvent making it a 
greener process. Compound 61 showed slow oxidation of the aldehyde, potentially due 
to some residual acid in the sample catalysing the reaction. This led to adaption of the 
work up incorporating monitoring of the pH of the brine washings until they were no 
longer acidic. This method was implemented rather than washing with aqueous base, as 
Cannizzaro reactions are possible with the aldehyde group present.  
The synthesis of compound 63 was found to be low yielding and analysis of the crude 
1H-NMR spectrum showed one major compound (63) was present; a large number of 
overlapping smaller peaks were observed, which could not be assigned. Analysis of the 
crude reaction mixture by LCMS indicated that no residual starting material remained 
Figure 3.1. Chromatograms of reaction to synthesise 63: top chromatogram of 62, middle chromatogram of 
pure  63, bottom crude reaction mixture.  
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and 63 was the major component (Figure 3.1). It was concluded that directing groups 
present in compound 62 were not conducive with one particular site of substitution. This 
led to the lower yield due to a wide variety of side products being formed.  
Assignment of a compound’s regiochemistry was initially performed using NMR 
spectroscopy techniques. An example of this is shown for compound 59, Figure 3.2. This 
1H NMR spectrum shows 3 different proton environments and these where assigned using 
the distinct JHF coupling constants. The 9 Hz suggests a 
3JHF coupling constant whereas 
the 6.5 Hz suggests a 4JHF coupling constant, thus these were assigned to positions 2 and 
5 respectively.19 The third proton environment, 10.31 ppm (position 7), is therefore 
assigned to the aldehyde proton. This peak is 0.1 ppm downfield of the typical range of 
9.9 - 10.2 ppm,20 which is possibly due to the fluorine atom in position 8 of compound 
59. 2-Fluorobenzaldehyde also exhibits this downfield movement of its benzaldehyde 
proton, which is observed at 10.32 ppm.21 
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Figure 3.2. 1H NMR spectra of compound 59. 
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The 13C NMR spectra (Figure 3.3) is assigned for compound 59, this was done with the 
aid of 2D NMR spectroscopy. The peak at 163.9 ppm has a distinct 1JCF coupling constant 
of 269.5 Hz due to the fluorine atom at position 8, this allowed an assignment to carbon 
1. 
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Figure 3.3. 13C NMR spectra of compound 59. 
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HMQC spectrum shows correlations between connected protons and carbons (Figure 
3.5). This technique allowed simple assignment of the peaks at positions 2 (123.8 ppm), 
Figure 3.5. HMQC NMR spectra of compound 59. 
Figure 3.4. HMBC NMR spectra of compound 59. 
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5 (126.0 ppm) and 7 (183.7 ppm) due to previous assignment of the 1H NMR spectrum. 
A carbon para to a fluorine atom in an aromatic ring typically has a coupling constant of 
3.3 Hz or lower. The peak at 146.9 ppm showed no carbon fluorine coupling thus it was 
assigned to position 4, as this is the carbon para to the fluorine in compound 59 (Figure 
3.3).  
HMBC NMR spectroscopy is a 2D NMR technique showing the correlation between 
protons and carbons 2 to 4 bonds away. An HMBC NMR spectrum is shown in Figure 
3.4 for compound 59, this assisted in the assignment of the two remaining carbon peaks 
at 122.4 ppm and 123.5 ppm. The 1H peak at 10.31 ppm, previously assigned to the 
aldehyde at position 7, correlates with the 13C peak at 123.5 ppm and is therefore assigned 
to the carbon at position 6, ipso to the aldehyde. This left the remaining carbon peak at 
122.4 ppm to be assigned to position 3 on the aromatic ring.  
This NMR assignment was performed on all compounds to identify the regiochemistry 
of the major isolated products. The structures were later confirmed for compounds 59, 61 
and 63 by single crystal x-ray diffraction, shown in Figure 3.6. The crystals were 
crystallised from diethyl ether in hexane and show the expected regiochemistry for the 
products.  
 
 
 
 
 
 
Figure 3.6. ORTEP diagrams showing crystal structures of 59 (left), 61 (middle) and 63 (right). 1b is 
shown in Table 3.1, 2b and 3b are shown in Table 3.2 entry 1 and 2 respectively. Red = oxygen         
blue = nitrogen, brown = bromine, green = fluorine, grey = carbon and white = hydrogen 
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3.3.2 Arylboronic Acids  
This body of work involved an investigation of the nitration of several trisubstituted 
phenyl boronic acids and their corresponding MIDA boronates and pinacol ester 
derivatives. The preparation of pinacol boronic acid esters are simple and high yielding 
reactions, which have been well documented in the literature on different boronic acids 
and therefore posed no problems.22,23 The MIDA boronates used in the work were 
synthesized using the methods described within chapter 2 of this thesis.  
Compounds containing aryl boronic acids, MIDAs or pinacol groups were found to be 
incompatible with nitrations involving nitronium tetrafluoroborate. The use of strong 
acids on phenyl boronic acid pinacol ester caused cleavage of the pinacol group and an 
inseparable mixture of products were formed. Due to these early negative results the 
nitronium tetrafluoroborate and the pinacol-protected reagents were withdrawn from this 
study.  
3-Fluoro-4-formylphenyl boronic acid (64) and its corresponding MIDA boronate (30) 
were very acid stable and both gave products in high yields (Table 3.3 entries 1 and 2) 
using the nitric acid method described above. It is also noteworthy that the MIDA group 
also worked as a handle to aid solubility, as the MIDA dissolved with far greater ease 
than its parent boronic acid. Compound 65 required no purification after a diethyl ether 
extraction; basic washes were avoided as this could extract the boronic acid into the 
aqueous layer. The stability of MIDA boronates under these conditions was expected, as 
MIDA boronates have been shown to withstand conditions for Jones oxidation, as using 
sulphuric acid (0).24 Phenyl boronic acids have also shown high stability under very 
similar nitration conditions in the synthesis of trisubstituted aromatic compounds.25  
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Table 3.3. Boron containing compounds formed by nitration. 
a12 mmol scale, b1 mmol scale, yield calculated by 1H NMR 
 
 
Conversely the 30 regioisomer, 4-fluoro-3-formylphenyl MIDA boronate (29), nitrated 
in the 5-position (Table 3.3 entry 3) to form compound 67. This reaction was low yielding 
due to the major product being the ipso nitration of the MIDA boronate forming 2-fluoro-
5-nitrobenzaldehyde (68) (Scheme 3.13). When the reaction conditions were attempted 
on the corresponding free boronic acid 28 no nitration in the 5-position was observed, 
forming the ipso nitrated 68 exclusively, observed via 1H-NMR spectra analysis of the 
 
Entry  Starting material Nitration Method Product Yield (%) 
1 
64 
H2SO4/HNO3 
0 °C – RT, 16 h  
 
65 
88a 
 
2 
30 
H2SO4/HNO3 
0 °C – RT, 16 h 
66 
 
 
85b 
3 
29 
H2SO4/HNO3 
0 °C – RT, 16 h 
67 
 
32b 
F
BMIDA
O
O2N
O
F
B(OH)2
O2N
O
F
BMIDA
O2N
O
F
B(OH)2
O
F
BMIDA
F
BMIDA
O
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crude mixture (Scheme 3.13). Ipso nitration of boronic acids under these conditions has 
previously been observed by Soloway.25 
This publication showed that if directing effects are all complementary making the site 
of substitution ipso to the boronic acid, then nitration of this position would be observed 
over an unsubstituted position on the aromatic ring. More recently, boronic acids have 
been used for an array of inter functional group conversions, including the formation of 
hydroxyl,26,27 nitro,28,29 amine,30 and fluoro groups.31     
Cheon et al. have used MIDA boronate as a blocking group, and this might why explain 
why less ipso nitration was observed for the MIDA boronate 29, over 28 (Scheme 3.10, 
section 3.1). This is shown by the quantitative yield of 68 observed when the 
corresponding boronic acid was used (Scheme 3.13). The yield of 67 is lower than the 
similar reactions described in Cheon’s publication. This is possibly due to either the 
reaction conditions being harsher than in Cheon’s work. Alternatively the directing 
effects of the functionalities of compound 29 are not leading to high ortho selectivity with 
respect to the fluorine group. The fluorine gives higher para selectivity over ortho,29 
compared to the aniline used in their work.32,33 
2-Fluoro-4-(trifluoromethyl)phenyl (56) was nitrated under the same conditions forming 
2-fluoro-5-nitro-4-(trifluoromethyl)phenyl MIDA boronate (69) in a very high yield 
(Table 3.3 entry 4). 
Compounds 66 and 69 only required simple purification involving precipitation of a solid 
from ice. In some cases diethyl ether washes were used to remove any non-MIDA 
boronate organic impurities from the filtrate.  
Scheme 3.13 Nitrations with phenylboronic acid / MIDA boronates containing compounds.  
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Table 3.4. Boron containing compounds formed by nitration. 
a1 mmol scale, b2 mmol scale, c1 mmol scale, yield calculated by 1H NMR spectra. 
 
2-Fluoro-4-methylphenyl MIDA boronate (57) was nitrated using the standard nitric acid  
nitration method to give 2-fluoro-4-methyl-5-nitrophenyl MIDA boronate (70), Table 3.4 
entry 2). The amount of nitric acid used was decreased to 1.02 equivalents due to the 
increased reactivity of this compound due to the presence of the activating methyl group. 
 
Entry  Stating material Nitration Method Product Yield (%) 
1 
56 
H2SO4/1.02 eq 
HNO3 
0 °C – r.t, 24 h 
69 
92a 
 
2 
57 
H2SO4/ 1.02 eq 
HNO3 
0 °C – r.t, 24 h 
 70 
 
 
39b 
3 
44 
H2SO4/1.02 eq 
HNO3 
0 °C – r.t, 24 h 
71 
 
 
71c 
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Scheme 3.14. Nitration of compound 44, yield calculated by 1H NMR spectra, this also 
included 4 % 44. 
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The nitration of 2-bromo-6-fluorophenyl MIDA boronate (44) gave one main product, 2-
bromo-6-fluoro-3-nitrophenyl MIDA boronate (71, Scheme 3.14, Table 3.4 entry 3). 
Purification of this compound to remove the regioisomer, 2-bromo-6-fluoro-5-
nitrophenyl MIDA (72) boronate was unsuccessful. Recrystallization from a variety of 
solvent systems, or chromatographic purification using either normal or reverse phase, 
only achieved the separation of starting material from the crude material. Structural 
similarities between the regioisomers were proposed as the likely cause of the purification 
issues.  
Identification of the two different regioisomers via crude 1H-NMR spectra was achieved 
by measuring JHF coupling constants. Figure 3.7 highlights the different couplings and 
how they were used in assignment. Regioisomer 71 exhibits a large 3JFH coupling of 10.1 
Hz not observed in 72. 
Figure 3.7 Coupling constants in 1H-NMR shown in Hz, showing remaining compound 44. 
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3.4 Bromination  
Cheon et al. achieved the direct bromination of aryl MIDA boronates, however the 
products have never been isolated as shown above in Scheme 3.10, as the MIDA boronate 
was used as a removable blocking group.16 Kamei et al attempted the bromination of 3-
methoxyphenyl MIDA boronate using NBS in DMF, but this was reportedly unsuccessful 
due to decomposition and the formation of a complex mixture of products.34  
As with the nitration of phenyl MIDA boronates, the bromination of compound 5a was 
the first synthetic foray of this subproject. Wang et al.’s methodology was considered 
impractical for scale up, due to the use of gold(III) catalyst, making it expensive even 
with the low catalyst loading (Scheme 3.7).12 Furthermore, it was considered 
incompatible with the highly deactivated systems that were used in this project, as Wang 
worked with more activated compounds i.e. anisole, toluene, and ortho/meta/para 
xylenes. Hall et al. use of silver(I) sulphate to brominate phenyl boronic acids, would 
require MIDA protection after the bromination to allow orthogonality, in palladium cross-
couplings. Hall’s work also has only produced results with activated systems; he showed 
that the presence of a trifluoromethyl group on an aryl boronic acid inhibits bromination, 
making these methods unsuitable in this body of work. 
Deactivated arenes have been brominated using NBS by Dolbier et al using TFA with 
catalytic sulphuric acid and by Saiganesh et al. using sulphuric acid as a solvent.9,10 The 
use of TFA as a solvent would be considerably more expensive than sulphuric acid alone. 
More importantly, TFA is toxic via inhalation and harmful to aquatic life, making it 
undesirable.35,36 This, combined with the positive results from the earlier nitration studies, 
meant that the use of sulphuric acid was the preferred method of study.  
Using NBS, method the bromination of 30 was achieved, giving 2-bromo-5-fluoro-4-
formylphenyl MIDA boronate (73) in acceptable yield (Table 3.5, entry 1).  
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The bromination of compound 29 gave a mixture, including starting material and the 
product of ipso bromination Scheme 3.15. Unfortunately no ratio of products cod be 
deduced as the mixture could not be purified to give any single isolated product.   
Table 3.5. Bromination of phenyl MIDA boronates. 
 
The bromination of 56 initially gave poor yields of the product, 5-bromo-2-fluoro-4-
(trifluoromethyl)phenyl MIDA boronate (74). Saiganesh found that some substrates 
could form by-products at higher temperatures. For this reason the reaction temperature 
was adjusted to 30 °C. Despite the fact this reaction required a longer reaction time, after 
four hours total conversion was observed by TLC analysis giving an excellent yield of 
the isolated product 774 (Table 3.5, entry 2). 
Due to the availability of an array of MIDA boronates synthesised in Chapter 2, a study 
of selectivity and stability of substituted phenyl MIDA boronates was carried out. The 
first substrates for bromination were the 3-formylphenyl MIDA boronate (33) and 4-
 
Entry  Starting material Bromination Method Product Yield (%) 
1 
30 
NBS 1.2 eq, H2SO4 
60 °C, 2 h 
 
73 
54 
 
2 
56 
NBS 1.2 eq, H2SO4 
30 °C, 2 h 
 
74 
 
 
99 
CF3
BMIDA
F
O
F
BMIDA
Scheme 3.15. Bromination of compound 3a. 
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formylphenyl MIDA boronate (34), as these compounds were expected to be compatible 
with this methodology. Compound 33 was used to test the stability of the MIDA boronate 
as it would expect to undergo meta-bromination with respect to the formyl moiety. This 
would lead to either ipso-bromination of the MIDA boronate or formation of the 1,3,5-
trisubstituted aromatic compounds. These reactions (Scheme 3.16, eq) 1a and 1b) yielded 
only a small amount of crude material which was a complex mixture of compounds, at 
both 30 °C and 60 °C.  
Compound 34 would be expected to brominate to form a 1,2,4-trisubstituted aromatic 
MIDA boronate derivative. However, reaction under the sulphuric acid /NBS conditions 
at both 30 °C and 60 °C led to a mixture of inseparable compounds (Scheme 3.16, eq) 2a 
and 2b). Tanemura et al. used iron(III) chloride and ammonium nitrate in a wide range of 
NBS-mediated brominations.14 Unfortunately, attempting using these conditions on 34 
led to no reaction (Scheme 3.16, eq) 2c and 2d). Due to the lack of selectivity observed 
under conditions that did cause bromination and purification been non-trivial, the 
formylphenyl MIDA boronates were withdrawn from further work. 
3-Hydroxyphenyl MIDA boronate (37) was the next target of this investigation and the 
first bromination trialled was the sulphuric acid /NBS methodology. Taking into account 
the increased reactivity of this substrate, the reaction temperature and duration were 
Scheme 3.16. Attempted bromination conditions used on 33 and 34. 
Scheme 3.17. Attempted bromination on 3-hydroxyphenyl MIDA boronate. 
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decreased as shown in Scheme 3.17. This reaction also gave multiple products even after 
only 15 minutes. Bovonsombat et al. showed that using NBS in MeCN with p-
toluenesulfonic acid (PTSA) provided high selectivity towards para bromination of 
phenols (Scheme 3.6).11 Using this method with sulphuric acid, 37 was successfully 
brominated para to the hydroxyl group giving a high yield of 75 ( Table 3.6, entry 1). 
Sulphuric acid was used over PTSA as this made the work-up easer by a simple 
separation. Employing Bovonsombat’s protocol also produced 5-bromo-2-
methoxyphenyl MIDA boronate (76) ( Table 3.6, entry 2). 
 Table 3.6. Bromination of phenyl MIDA boronates. 
 
Entry  Starting material Bromination Method Product Yield (%) 
1 
37 
NBS 1 eq, H2SO4 0.5 
eq, MeCN, rt , 12 hr 
 
75  
 
76 
 
2 
 
47 
NBS 1 eq,  H2SO4 
0.5 eq 
MeCN, rt , 12 hr 
  76 
87 
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Using a similar procedure to that used on the phenols above test reactions were attempted 
on m-tolyl MIDA boronate (77), phenyl MIDA boronate (42), 3-fluorophenyl MIDA 
boronate (46) and 2-fluorophenyl MIDA boronate (61) (Scheme 3.18, eq) 1, 2, 3 and 4). 
All of these reactions showed poor results, under a variety of different conditions 
including increasing the amount of acid and / or altering the temperature. This shows that 
high selectivity is key in order to obtain brominated products; otherwise purification of 
the resultant mixtures is nontrivial and does not yield the desired pure product at all.  
 Bromination of 3-fluoro-4-methylphenyl MIDA boronate and 2-fluoro-4-methylphenyl 
MIDA boronate (57) became the next synthetic challenge. Initial attempts using 3-fluoro-
4-methylphenyl MIDA boronate led to multiple products, suggesting that its functionality 
did not have complementary directing effects (Scheme 3.19). However, the regioisomer 
57 gave the desired compound 5-bromo-2-fluoro-4-methylphenyl MIDA boronate (77), 
as the major product. The reaction conditions required a small amount of modification 
from those used on the phenolic compounds, to tune them to the reduced reactivity of this 
compound (Table 3.7, entry 1). The reaction temperature was increased from room 
Scheme 3.19. Attempted bromination of fluoro-4-methylphenyl MIDA boronate 
Scheme 3.18. Attempted bromination on phenyl MIDA boronates. 
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temperature to 70 °C, and the amount of sulfuric acid used was increased to one 
equivalent. In an earlier experiment it was noted that there was a small amount of side 
product formed as a result of the bromination of the benzyl methyl moiety. Excluding 
light from the reaction mixture prevented this, as these types of radical reactions have 
shown to be initiated by household fluorescent lamps.37 
Table 3.7 Bromination of phenyl MIDA boronates. 
Bedford et al. synthesised a variety of different ortho-bromophenylacetamides via ortho-
selective palladium catalysed C-H halogenation (Scheme 3.9).15 This protocol was 
employed for the bromination of acetamidophenyl MIDA boronates, except the solvent 
was changed from toluene to MeCN due the poor solubility of the MIDA boronate. 4-
Acetamidophenyl MIDA boronate (32) led to complete ipso-bromination of the MIDA 
boronate, forming N-4-bromophenylacetamide (79) in a quantitative yield (Scheme 
3.20a).  This shows that no C-H activation was achieved on this compound under these 
conditions, and that the para-substituted product was prevalent.  
3-Acetamidophenyl MIDA boronate (31) was also subjected to the ortho-selective C-H 
halogenation and in this case only para-substitution occurred leading to 5-acetamido-2-
bromophenyl (78) (Scheme 3.20b). These same conditions were also investigated using 
DMF as the solvent, giving 78 in comparable yield; hence MeCN was kept as the solvent 
of choice due to its relative ease of handling i.e. low boiling point. The reaction was also 
attempted without the palladium(II) acetate in MeCN (Scheme 3.20c); 78 was again 
 
Entry  Starting material Bromination Method Product Yield (%) 
1 
57 
NBS 1 eq, H2SO4 
0.5 eq 
MeCN, 70 °C, 12 h 
 
77 
 
 
72 
2 
31 
NBS 1 eq, PTSA 0.5 
eq 
MeCN, rt, 12 h 
 78 
60 
BMIDA
F
Me
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obtained in comparable yield (Table 3.7 entry 6). This expected due to the lack of C-H 
activation observed in the previous reaction on 78. Upon crystallization of 78 
corresponding boronic acid formed, X-ray crystallography confirmed the regiochemistry 
shown.   
 
 
 
 
 
 
 
 
 
 
Scheme 3.20. Bromination via C-H activation.  
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3.5   Conclusion  
In this chapter, twelve tetrasubstituted aromatics were synthesised, ten of which were 
novel. Furthermore, three trisubstituted phenyl MIDA boronates were synthesised via 
bromination methodology. These methods were shown to be scalable and gave the desired 
products containing orthogonal groups, with the preferred regiochemistry.  
The methodologies of direct bromination and nitration via electrophilic aromatic 
substitution of phenyl MIDA boronates described within this chapter are novel. They 
show that this masked boronic acid functionality can withstand these harsh reaction 
conditions. This work has highlighted the importance of having complementary directing 
groups, as the purification of the substituted-phenyl MIDA boronates via flash 
chromatography is nontrivial, particularly in regard to removing undesired regioisomers. 
The MIDA boronate group in these specific examples do not appear to give a directing 
effect, and the other functionalities govern reaction selectivity.  
We are now in a position to show the potential and chemical relevance of multiple 
scaffolds through exploring the orthogonal behaviour of these functional group handles 
in a range of different processes. In chapter 4 the brominated MIDA boronates are used 
in iterative Suzuki cross coupling reactions. Chapter 5 consists of multiple modifications 
on three different bromo-fluoro-nitro-benzaldehyde scaffolds to afford novel, potential 
kinase inhibitors. 
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3.6 Experimental  
Solvents and reagents were purchased from commercial suppliers and used without 
further purification. NMR spectra were recorded on a Varian 500 MHz or 400 MHz 
spectrometer. Chemical shifts are reported in ppm and are referenced to the residual 
solvent peak or to TMS used as an internal standard; note that in some cases the carbon 
bonded to the boron is not detectable in the 13C NMR23. LCMSs were ran on a Shimadzu 
LCMS-2020 equipped with a Gemini® 5 µm C18 110 Å column. Percentage purities 
were performed using a 30 minutes method in water/acetonitrile with 0.1% Formic acid 
(5min at 5%, 5%-95% over 20 min, 5min at 95%) with the UV set to 254 nm. High 
resolution mass spectrometry (HRMS) was done ether internally or by the National Mass 
Spectrometry Facility, Swansea University. A number of the products described below 
are commercially available or known, e.g. in patents. In these cases, 1H, 13C, HRMS and 
% purity data are presented since in many cases these data are not published. For 
compounds that appear to be novel, more analytical data are presented including 11B 
NMR. 
3.6.1 Nitration 
General procedure for nitration of benzaldehyde derivatives.  
A benzaldehyde derivative (12 mmol) was dissolved in sulphuric acid (98%, 25 mL) then 
cooled to 0 °C. Nitric acid (70%, 3 mL, 47 mmol) in sulphuric acid (98%, 30 mL) then 
was added drop-wise over 20 minutes maintaining the internal temperature at 0 °C. The 
mixture was allowed to warm to RT and left overnight. The mixture was poured onto ice 
(300 g). This was allowed to warm to RT and then extracted with diethyl ether (3 x 100 
mL). The combined organic layers were washed with brine. The pH of the brine washings 
was monitored until they were no longer acidic and reached pH 7. The organic layer was 
then dried (MgSO4) and evaporated under reduced pressure. 
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4-Bromo-2-fluoro-5-nitrobenzaldehyde, 59.1 
 
 
Method A 
 
The general nitration procedure was used on a 25 mmol scale and the crude material was 
recrystallised from diethyl ether/hexane to give to give title compound as a yellow 
crystalline solid. 
  
Yield: 5.13 g (84%) Analytical data are presented below. 
 
Method B 
 
Nitronium tetrafluoroborate (2.62 g, 20 mmol) was stirred at -20 °C under anhydrous 
conditions dry DCM (15 mL). A solution of 4-bromo-2-fluoro-benzaldehyde (2.50 g, 12.3 
mmol) in dry DCM (15 mL) was added drop wise over 20 minutes whilst maintaining the 
internal temperature at -20 °C. The mixture was allowed to warm to room temperature 
and left to stir over night. Water (30 mL) was added slowly to the reaction. Ethyl acetate 
(3 x 30 mL) was used to extract from the aqueous layer, then the combined organic layers 
were then washed with brine (3 x 30 mL). The organic layer was then dried (MgSO4) and 
evaporated under reduced pressure. It was then purified via flash chromatography (diethyl 
ether: hexane 2:8) to give the title compound as a yellow crystalline solid. 
 
Yield: 2.58 g (88%). 
 
Mpt: 36-39 °C. 
TLC (hexane:diethyl ether 8:2) Rf = 0.37. 
FTMS + p APCI (m/z) found 247.9357, calcd for [C7H3
79BrFNO3H]
+ 247.9353. 
1H NMR (500 MHz, CDCl3) δ 10.30 (s, 1H), 8.39 (d, 4JFH = 6.5 Hz, 1H), 7.66 (d, 3JFH = 
9.0 Hz, 1H). 
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13C NMR (126 MHz, CDCl3) δ 184.0 (d, 3JFC = 5.5 Hz), 164.2 (d, 1JFC = 269.5 Hz), 146.9 
(s), 126.2 (d, 3JFC = 4.0 Hz), 124.1 (d, 
2JFC = 25.0 Hz), 123.7 (d, 
4JFC = 10.5 Hz), 122.7 
(d, 2JFC = 11.0 Hz). 
19F NMR (376 MHz, CDCl3) δ -113.1 (dd, J = 9.0, 6.5 Hz). 
Elemental analysis CHN (%) found C: 34.00, H: 1.18, N: 5.73, calcd for C7H3BrFNO3 C: 
33.90, H: 1.22, N: 5.65. 
 
5-Bromo-4-fluoro-2-nitrobenzaldehyde, 61.2 
 
 
 
The general nitration procedure was used on a 30 mmol scale and the crude material was 
recrystallised from diethyl ether/hexane to give the title compound as an orange 
crystalline sold. 
 
Yield: 4.52 g (61%).  
Mpt: 52-55 °C. 
FTMS + p APCI (m/z) found 247.9354, calcd for [C7H3
79BrFNO3H]
+ 247.9353. 
1H NMR (500 MHz, CDCl3)
 δ 10.38 (s, 1H), 8.22 (d, 3JFH = 6.5 Hz, 1H), 7.90 (d, 4JFH = 
7.5 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 185.6, 161.4 (d, 1JFC = 260.0 Hz), 149.4, 135.4, 128.3 (d, 
4JFC = 4.0 Hz), 117.1 (d, 
2JFC = 21.5 Hz), 113.4 (d, 
2JFC = 28.0 Hz). 
19F NMR (376 MHz, CDCl3) δ -94.1 (pt, J = 7.0 Hz). 
Elemental analysis CHN (%) found C: 34.01, H: 1.23, N: 5.73, calcd for C7H3BrFNO3 C: 
33.90, H: 1.22, N: 5.65. 
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3-Bromo-6-fluoro-2-nitrobenzaldehyde, 63. 
 
 
The general nitration procedure was used on a 30 mmol scale and the crude material was 
twice recrystallised from diethyl ether/hexane to give title compound as a light yellow 
crystalline solid. 
Yield: 2.18 g (30%).  
Mpt: 71-75 °C. 
FTMS + p APCI (m/z) found 247.9357, calcd for [C7H3
79BrFNO3H]
+ 247.9353. 
1H NMR (500 MHz, CDCl3) δ 10.20 (s, 1H), 7.92 (dd, 3JHH = 9.0, 4JHF = 5.0 Hz, 1H), 
7.32 (pt, 3JHH ,
3JFH  J = 9.0 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 182.0 (d, 3JFC = 8.0 Hz), 163.2 (d, 1JFC = 263.5 Hz), 148.6 
(s), 140.4 (d, 3JFC = 9.5 Hz), 120.1 (d, 
2JFC = 22.5 Hz), 117.5 (d, 
2JFC = 12.5 Hz), 110.1 
(d, 3JFC = 4.0 Hz).  
19F NMR (376 MHz, CDCl3) δ -118.3 (dd, 3JFH = 9.0, 4JFH = 5.0 Hz). 
Elemental analysis CHN (%) found C: 33.86, H: 1.17, N: 5.57, calcd for C7H3BrFNO3 C: 
33.90, H: 1.22, N: 5.65. 
 
5-Fluoro-4-formyl-2-nitrophenyl boronic acid, 65. 
 
 
 
3-Fluoro-4-formylphenyl boronic acid (2.02 g, 12 mmol) was dissolved in sulphuric acid 
(98%, 12 mL) at rt then cooled to 0 ⁰C. Nitric acid (70%, 1.46 mL, 22 mmol) in sulphuric 
acid 98% (15 mL) was added drop-wise over 20 minutes and maintained at 0 ⁰C. The 
mixture was allowed to warm to RT and left overnight. The mixture was poured on to ice 
(150g) then was allowed to warm to RT and extracted with diethyl ether (3 x 50 mL). The 
combined organic layers were washed with brine. The pH of the brine washings was 
monitored until they were no longer acidic and reached pH 7. The organic layer was then 
 128 
dried (MgSO4) and evaporated under reduced pressure to give the title compound as a 
light yellow powder.  
 
Yield: 2.26 g (88%). 
Mpt: decomposes at 135 oC. 
HRMS-ES (m/z) found 238.0430, calcd for (ethlyglycol adduct)[C9H7O5NBF]+ 
238.0432.  
1H NMR (500 MHz, DMSO-D6) δ 10.20 (s, 1H), 8.54 (d, 4JFH = 5.5 Hz, 1H), 8.46 (s, 2H), 
7.61 (d, 3JFH  = 10.0 Hz, 1H). 
13C NMR (126 MHz, DMSO-D6) δ 186.8 (d, 3JFC = 2.0 Hz), 165.3 (d, 1JFC = 268.0 Hz), 
146.3 (d, 4JFC = 2.0 Hz), 145.1, 124.7 (d, 
3JFC = 2.0 Hz), 123.7 (d, 
2JFC = 11.0 Hz), 120.7 
(d, 2JFC = 21.5 Hz). 
19F NMR (376 MHz, DMSO-D6) δ -111.7 (dd, 3JFH = 10.0, 4JFH = 5.5 Hz). 
11B NMR (128 MHz, DMSO-D6) δ 27.8. 
Elemental analysis CHN (%) found C: 39.36, H: 2.50, N: 6.39, calcd for C7H5BFNO5 C: 
39.49, H: 2.37, N: 6.58 
 
5-Fluoro-4-formyl-2-nitrophenyl MIDA boronate, 66. 
 
 
 
3-Fluoro-4-formylphenyl MIDA boronate (250 mg, 1 mmol) was dissolved in sulphuric 
acid (98%, 1.5 mL) at rt then cooled to 0 ⁰C. Nitric acid (70%, 0.5 mL, 7.7 mmol) in 
sulphuric acid (98% 1.5 mL) was added drop-wise over 20 minutes and the reaction 
temperature was maintained at 0 °C. The mixture was allowed to warm to RT and was 
left to stir overnight. The mixture was poured on to ice (8 g); this then formed a precipitate 
was filtered under reduced pressure. The precipitate was then washed with water (3 x 10 
mL) and then cold diethyl ether (3 x 5 mL) and then oven dried (100 °C) to give the title 
compound as a light yellow powder. 
O
O
O
N
O
NO2
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O
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Yield: 275 mg (85%). 
TLC (diethyl ether:MeCN 7:3) Rf = 0.47. 
FTMS APCI (m/z) found 325.0638, calcd for [C12H10BFN2O7H]
+ 325.0638. 
1H NMR (500 MHz, DMSO-d6) δ 10.17 (s, 1H), 8.23 (d, 4JFH = 5.5 Hz, 1H), 7.67 (d, 3JFH 
= 11.0 Hz, 1H), 4.46 (d, J = 17.5 Hz, 2H), 4.25 (d, J = 17.5 Hz, 2H), 2.89 (s, 3H). 
13C NMR (126 MHz, DMSO-d6) δ 187.0 (d, 3JFC = 3.5 Hz), 169.2, 163.4 (d, 1JFC = 264.7 
Hz), 151.4 (d, 4JFC = 2.5 Hz), 125.6 (d, 
3JFC = 3.0 Hz), 125.2 (d, 
2JFC = 11.0 Hz), 125.0 
(d, 2JFC = 21.5 Hz), 64.8, 49.9.  
19F NMR (376 MHz, DMSO-d6) δ -114.38 (dd, 3JFH = 11.0, 4JFH = 6.0 Hz). 
11B NMR (128 MHz, DMSO-d6) δ 10.1. 
LCMS purity >95 % (UV), Ret. time = 11.09 min. 
 
4-Fluoro-3-formyl-5-nitrophenyl MIDA boronate, 67. 
 
 
 
4-Fluoro-3-formylphenyl MIDA boronate (250 mg, 1 mmol) was dissolved in sulphuric 
acid (98%, 1.5 mL) at rt then cooled to 0 °C. Nitric acid (70 %, 0.5 mL, 7.7 mmol) in 
sulphuric acid (98 %, 1.5 mL) was added drop-wise over 20 minutes and maintained at 0 
°C. The mixture was allowed to warm to RT and left overnight. The mixture was poured 
on to ice (8 g); this the formed a precipitate which was collected by vacuum filtration. 
The precipitate was then washed with water (3 x 10 mL) and then cold diethyl ether (3 x 
5 mL). This was then oven dried (100 °C) to give the title compound as a light yellow 
powder. 
 
Yield: 105 mg (32 %). 
TLC (diethyl ether:MeCN 7:3) Rf = 0.44. 
FTMS APCI (m/z) found 325.0638, calcd for [C12H10BFN2O7H]
+ 325.0638. 
O
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1H NMR (399 MHz, DMSO-d6) δ 10.28 (s, 1H), 8.44 (d, 4JFH = 7.0 Hz, 1H), 8.27 (d, 4JFH 
= 6.0 Hz, 1H), 4.40 (d, J = 17.0 Hz, 2H), 4.19 (d, J = 17.0 Hz, 2H), 2.62 (s, 3H). 
13C NMR (126 MHz, DMSO-d6) δ 187.4 (d, 3JFC = 5.5 Hz), 169.52, 156.9 (d, 1JFC = 275.5 
Hz), 139.7 (d, 3JFC = 2.5 Hz), 137.7 (d, 
2JFC = 6.5 Hz), 135.7, 125.5 (d, 
2JFC = 7.0 Hz), 
62.9, 48.5. 
19F NMR (376 MHz, DMSO-d6) δ -128.36 (s). 
11B NMR (128 MHz, DMSO-d6) δ 10.3. 
LCMS purity >99% (UV), Ret. time = 10.43 min. 
 
2-Fluoro-5-nitro-4-(trifluoromethyl)phenyl MIDA boronate, 69. 
 
 
 
2-Fluoro-(trifluoromethyl)phenyl MIDA boronate (321 mg, 1 mmol) was dissolved in 
sulphuric acid (98%, 2 mL) and cooled to 0 °C. Nitric acid (70%, 315 µL, 22 mmol) was 
added to the mixture at 0 °C, which was allowed to warm to RT and left overnight. The 
mixture was poured onto ice (20 g) and then was allowed to warm to RT forming a 
precipitate, which was collected by filtration, washed with water (3 x 50 mL) and then 
diethyl ether (10 mL). This was then dried overnight in a vacuum desiccator over CaCl2 
giving title compound as a bright yellow powder. 
 
Yield: 344 mg (92 %). 
Mpt: decomposes at 232-234oC. 
FTMS (m/z) found 381.0865, calcd for [C12H9BF4N2O6NH4]
+ 381.0864. 
1H NMR (500 MHz, MeCN-d3) δ 8.20 (d, J = 5.5 Hz, 1H), 7.65 (d, J = 9.5 Hz, 1H), 4.20 
(d, J = 17.5 Hz, 2H), 4.01 (d, J = 17.5 Hz, 2H), 2.72 (s, 3H). 
13C NMR (126 MHz, MeCN-d3) δ 168.8, 167.8 (1JFC  = 251.5 Hz), 145.0, 134.0 (d, 1JFC 
= 11.5 Hz), 127.4 (qd, 2JFC = 35.0,
 3JFC = 10.0 Hz), 122.7 (qd, 
1JFC = 272.5, 
4JFC 2.1 Hz), 
117.2 (dq, 2JFC = 32.5, 
3JFC =5.5 Hz), 63.9(s),48.8. 
19F NMR (376 MHz, MeCN-d3) δ -61.03 (s), -97.13 (dd, 3JFH = = 9.5, 4JFH =5.5 Hz). 
11B NMR (128 MHz, MeCN-d3) δ 10.13. 
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Elemental analysis CHN (%) found C: 39.49, H: 2.47, N: 7.68, calcd for C12H9BF4N2O6 
C: 39.59, H: 2.49, N: 7.70. 
2-Fluoro-4-methyl-5-nitrophenyl MIDA boronate, 70. 
 
 
2-Fluoro-4-methylphenyl MIDA boronate (530 mg, 2 mmol) was dissolved in sulphuric 
acid (98%, 6 mL) and cooled to 0 °C. Nitric acid (70%, 126 µL, 2.04 mmol) was added 
to the mixture at 0 °C, which was allowed to warm to RT and left overnight. The mixture 
was poured onto ice (10 g) and this was allowed to warm to RT forming a precipitate, 
which was collected by filtration, washed with water (3 x 50 mL) and then diethyl ether 
(10 mL). This was then dried over night in a vacuum desiccator over CaCl2 giving title 
compound as a white powder. 
 
Yield: 242 mg (39 %). 
FTMS APCI MS m/z found 381.0865, calcd for [C12H12BFN2O6H]
+ 311.0845. 
TLC (DCM:MeCN 7:3) Rf = 0.80 
1H NMR (399 MHz, DMSO-d6) δ 8.11 (d, 4JFH  = 6.0 Hz, 1H), 7.35 (d, 3JFH  = 10.0 Hz, 
1H), 4.45 (d, J = 17.5 Hz, 2H), 4.13 (d, J = 17.5 Hz, 2H), 2.68 (s, 3H), 2.56 (s, 3H). 
13C NMR (126 MHz, DMSO-d6) δ 168.7, 166.9 (d, 1JFC = 251.0 Hz), 145.1, 138.2 (d, 3JFC 
= 11.0 Hz), 131.8 (d, 3JFC = 12.0 Hz), 119.2 (d, 
2JFC = 27.5 Hz), 62.5, 47.6, 19.7. 
19F NMR (376 MHz, DMSO-d6) δ -98.29 (dd, 4JFH  = 10.0, 3JFH  = 6.0 Hz). 
11B NMR (128 MHz, DMSO-d6) δ 10.47. 
LCMS purity 95 % (UV), Ret. time = 16.29 min. 
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3.6.2 Bromination 
 
2-Bromo-5-fluoro-4-formylphenyl MIDA boronate, 73. 
 
3-Fluoro-4-formylphenyl MIDA boronate (279 mg, 1 mmol) was dissolved in sulphuric 
acid (98%, 4 mL) and the temperature was then increased to 60 °C. N-Bromosuccinimide 
(214 mg, 1.2 mmol) was added in three portions at 15 min intervals. After a further 1.5 
h, the cooled reaction mixture was poured onto crushed ice (20 g). This resulted in a white 
precipitate, which was collected by vacuum filtration. The resulting powder was purified 
by flash chromatography on silica gel (DCM:MeCN 7:3) to afford the title compound as 
a white powder. 
 
Yield: 93 mg (54%). 
Mpt: decomposes at 232-234 oC. 
TLC (DCM:MeCN 7:3) Rf = 0.53. 
FTMS APCI (m/z) found 356.9928, calcd for [C12H10B
79BrFNO5H:]
+ 356.9929. 
1H NMR (500 MHz, DMSO-d6) δ 10.15 (s, 1H), 7.97 (d, 4JFH = 6.0 Hz, 1H), 7.50 (d, 3JFH 
= 11.5 Hz, 1H), 4.46 (d, J = 17.5 Hz, 2H), 4.20 (d, J = 17.5 Hz, 2H), 2.75 (s, 3H). 
13C NMR (126 MHz, DMSO-d6) δ 187.0 (d, 3JFC = 3.5 Hz), 169.0, 161.2 (d, 1JFC = 259.0 
Hz), 133.6 (d, 3JFC = 2.0 Hz), 125.5 (d, 
2JFC = 10.0 Hz), 124.5 (d, 
2JFC = 21.0 Hz), 121.9 
(d, 4JFC = 3.0 Hz), 64.2, 48.4. 
19F NMR (376 MHz, DMSO-d6) δ -123.4 (dd, 3JFH  = 11.5,  4JFH  = 6.0 Hz). 
11B NMR (128 MHz, DMSO-d6) δ 10.4. 
Elemental analysis CHN (%) found C: 40.31, H: 2.81, N: 4.04, calcd for C12H10BBrFNO5 
C: 40.27, H: 2.82, N: 3.91. 
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5-Bromo-2-fluoro-4-(trifluoromethyl)phenyl MIDA boronate, 74. 
 
2-Fluoro-4-(trifluoromethyl)phenyl MIDA boronate (321 mg, 2 mmol) was dissolved in 
sulphuric acid (98%, 8 mL). The temperature was increased to 30 °C and then N-
bromosuccinimide (427 mg, 2.4 mmol) was added in three portions at 15 min intervals. 
After a further 4 h the cooled reaction mixture was poured on to crushed ice (20 g) 
resulting in a white precipitate, which was filtered under vacuum. This resulting white 
powder required no further purification giving the tile compound.  
 
Yield: 787 mg (99%).  
FTMS APCI MS m/z found 397.9818, calcd for [C12H9B
79BrF4NO4H]
+ 397.9817. 
TLC (DCM:MeCN 7:3) Rf = 0.72. 
Mpt: decomposes at 232-234 oC. 
1H NMR (500 MHz, MeCN-d3) δ 7.93 (d, 4JFH = 6.0 Hz, 1H), 7.51 (d, 3JFH = 10.0 Hz, 
1H), 4.16 (d, J = 17.0 Hz, 2H), 3.98 (d, J = 17.0 Hz, 2H), 2.70 (s, 3H). 
13C NMR (126 MHz, MeCN-d3) δ 168.8, 165.5 (d, 1JFC = 243.5 Hz),142.4 (d, J 3JFC = 9.5 
Hz), 133.0 (dq, 2J FC = 32.5 Hz,  
3J FC = 9.0 Hz), 123.4 (dq, 
1JFC = 272.5, 
4JFC = 2.5 Hz), 
116.8 (dq, 2JFC = 31.5,
 3JFC =  6.0 Hz), 115.0, 63.8, 48.7. 
19F NMR (376 MHz, MeCN-d3) δ -63.7 (s), -107.3 (dd, 3JFH  =10.0, 4JFH  = 6.0 Hz). 
11B NMR (128 MHz, MeCN-d3) δ 10.3 (s).  
Elemental analysis CHN (%) found C: 36.18, H: 2.30, N: 3.61, calcd for C12H9BBrF4NO4: 
36.22, H: 2.28, N: 3.52. 
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2-Bromo-5-hydroxyphenyl MIDA boronate, 75. 
 
3-Hydroxyphenyl MIDA boronate (498 mg, 2 mmol) was dissolved in acetonitrile (40 
mL), and sulphuric acid (98%, 1 mmol, 55 μL) was added to this mixture. N-
Bromosuccinimide (356 mg, 2 mmol) was added in three portions at 15 min intervals and 
the reaction was left to stir overnight at RT. The reaction mixture was evaporated directly 
on to Celite. The resulting powder was purified by flash chromatography on silica gel 
(acetonitrile: diethyl ether 10 %: 30 %) to afford the title compound as a white powder. 
 
Yield: 501 mg (76 %). 
TLC (diethyl ether:MeCN 7:3) Rf = 0.78. 
(FTMS m/z) found 327.0023, calcd for [C11H11B
79BrNO5H]
+ 327.9986 . 
1H NMR (500 MHz, Acetonitrile-d3) δ 7.41 (d, J = 8.5 Hz, 1H), 7.14 (d, J = 3.0 Hz, 1H), 
7.02 (s, 1H), 6.75 (dd, J = 8.5, 3.0 Hz, 1H), 4.11 (d, J = 17.5 Hz, 2H), 4.01 (d, J = 17.5 
Hz, 2H), 2.73 (s, 3H). 
 13C NMR (126 MHz, Acetonitrile-d3) δ 169.5, 157.0, 135.6, 124.1, 119.2, 117.8, 65.2, 
49.5. 
Elemental analysis CHN (%) found C: 40.18, H: 3.31 N: 4.46, calcd for 
C11H11BBrF4NO5: 40.29, H: 3.38, N: 4.40. 
 
5-Bromo-2-methoxyphenyl MIDA boronate, 76. 
 
2-Methoxyphenyl MIDA boronate (263 mg, 1 mmol) was dissolved in acetonitrile (40 
mL), and sulphuric acid (98%, 0.5 mmol, 28 μL) was added to this mixture. N-
bromosuccinimide (178 mg, 1 mmol) was added in three portions at 15 min intervals and 
the reaction was left to stir over night at RT. The reaction mixture was evaporated directly 
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onto Celite. The resulting powder was purified by flash chromatography on silica gel 
(acetonitrile: diethyl ether 10 %: 30 %) to afford the title compound as a white powder. 
 
Yield: 298 mg (87 %). 
TLC (diethyl ether:MeCN 7:3) Rf = 0.82. 
FTMS APCI MS m/z found 342.0123, calcd for [C12H13
79BBrNO5H]
+ 342.0141. 
1H NMR (399 MHz, DMSO-d6) δ 7.50 – 7.45 (m, 2H), 6.91 (d, J = 9.4 Hz, 1H), 4.33 (d, 
J = 17.1 Hz, 2H), 3.99 (d, J = 17.1 Hz, 2H), 3.69 (s, 3H), 2.59 (s, 3H). 
13C NMR (100 MHz, DMSO-d6) δ 169.6, 161.7, 136.6, 133.5, 113.4, 112.8, 63.7, 55.8, 
47.8. 
11B NMR (128 MHz, DMSO-d6) δ 11.1. 
Elemental analysis CHN (%) found C: 40.25, H: 3.88 N: 4.15, calcd for 
C12H13BBrF4NO5: 40.15, H: 3.83, N: 4.10. 
 
5-Bromo-2-fluoro-4-methylphenyl MIDA boronate, 77. 
 
2-Fluoro-4-methylphenyl MIDA boronate (3.69 g, 13.9 mmol) was dissolved in 
acetonitrile (70 mL), and sulphuric acid (98%, 13.9 mmol, 778 μL) was added to this 
mixture and it was then heated to 70 °C. N-Bromosuccinimide (2.72 g, 15.3 mmol) was 
added in three portions at 15 min intervals and the reaction was left to stir overnight. The 
reaction mixture was evaporated directly to dryness under reduced pressure. Water (100 
mL) was added, and this aqueous layer was extracted with 50 % ethyl acetate in acetone 
(3 x 150 mL). The combined organic layers were washed with brine (3 x 100 mL), then 
dried with MgSO4 and evaporated under reduced pressure. The resulting powder was 
dissolved in the minimum amount of DMSO and loaded on to a reversed phase flash 
chromatography column. A 0.1 % formic acid modifier was used throughout the column 
chromatography; 5 column volumes at 100 % water (removing the DMSO) then a 
gradient of 20 %-90 % acetonitrile in water was used to elute the desired product. The 
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desired samples were dried by lyophilisation to afford the title compound as a white 
powder. 
 
Yield: 3.457 mg (72 %). 
TLC (diethyl ether:MeCN 7:3) Rf = 0.69. 
(FTMS m/z) found 342.0141, calcd for [C12H12B
79BrFNO4H ]
+ 342.0143. 
1H NMR (500 MHz, DMSO-d6) δ 7.58 (d, 4JFH = 6.0 Hz, 1H), 7.20 (d, 3JFH = 10.0 Hz, 
1H), 4.41 (d, J = 17.5 Hz, 2H), 4.09 (d, J = 17.5 Hz, 2H), 2.66 (s, 3H), 2.35 (s, 3H). 
13C NMR (100 MHz, DMSO-d6) δ 169.3, 164.9 (d, 1JFC = 242.0 Hz), 141.5 (d, 3JFC = 9.5 
Hz), 138.0 (d, 3JFC = 10.0 Hz), 119.4 (d, 
4JFC = 2.5 Hz), 118.3 (d, 
2JFC = 26.5 Hz), 62.9, 
48.1, 22.8. 
19F NMR (376 MHz, DMSO-d6) δ -108.43 (dd, 3JFH = 10.0, 4JFH =6.0 Hz). 
11B NMR (128 MHz, DMSO-d6) δ 10.5. 
LCMS purity >99% (UV), Ret. time = 16.21 min. 
 
5-Acetamido-2-bromophenyl MIDA boronate, 78. 
 
 
3-Acetamidophenyl MIDA boronate (290 mg, 1 mmol) was dissolved in acetonitrile (4 
mL), and p-toluenesulfonic acid (0.5 mmol, 95 mg) was added to this mixture. N-
bromosuccinimide (185 mg, 1.04 mmol) was added in three portions at 15 min intervals 
and the reaction was left to stir over night at RT. The reaction mixture was evaporated 
directly on to celite. The resulting powder was purified by flash chromatography on silica 
gel (acetonitrile: DCM 0 %: 40 %) to afford the title compound as a white powder. 
 
Yield: 222 mg (60 %). 
TLC (DCM:MeCN 7:3) Rf = 0.57. 
(FTMS m/z) found 371.0233, calcd for [C13H14B
81BrN2O5H]
+ 371.0232. 
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1H NMR (399 MHz, DMSO-d6) δ 10.03 (s, 1H), 7.78 (dd, J = 8.5, 3.0 Hz, 1H), 7.52 (d, 
J = 3.0 Hz, 1H), 7.46 (d, J = 8.5 Hz, 1H), 4.39 (d, J = 17.5 Hz, 2H), 4.14 (d, J = 17.5 Hz, 
2H), 2.66 (s, 3H), 1.99 (s, 3H). 
13C NMR (100 MHz, DMSO-d6) δ 169.5, 168.8, 138.7, 134.0, 127.0, 122.1, 120.7, 64.3, 
48.9. 
11B NMR (128 MHz, DMSO-d6) δ 11.0. 
LCMS purity >99% (UV), Ret. time = 13.13 min. 
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4. Iterative Suzuki Cross-Couplings 
4.1. Overview 
The aim of this chapter is to demonstrate the value and orthogonal behaviour of the 
bromophenyl MIDA boronates synthesised in Chapter 3 to produce a range of 
tetrasubstituted aromatic targets. This will be performed using iterative Suzuki cross-
couplings to introduce new aromatic and heteroaromatic groups. The target was to 
produce a faster method for the anhydrous cross coupling, with the hypothesis that 
microwave heating could enhance reaction times of these iterative Suzuki cross-couplings 
reactions.   
4.2. Introduction  
 
Suzuki, Miyaura and Yamada first reported the Suzuki reaction in 1979, when they 
outlined the cross-couplings of alkenyboranes with alkenyl or aryl halides.1,2 Since then, 
Suzuki reactions have become the most used palladium catalysed cross-coupling reaction. 
Between 2001-2010 the number of publications and patents concerning Suzuki cross-
couplings by far outweighed all other cross-couplings.3   
Suzuki cross-couplings are favoured due to their mild reaction conditions, high functional 
group tolerance, wide-ranging commercial availability of precursors, lower toxicity of 
by-products than other reactions (e.g. tin in Stille reactions) and high yielding reactions 
when optimised. For these reasons the Suzuki reaction has become the principal synthetic 
pathway towards the biphenyl motif. The biphenyl motif is considered a privileged 
structure in medicinal chemistry, appearing in 4.3% of drugs in the year 2000.4 
In 1986 Mancilla employed N-methyliminodiacetic acid reacting it with boronic acids to 
form the bicyclic aryl boronic ester now known as a MIDA boronate.5 Mancilla 
demonstrated that MIDA boronates could easily be prepared from the free phenyl boronic 
acid and N-methyliminodiacetic acid in DMSO with the addition of benzene, to aid the 
azeotropic removal of water. Burke et al. in 2008 outlined the use of MIDA boronates in 
interactive Suzuki cross-couplings.6 The MIDA boronate enables iterative coupling by 
means of inhibiting transmetalation of the boron. This is due to the formation of a very 
stable dative covalent bond between the nitrogen and boron, making an sp3-hybridized 
boron.  
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Examples of Burke’s earlier work are shown in Scheme 4.1. This work shows parallels 
to peptide synthesis, as it uses coupling cycles followed by deprotection facilitating a 
second coupling. The coupling cycles in the presence of a MIDA boronate require 
anhydrous Suzuki cross-coupling conditions, as aqueous basic conditions cause the 
deprotection of the MIDA boronate. Within this first publication by Burke, his group 
achieved the first total synthesis of the natural product ratanhine, using 3 different 
protection deprotection cycles (Scheme 1.43). 
 
Different anhydrous palladium cross-coupling reactions have been achieved since this 
original publication i.e. Buchwald-Hartwig, Negishi, Sonogashira (with ethynyl MIDA 
boronate), Heck and Stille.7–12 This work is reviewed in greater depth within the 
Introduction (0).  
Scheme 4.1. Examples of Burke’s protected Suzuki cross-coupling followed by deprotection.  
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Burke also used this methodology to synthesise the terphenyl shown in Scheme 4.2.13 His 
work used a one-pot approach where the first Suzuki coupling employs anhydrous 
conditions with compound 36. This is followed by the addition of a second aryl bromide 
and water which cleaves the MIDA boronate facilitating the sequential second Suzuki 
cross-coupling. This type of reaction is known as a telescopic reaction as it enables 
multiple bond formations within one-pot.14 Telescopic reactions lower the amount of 
reagents used in both synthesis and reaction workup e.g. solvent, expensive metal 
catalysts, and so are of current interest as sustainable practices favoured in modern day 
laboratories. King Kuok’s multistep synthesis of the same terphenyl is also outlined in 
Scheme 4.2.15 Comparison of these two differing methods demonstrates the improvement 
of Burke’s methodology, in terms of the environmental impact of the synthesis i.e. less 
solvent and catalyst used.  
Xu and co-workers demonstrated the use of iridium C-H borylations of aromatic MIDA 
boronates to make a library of molecules able to do iterative Suzuki couplings (Scheme 
1.52).16 This approach made a large range of poly-functional aromatic compounds 
containing orthogonal boron species. Xu outlined the use of compound a Scheme 4.3 
which was formed via C-H activation. Compound a was used to prepare a high-
performance donor–acceptor dye (compound b, Scheme 4.3), which is used in dye-
sensitized solar cells, via a new iterative cross-couplings route (Scheme 4.3).17 
Scheme 4.2. Methods towards 1-(4''-methyl-[1,1':4',1''-terphenyl]-4-yl)ethanone. 
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Burke has recently published papers outlining the automated synthesis of different 
complex molecules using iterative cross coupling reactions. 18,19 This machine can do 
coupling, deprotection and purification cycles. Purification is enabled using a catch and 
release method, the crude MIDA boronate is passed over silica gel and immobilised onto 
the gel with 1.5 % methanol in diethyl ether. The 1.5 % methanol in diethyl ether which 
is used to elute the remaining organic impurities and then THF is used to elute the purified 
MIDA boronate.  
Figure 4.1. Examples of ligands and precatalysts used in palladium cross coupling reactions. 
Scheme 4.3. Synthesis of a high-performance donor–acceptor dye for use in dye-sensitized solar cells, 
using iterative cross-couplings. 
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The bulk of early palladium cross-coupling reactions typically used triaryl phosphines as 
ligands. These ligands are used to aid the formation of the active Pd(0) catalyst during 
the reaction, from palladium sources such as palladium acetate. Since 1998 there has been 
a large amount of development in the field of ligands that facilitate cross-couplings with 
more difficult coupling partners i.e. aryl chlorides, with higher efficiency and 
selectivity.20 Dialkylbiaryl phosphines, known as Buchwald ligands, are extensively used, 
examples of which included CyJohnPhos, SPhos, and XPhos Figure 4.1. Examples of the 
use of CyJohnPhos and SPhos are shown in Scheme 4.1 and Scheme 4.3. Buchwald 
showed examples of SPhos, and XPhos’s high activity in the coupling aryl chlorides with 
catalyst loadings below 1 mol% (Scheme 4.4).21 In this publication they also outlined 
room temperature couplings with XPhos, but the duration of these reactions was not 
disclosed.  
 
 
Buchwald later introduced a second generation precatalysts Figure 4.1.22 The XPhos Pd 
G2 in the publication showed a very high yielding, 30 min coupling of aryl chlorides at 
room temperature with 2 mol % catalyst loading. The conditions were faster than the rate 
of protodeboronation of 2-heteroaryl boronic acids, and so facilitated the coupling of 
these sensitive compounds. 
1,10-Bis(di-tert-butylphosphino) ferrocene palladium dichloride (Pd(dbpf)Cl2, or Pd-
118) is an air stable palladium precatalyst that is made up from a bidentate ferrocene 
containing phosphorus ligand, Figure 4.1. Colacot et al were the first to use Pd0118 in 
Suzuki couplings showing that aryl chlorides could be coupled with 1 mol% catalyst 
Scheme 4.4. Examples of the use of Buchwald ligands in Suzuki couplings.  
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loading.23 Moseley et al improved upon this work by demonstrating that this catalyst can 
couple sterically and electronically challenging aryl bromides, with 100% conversion 
showed by LCMS analysis after 2 hours, in acetonitrile and water at 60 °C.24 They also 
found that these conditions could be used to couple aryl chlorides. The reaction times did 
increase to 24 hours but they showed that super-heating the reaction mixture to 120 °C 
reduced reaction times to two hours. Phosphorus containing ligands still are used the 
most, but closely followed by the use of N-heterocyclic carbenes.3 
Organ et al first synthesized PEPPSI-IPr, which is a N-heterocyclic carbene palladium 
precatalyst that has shown use in Suzuki reactions.25 This publication outlined the 
coupling of aryl chlorides that showed conversions as high as 97% at 60 °C in less than 
2 hours in dioxane, with potassium carbonate. They also showed examples of room 
temperature coupling under these conditions but conversions dropped to 74%. They 
adopted the use of potassium tert-butoxide in isopropanol to regain conversion as high as 
97%. All of the ligands and precatalysts that have been discussed have become 
commercially available.  
Within this chapter the bromophenyl MIDA boronates synthesised in Chapter 3 will be 
used in anhydrous Suzuki cross-couplings followed by subsequent aqueous MIDA 
cleavage Suzuki reactions. This will be done with particular emphasise on using standard 
Schlenk line techniques.  
4.3. Anhydrous Suzuki cross-couplings.  
The aim of this chapter was to achieve iterative Suzuki cross-coupling reactions on the 
compounds synthesised via bromination in Chapter 3. The work had a particular emphasis 
on fast coupling methods that do not require the use of a glove box. The system that was 
used to optimise the Suzuki cross-coupling is shown in Scheme 4.5. This was due to 
Scheme 4.5. System used for Suzuki coupling optimisation. 
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having ready access to bromophenyl MIDA boronate, and its synthesis is quick and high 
yielding as outlined in Chapter 2. The final product in Scheme 4.5 is a known compound 
thus making its characterisation of the final product undemanding, enabling faster 
optimisation. Unlike Burke’s work, outlined in Scheme 4.2, the electronics of the 
coupling partners in both steps were chosen to be electronically unattractive coupling 
partners i.e. an electron poor 4-acetylphenylboronic acid and electron-rich 4-
bromotoluene. These more demanding cross coupling partners were chosen, as the final 
optimised conditions would be effective on a wider range of coupling partners.  
Microwave heating was trialled to reduce reaction times, as this has shown positive results 
in a number of studies.26–29 A catalyst screen of commercially available precatalysts 
commenced. Percentage conversions were calculated by LCMS comparing the bromide 
peak (36) to product peak (80).  
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Table 4.1. Precatalysts microwave optimisation.   
 
a Calculated by LCMS. Reactions performed with the bromide (0.25 mmol, 78 mg), boronic acid (1.1 eq, 28 mmol, 
45mg) all other solid components were added to a microwave vial sealed, degassed and purged with nitrogen then dry 
MeCN (1 mL) was added to the mixture. 
 
Pd 118 showed the best conversions but the reaction never proceeded to completion. A 
theory as to why the reactions never reached completion was that due to the anhydrous 
nature of these reactions the inorganic bases formed a sediment at the bottom of the 
microwave vial, which disabled stirring of the reaction. As discussed in Chapter 2 stirring 
is key to uniform heating of the reaction mixture. In the absence of adequate stirring, 
temperatures within a microwave can differ up to 30 °C between the middle and outside 
of the vessel. Due to a lack of efficient stirring, hot spots can occur within the reaction 
mixture, which could cause the decomposition of the catalyst. Unfortunately, at the time 
this research was conducted, at AstraZeneca, the microwave camera, which could have 
 
Entry Catalyst Base Time (min) Conversion (%)a 
1 XPHOS Pd G2 K3PO4 30 47 
2 XPHOS Pd G2 K3PO4 60 49 
3 SPHOS Pd G2 K3PO4 30 35 
4 SPHOS Pd G2 K3PO4 60 56 
5 PEPPIS iPr K3PO4 30 33 
6 PEPPSI-iPr K3PO4 60 40 
7 Pd 118 K3PO4 30 38 
8 Pd 118 K3PO4 60 61 
9 Pd 118 KF 60 35 
10 Pd 118 Cs2CO3 60 50 
11 Pd 118 MeONa 60 52 
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confirmed this hypothesis was not available but similar observations of sedimentation of 
low solubility materials were discussed in Chapter 2.  Considering this, the best 
conditions from Table 4.1 were attempted using thermal heating, as the stirring could be 
monitored visually throughout the reaction, as in Table 4.2.  
Table 4.2. Cross-couplings with Pd 118 using thermal heating.   
 
Reactions done with the bromide (0.25 mmol, 78 mg), boronic acid (1.1eq, 0.28 mmol, 45mg) all other solid 
components were added reaction vessel, degassed and purging with nitrogen then dry MeCN (1 mL) was added to the 
mixture and stirred for 1h. a conversion calculated by LCMS. 
Thermal heating led to higher conversion than microwave heating after 1 hour, comparing 
Table 4.1 entry 8 to Table 4.2 entry 2. Using 5 equivalents of base led to a slight 
improvement, showing no residual starting bromide. Scaling up this reaction gave a 
isolated yield of 68 % shown in Scheme 4.6, of 80.  
 
Entry Equivalents of base  Conversion (%)a 
1 5 >99 
2 3 97 
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Using these conditions an array of different coupling partners were synthesised utilising 
the compounds formed via bromination in Chapter 3, with many based on a 
tetrasubstituted aromatic core.  
The isolated yields varied from very good for example 82, to satisfactory i.e. 84. The 
conversions in these reactions had to be high, as the separation of two different MIDA 
boronate-containing species (starting material and product) proved problematic, as 
discussed in Chapter 3. Monitoring the loss of the bromide starting material via LCMS 
showed that conversions were high but the isolation of pure product proved difficult and 
this was reflected in the isolated yields. In most cases the trituration of product using ethyl 
acetate, with the addition of diethyl ether gave the pure compound, but some reactions 
Scheme 4.6. Compounds synthesised via anhydrous Suzuki cross-couplings.  
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required Burke’s catch and release method using 1.5 % methanol in diethyl ether to wash 
off by-products followed by THF to release the MIDA boronate.   
Different boronic acid coupling partners were trialled in this study, shown in Figure 4.2.  
2,6-Dimethylphenyl boronic acid (88) was used to test this coupling methodology with a 
sterically demanding substrate. This proved to be too sterically challenging as, no reaction 
was shown with either 2-bromo-5-fluoro-4-formylphenyl MIDA boronate (73) or 5-
bromo-2-fluoro-4-trifluoromethylphenyl MIDA boronate (74) even after 24 h.  LCMS 
showed no loss of either starting material or 2,6-dimethylphenyl boronic acid and no 
appearance of a new peak in either case.  3-Cyanophenyl boronic acid (89) showed no 
reaction with 73, and only a small amount of conversion when used with 74 but this was 
only a minor product and could therefore not be isolated.   
4.1. Deprotection Suzuki cross-couplings.  
Microwave heating was used for the second aqueous coupling, with Pd-118, and 
potassium phosphate. A solvent optimization study for this second stage is shown in Table 
4.3.  The conversions of the different conditions were calculated via NMR spectra after 
using a hydrophobic phase separator to remove any inorganic impurities.   
 
 
 
 
Figure 4.2 Boronic acid coupling partners that showed poor results under these conditions; left, 2,6-
dimethylphenyl boronic acid; right, 3-cyanophenyl boronic acid. 
B(OH)2 B(OH)2
N
88 89
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Table 4.3. Showing optimisation of aqueous Suzuki coupling.   
Reactions performed with the bromide (0.11 mmol, 18.8 mg), 1b (0.1 mmol, 35 mg) all other solid components were 
Solid materials added to a 10 mL microwave vial, degassed and purging with nitrogen then degassed solvent was added 
to the reactions (0.5 mL organic solvent, 0.2 mL water) this was then heated at 80 °C for 15 min. a calculated via 1H-
NMR spectra. 
  
Table 4.3 entry 1 showed the best results of the solvent systems trialled. Maintaining this 
solvent system but reducing catalyst loading as shown in entry 4, led to a lower 
conversion. These microwave conditions were used on some of the compounds 
synthesized by the anhydrous cross-coupling methodologies (shown in Scheme 4.6) with 
the resulting compounds shown in Scheme 4.7.  
 
Entry Solvent Catalyst loading (mol %) Conversion (%)a 
1 THF/H
2
O 5 >99 
2 MeCN/H2
O 5 70 
3 Dioxane/H2
O 5 56 
4 THF/H2
O 2.5 73 
Scheme 4.7. Compounds synthesised via aqueous coupling cross-conditions 
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The low yields shown in Scheme 4.7 were of concern, in comparison to the conversions 
in Table 4.3. Due to the time constraints of this project, an investigation into this could 
not proceed. Reflecting on this work, the acetyl-containing compound 80 may have not 
been the best candidate for use in optimisation even though it produced a known 
compound. A better candidate for optimisation would have included its corresponding 
formyl derivative due to observations by Moseley et al, that a formyl functionality can 
increase the reaction duration.24 Also the increased steric bulk around the bond around 
the MIDA boronate in 81 and 87 in Scheme 4.7, i.e. thiophene could have made these 
couplings more troublesome.  
This methodology led to a 15 min microwave-mediated, deprotection and cross-coupling 
method from which we synthesized four novel final compounds. This highlights that this 
approach is applicable for masking a boronic acid, to enable a late stage Suzuki reaction. 
In a medicinal chemistry context a small library has been formed and compounds are 
available to test for bioactivity. 
4.4. Conclusion  
Examples of iterative Suzuki cross-couplings were found, illustrating the potential of 
some of the tetrasubstituted aromatic compounds synthesised in Chapter 3. The iterative 
cross-couplings validate that these compounds contain orthogonal groups, meeting the 
original project aims. Following Chapter 2 through to the current chapter, demonstrates 
how complex polyaromatics with tetrasubstituted cores can be synthesised in a simple 
four-step procedure i.e. MIDA protection, bromination, anhydrous cross-coupling and 
aqueous cross-coupling. This was done using inexpensive reagents starting from 
commercially available trisubstituted boronic acids and the procedure was partially 
automated via the use of a robotic microwave unit. Due to the nature of the first anhydrous 
cross-coupling, it could not be applied to a microwave heating reaction format, as stirring 
could not be initiated.  
The Suzuki cross-coupling reactions, both anhydrous and aqueous, suffered from low 
yields, particularly the latter. In the case of the anhydrous cross-coupling, purification 
created difficulties, since isolating pure product led to low yields, even though observed 
conversions were high by analysis of LCMS data. These reactions were quicker than the 
examples reported in Xu’s or Burke’s work in the introduction of this chapter.6,17 
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The aqueous cross-coupling required further study to optimise yields in the reactions with 
tetrasubstituted compounds. Unfortunately the time constraints of this project became too 
tight to finalise this study; this would be of high priority if this project were to continue.  
4.5. Experimental  
Solvents and reagents were purchased from commercial suppliers and used without 
further purification. NMR spectra were recorded on a Varian 500 MHz or 400 MHz 
spectrometer. Chemical shifts are reported in ppm and are referenced to the residual 
solvent peak or to TMS used as an internal standard; note that in some cases the carbon 
bonded to the boron is not detectable in the 13C NMR.27 LCMSs were ran on a Shimadzu 
LCMS-2020 equipped with a Gemini® 5 µm C18 110 Å column. Percentage purities 
were performed using a 30 minutes method in water/acetonitrile with 0.1% Formic acid 
(5min at 5%, 5%-95% over 20 min, 5min at 95%) with the UV set to 254 nm. High 
resolution mass spectrometry (HRMS) was done ether internally or by the National Mass 
Spectrometry Facility, Swansea University. A number of the products described below 
are commercially available or known, e.g. in patents. In these cases, 1H, 13C, HRMS and 
% purity data are presented since in many cases these data are not published. For 
compounds that appear to be novel, more analytical data are presented including 11B 
NMR. 
General procedure for anhydrous Suzuki cross-couplings on a 1 mmol scale.  
A bromophenyl MIDA boronate (1 mmol), potassium phosphate (5 mmol, 1.06 g), Pd 
118 (5 mol %, 33 mg) and an aromatic boronic acid (1.1 mmol) were loaded into a 
reaction tube and sealed. This mixture was placed under vacuum and purged with argon 
3 times. Then dry degassed acetonitrile (5 mL) was added to this mixture to form a yellow 
suspension, this stirred mixture was then heated to 80 °C and monitored via LCMS. After 
completion of the reaction the mixture was cooled filtered though a pad of celite, which 
was then washed though with dry acetonitrile (40 mL). The combined filtrates were then 
evaporated under reduced pressure to yield crude product.  
Specific examples of purification are given below.  
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4'-Acetyl-[1,1'-biphenyl]-4-yl MIDA boronate, 80. 
 
 
The reaction was followed by LCMS and after 1h 50 min it had gone to completion. The 
crude material was triturated with ethyl acetate, and then this solid was washed with 5 
mL of cold ethyl acetate, to give the title compound as a light brown powder.  
 
Yield: 231 mg (68 %). 
(TOFMS EI+) found 350.1193, calcd for [C19H17
11BNO5]
- 350.1200. 
1H NMR (400 MHz, DMSO-D6) δ 8.04 (d, J = 8.5 Hz, 2H), 7.85 (d, J = 8.5 Hz, 2H), 7.75 
(d, J = 8.0 Hz, 2H), 7.58 (d, J = 8.0 Hz, 2H), 4.37 (d, J = 17.0 Hz, 2H), 4.15 (d, J = 17.0 
Hz, 2H), 2.61 (s, 3H), 2.57 (s, 3H). 
13C NMR (101 MHz, DMSO-D3) δ 197.4, 169.2, 144.4, 139.1, 135.6, 133.1, 128.8, 126.7, 
126.1, 61.8, 47.6, 26.7. 
11B NMR (128 MHz, Acetonitrile-D3) δ 11.21. 
LCMS purity 95% (UV), Ret. time = 16.59 min. 
 
5-Fluoro-4-formyl-2-(thiophen-3-yl)phenyl MIDA boronate, 81. 
 
 
The reaction was followed by LCMS and after 12 hours it had gone to completion. The 
crude material was triturated with ethyl acetate, and then this solid was then washed with 
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5 mL of cold ethyl acetate. This was then absorbed on to silica and loaded onto a silica 
column washed with a solution of 1.5 % methanol in diethyl ether. The compound was 
then eluted with 100 % THF, then evaporated to give the title compound.  
 
Yield: 223 mg (62 %). 
1H NMR (500 MHz, Acetonitrile-D3) δ 10.32 (s, 1H), 7.65 (d, 3JFH = 12.0 Hz, 1H), 7.61 
(d, 4JFH = 7.0 Hz, 1H), 7.45 (dd, J = 5.0, 3.0 Hz, 1H), 7.34 (dd, J = 3.0, 1.5 Hz, 1H), 7.11 
(dd, J = 5.0, 1.5 Hz, 1H), 3.88 (d, J = 17.0 Hz, 2H), 3.39 (d, J = 17.0 Hz, 2H), 2.54 (s, 
3H). 
13C NMR (126 MHz, Acetonitrile-D3) δ 187.56 (d, 3JFC = 5.0 Hz), 167.6, 162.7 (d, 1JFC 
= 258.0 Hz), 141.5, 139.0 (d, 4JFC = 4.0 Hz), 131.5, 130.0, 125.8, 124.5, 123.8 (d, 
3JFC = 
9.0 Hz), 122.2 (d, 4JFC = 20.0 Hz), 62.8, 47.8. 
19F NMR (376 MHz, Acetonitrile-D3) δ -125.61 (dd, J = 12.0, 7.0 Hz). 
11B NMR (128 MHz, Acetonitrile-D3) δ 10.84. 
LCMS purity 90% (UV), Ret. time = 16.65 min. 
 
4'-Acetyl-4-fluoro-6-(trifluoromethyl)-[1,1'-biphenyl]-3-yl MIDA boronate, 82. 
 
 
The reaction was followed by LCMS and after 2 hours the reaction had gone to 
completion. The crude material was absorbed on to silica immobilizing it and then loaded 
onto a silica column. This was washed with 1.5 % methanol in diethyl ether and then the 
compound was then eluted with 100 % THF, then evaporated to give the title compound 
as a light brown solid.  
 
Yield: 411 mg (94 %). 
FTMS APCI (m/z) found 436.0977, calcd for [C20H15BF4NO5]
- 436.0985. 
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1H NMR (500 MHz, Acetonitrile-D3) δ 8.08 – 8.02 (m, 2H), 7.59 – 7.54 (m, 2H), 7.53 – 
7.48 (m, 2H), 4.20 (d, J = 17.0 Hz, 2H), 4.02 (d, J = 17.0 Hz, 2H), 2.75 (s, 3H), 2.64 (s, 
3H). 
13C NMR (100 MHz, Acetonitrile-D3) δ 198.6, 169.0, 166.0 (d, 1JFC 243.0 Hz), 144.7, 
139.9 (d, 3JFC = 9.5 Hz), 137.6, 136.9 (dd, 
3JFC = 4.0, 
4JFC = 2.0 Hz), 131.5 (dd, 
2JFC = 
31.1, 3JFC = 9.0 Hz), 130.5 (d, 
5JFC = 1.0 Hz), 128.9, 124.5 (dd, 
1JFC = 273.5, 
4JFC =2.5 
Hz), 114.4 (dq, 2JFC = 30.0, 
3JFC = 5.5 Hz), 63.8, 48.7, 27.1. 
19F NMR (376 MHz, Acetonitrile-D3) δ -57.91 (s), -107.07 – -107.16 (m). 
11B NMR (128 MHz, Acetonitrile-D3) δ 10.72. 
LCMS purity 94 % (UV), Ret. time = 18.50 min. 
 
4-Fluoro-2'-methoxy-6-(trifluoromethyl)-[1,1'-biphenyl]-3-yl MIDA boronate, 83. 
 
 
 
The reaction was done on a 0.86 mmol scale of 3c and had gone to completion after 2 
hours. The crude material was absorbed on to silica immobilizing it and then loaded onto 
a silica column. This was washed with 1.5% methanol in diethyl ether and then the 
compound was then eluted off the column with 100% ethyl acetate, then was evaporated 
to give the title compound as a light white solid.  
 
Yield: 234 mg (64%). 
(TOFMS EI+) found 448.0942, calcd for [C19H16
11BNO5F4Na]
+ 448.0942. 
1H NMR (500 MHz, Acetonitrile-D3) δ 7.44 (d, 4JFH = 6.5 Hz, 1H), 7.37 (d, 3JFH = 10.0 
Hz, 1H), 7.32 – 7.25 (m, 1H), 7.05 – 7.02 (m, 1H), 6.98 – 6.95 (m, 1H), 6.91 – 6.85 (m, 
1H), 4.36 (d, J = 17.0 Hz, 2H), 4.11 (d, J = 17.0 Hz, 2H), 3.61 (s, 3H), 2.88 (s, 3H). 
13C NMR (126 MHz, Acetonitrile-D3) δ 167.6, 164.6 (d, 1JFC = 242.5 Hz), 157.0, 139.5 
(d, 3JFC = 9.5 Hz), 133.4, 131.4 (dd, 
2JFC = 31.0, 
3JFC = 9.0 Hz), 130.5, 129.5, 127.6, 123.4 
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(dd, 1JFC = 274.0, 
4JFC = 2.0 Hz), 119.6, 112.6 (dq, 
2JFC = 29.5, 
3JFC = 5.5 Hz), 110.7, 
62.7, 54.8, 47.5. 
19F NMR (376 MHz, Acetonitrile-D3) δ -60.32, -107.91 (dd, 3JFH = 10.0, 4JFH = 6.5 Hz). 
11B NMR (128 MHz, Acetonitrile-D3) δ 10.80. 
LCMS purity >99% (UV), Ret. time = 19.23 min. 
 
2-Fluoro-5-(thiophen-3-yl)-4-(trifluoromethyl)phenyl MIDA boronate, 84.  
 
 
The reaction was followed by LCMS and, after 1 hour, had gone to completion. The crude 
material was triturated with ethyl acetate, and then this solid was then washed with 2.5 
mL of cold ethyl acetate, to give the title compound as a white solid.  
 
Yield: 105 mg (52%). 
(TOFMS EI+) found 402.0590, calcd for [C16H13
11BNO4F4S]
+ 402.0594. 
1H NMR (399 MHz, Acetonitrile-D3) δ 7.60 (d, 4JFH = 6.5 Hz, 1H), 7.51 (d, 3JFH = 10.0 
Hz, 1H), 7.48 (dd, 3JHH = 5.0, 
4JHH = 3.0 Hz, 1H), 7.41 (d, 
4JFH = 3.0 Hz, 1H), 7.18 (d, 
3JHH = 5.0 Hz, 1H), 4.16 (d, J = 17.0 Hz, 2H), 3.98 (d, J = 17.0 Hz, 2H), 2.71 (s, 3H) 
13C NMR (100 MHz, Acetonitrile-D3) δ 169.0, 165.7 (d, 1JFC = 243.0 Hz), 140.3 (d, 3JFC 
= 9.5 Hz), 139.6, 133.0 – 132.8 (m), 131.6 (qd, 2JFC = 31.0, 3JFC = 9.0 Hz), 130.1 (d, 6JFC 
= 2.0 Hz), 126.5, 125.31 (d, 5JFC = 2.0 Hz), 124.5 (dd, 
1JFC = 273.0, 
4JFC = 3.0 Hz), 114.4 
(dq, 2JFC = 30.0, 
3JFC = 5.5 Hz), 63.8, 48.7. 
19F NMR (376 MHz, Acetonitrile-D3) δ -58.84 (s), -107.68 (dd, 3JFH = 10.0, 4JFH = 6.5 
Hz). 
11B NMR (128 MHz, Acetonitrile-d3) δ 10.81. 
LCMS purity > 99% (UV), Ret. time = 19.39 min. 
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2',4-Dimethoxy-[1,1'-biphenyl]-3-yl MIDA boronate, 85. 
 
 
The reaction was followed by LCMS and after 2 hours, had gone to completion. The 
crude material was triturated with ethyl acetate, and then this solid was washed with 5 
mL of cold ethyl acetate, to give the title compound as a white solid.  
 
Yield: 285 mg (56%). 
 (TOFMS EI+) found 408.1028, calcd for [C20H20
11BNO6K]
+ 408.1021 
1H NMR (600 MHz, Acetonitrile-D3) δ 7.66 (s, 1H), 7.61 – 7.55 (m, 1H), 7.36 – 7.29 (m, 
2H), 7.11 – 6.97 (m, 3H), 4.10 (d, J = 17.0 Hz, 2H), 3.99 (d, J = 17.0 Hz, 2H), 3.83 (s, 
3H), 3.81 (s, 3H), 2.68 (s, 3H). 
13C NMR (100 MHz, Acetonitrile-d3) δ 168.7, 161.5, 156.5, 135.5, 132.0, 130.7, 130.4, 
128.3, 120.8, 111.6, 109.8, 63.5, 55.2, 54.8, 47.3. 
11B NMR (128 MHz, Acetonitrile-D3) δ 11.95. 
LCMS purity >99% (UV), Ret. time = 17.69 min. 
 
4'-Acetyl-4-methoxy-[1,1'-biphenyl]-3-yl MIDA boronate, 86. 
 
 
The reaction was followed by LCMS and after 2 hours, had gone to completion. The 
crude material was triturated with ethyl acetate, and then this solid was then washed with 
5 mL of cold ethyl acetate, to give the title compound as a white solid.  
 
Yield: 214 mg (56%). 
(FTMS m/z) found 380.1307, calcd for [C20H19BNO6]
- 380.1311. 
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1H NMR (500 MHz, Acetonitrile-D3) δ 8.06 – 8.00 (m, 2H), 7.92 – 7.89 (m, 1H), 7.79 – 
7.73 (m, 3H), 7.10 – 7.06 (m, 1H), 4.10 (d, J = 17.0 Hz, 2H), 3.99 (d, J = 17.0 Hz, 2H), 
3.83 (s, 3H), 2.67 (s, 3H), 2.59 (s, 3H). 
13C NMR (126 MHz, Acetonitrile-D3) δ 198.5, 169.7, 163.9, 146.3, 136.5, 134.4, 130.8, 
129.9, 127.5, 111.9, 111.0, 64.6, 56.0, 48.4, 27.0. 
11B NMR (128 MHz, Acetonitrile-D3) δ 12.00. 
LCMS purity > 99% (UV), Ret. time = 16.46 min. 
 
2-Fluoro-4-methyl-5-(thiophen-3-yl)phenyl MIDA boronate, 87. 
 
 
This was followed by LCMS and after 30 minutes the reaction had gone to completion. 
The crude material was triturated with ethyl acetate, and then this solid was then washed 
with 5 mL of cold ethyl acetate, to give the title compound as a yellow solid.  
 
Yield: 202 mg (56%). 
(TOFMS EI+) found 347.0792, calcd for [C16H15
11BNO4FS]
+ 347.0799. 
1H NMR (400 MHz, DMSO-D6) δ 7.62 (dd, J = 5.0, 3.0 Hz, 1H), 7.51 (dd, J = 3.0, 1.5 
Hz, 1H), 7.36 (d, 4JFH = 7.0 Hz, 1H), 7.23 (dd, J = 5.0, 1.5 Hz, 1H), 7.07 (d, 
3JFH = 11.0 
Hz, 1H), 4.39 (d, J = 17.5 Hz, 2H), 4.08 (d, J = 17.5 Hz, 2H), 2.66 (s, 3H), 2.31 (s, 3H). 
13C NMR (101 MHz, DMSO-D6) δ 168.9, 164.5 (d, 1JFC = 241.5 Hz), 140.7, 139.2 (d, 
3JFC = 9.0 Hz), 135.8 (d, 
2JFC = 10.0 Hz), 132.0 (d, 
4JFC = 3.0 Hz), 128.9, 125.8, 123.1, 
116.5 (d, 2JFC = 25.0 Hz), 62.3, 47.6, 20.3. 
19F NMR (376 MHz, DMSO-D6) δ -109.15 – -109.25 (m). 
11B NMR (128 MHz, DMSO-D6) δ 10.59. 
LCMS purity >99% (UV), Ret. time = 18.52 min. 
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General procedure for one-pot MIDA deprotection Suzuki cross-couplings.  
The phenyl MIDA analogue (0.20 mmol), aryl bromide (0.22 mmol), potassium 
phosphate (1.00 mmol, 212 mg) and Pd-118 (0.004 mmol, 6.5 mg) were added to a 10mL 
microwave vial equipped with a magnetic stirrer and a Teflon cap. Then this mixture was 
placed under vacuum and purged with argon 3 times. Next, dry degassed THF (1 mL), 
followed by degassed water (0.4 mL) were added to this mixture to form a yellow 
solution. This reaction mixture was heated using the dynamic heating method, with the 
power set to 150 W, max pressure 300 psi, max temperature 80 °C, high stirring 
throughout and power max turned off. This method was used to hold the reaction mixture 
at 80 °C for 15 min. After cooling, sodium hydroxide solution was added (5 mL, 2 M), 
this aqueous phase was then extracted with ethyl acetate (3 x 10 mL). The combined 
organic layers were washed with brine (3 x 10 mL), and then dried with MgSO4 and 
evaporated under reduced pressure. This crude material was then absorbed on to silica 
and purified by flash chromatography.  Specific examples of flash chromatography 
mobile phases are given below.  
 
2-Fluoro-4-(pyridin-2-yl)-5-(thiophen-3-yl)benzaldehyde, 91. 
 
 
This was purified by flash chromatography on silica gel on a gradient of 0-20 % ethyl 
acetate in hexane.  
Yield: 9 mg (16%).  
(TOFMS EI+) found 284.0551, calcd for [C16H11NOFS]
+ 284.0545. 
1H NMR (500 MHz, Acetone-D6) δ 10.39 (s, 1H), 8.68 – 8.64 (m, 1H), 7.94 (d, 4JFH = 
7.0 Hz, 1H), 7.68 – 7.62 (m, 1H), 7.57 (d, 3JFH = 11.5 Hz, 1H), 7.40 – 7.36 (m, 1H), 7.36 
– 7.32 (m, 1H), 7.32 – 7.30 (m, 1H), 7.16 – 7.10 (m, 1H), 6.78 – 6.73 (m, 1H).  
13C NMR (126 MHz, Acetone-D6) δ 186.4 (d, 3JFC = 5.0 Hz), 162.9 (d, 1JFC = 258.0 Hz), 
156.7, 149.7, 147.3 (d, 2JFC = 8.5 Hz), 139.7, 135.9, 132.4 (d, 
3JFC = 3.5 Hz), 130.7 (d, 
3JFC = 2.5 Hz), 128.5, 125.7, 124.5, 123.8, 122.9, 118.3 (d, 
2JFC = 22.0 Hz). 
19F NMR (376 MHz, Benzene-D6) δ -120.15 (dd, 3JFH  = 11.5,  4JFH  = 7.0 Hz). 
LCMS purity >99% (UV), Ret. time = 19.75 min. 
 161 
5-Fluoro-2'-methoxy-2-(thiophen-3-yl)-[1,1'-biphenyl]-4-carbaldehyde, 92. 
 
 
This was purified by flash chromatography on silica gel on a gradient of 0-3 % diethyl 
ether in hexane.  
 
Yield: 20 mg (32%).  
(FTMS m/z) found 313.0690, calcd for [C18H13FO2SH]
+ 313.0693. 
1H NMR (500 MHz, Chloroform-D) δ 10.41 (s, 1H), 7.96 (d, 4JFH = 7.0 Hz, 1H), 7.36 – 
7.29 (m, 1H), 7.18 (d, 3JFH = 11.0 Hz, 1H), 7.18 – 7.11 (m, 1H), 7.13 – 7.10 (m, 1H), 7.00 
– 6.95 (m, 1H), 6.94 – 6.89 (m, 1H), 6.84 – 6.78 (m, 1H), 6.78 – 6.75 (m, 1H), 3.46 (s, 
3H). 
13C NMR (126 MHz, Chloroform-D) δ 186.8 (d, 3JFC = 6.0 Hz), 163.3 (d, 1JFC = 259.0 
Hz), 156.1, 146.1 (d, 2JFC = 9.0 Hz), 140.2, 133.5 (d, 
3JFC = 3.5 Hz), 130.6, 129.9, 129.1 
(d, 4JFC = 2.5 Hz), 128.7, 128.0, 124.5, 122.9 (d, 
3JFC = 8.5 Hz), 122.6, 120.7, 118.9 (d, 
2JFC = 21.0 Hz), 111.1, 55.2. 
19F NMR (376 MHz, Chloroform-D) δ -125.16 (dd, 3JFH  = 11.0, 4JFH  = 7.0 Hz). 
LCMS purity >99% (UV), Ret. time = 23.46 min. 
 
2-Fluoro-4-(1H-indol-5-yl)-5-(thiophen-3-yl)benzaldehyde, 93. 
 
 
This was purified by flash chromatography on silica gel on a gradient of 0-10% DCM in 
hexane.  
Yield: 17 mg (26%). 
(TOFMS EI+) found 344.0505, calcd for [C19H12NOFSNa]
+ 344.0521. 
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1H NMR (500 MHz, Acetone-D6) δ 10.36 (s, 1H), 10.35 (bs, 1H), 7.93 (d, 4JFH = 7.0 
Hz, 1H), 7.55 – 7.52 (m, 1H), 7.39 – 7.33 (m, 3H), 7.31 – 7.27 (m, 1H), 7.26 – 7.21 (m, 
1H), 6.95 – 6.90 (m, 1H), 6.71 – 6.67 (m, 1H), 6.49 – 6.45 (m, 1H). 
13C NMR (126 MHz, Acetone-D6) δ 187.3 (d, 3JFC = 5.0 Hz), 163.8 (d, 1JFC = 258.0 Hz), 
151.5 (d, 2JFC = 9.0 Hz), 141.5, 137.0, 133.4 (d, 
3JFC = 3.5 Hz), 131.5, 131.3 (d, 
4JFC = 
2.5 Hz), 129.6, 129.2, 127.0, 126.0, 124.4, 123.6, 123.4 (d, 3JFC = 9.0 Hz), 122.1, 119.4 
(d, 2JFC = 21.0 Hz), 112.0, 103.0. 
19F NMR (376 MHz, Acetone-D6) δ -125.64 (dd, 3JFH  = 11.5, 4JFH  = 7.0 Hz). 
LCMS purity 96% (UV), Ret. time = 17.28 min. 
 
2-(2-Fluoro-4-methyl-5-(thiophen-3-yl)phenyl)pyridine, 94. 
 
 
This was purified by flash chromatography on silica gel, 10% ethyl acetate in hexane.  
Yield: 26 mg (48%). 
TLC (hexane 90%: ethyl acetate, 10%) Rf = 0.48. 
(TOFMS EI+) found 270.0748, calcd for [C16H13NFS]
+ 270.0753. 
1H NMR (500 MHz, Acetone-D6) δ 8.70 – 8.67 (m, 1H), 8.02 (d, 3JFH = 8.5 Hz, 1H), 7.88 
– 7.85 (m, 2H), 7.57 (dd, J = 5.0, 3.0 Hz, 1H), 7.47 (d, J = 3.0 Hz, 1H), 7.36 – 7.32 (m, 
1H), 7.26 (dd, J = 5.0, 1.5 Hz, 1H), 7.18 (d, 4JFH = 12.5 Hz, 1H), 2.39 (s, 3H). 
13C NMR (126 MHz, Acetone-D6) δ 160.4 (d, 1JFC = 248.5 Hz), 153.8 (d, 3JFC = 3.5 Hz), 
150.7, 141.9, 139.9 (d, 3JFC = 8.5 Hz), 137.4, 134.2 (d, 
4JFC = 3.5 Hz), 132.9 (d, 
3JFC = 
3.5 Hz), 129.7, 126.4, 125.6 (d, 2JFC = 12.0 Hz), 124.9 (d, 
4JFC = 10.0 Hz), 124.0, 123.4, 
118.6 (d, 2JFC = 23.5 Hz), 20.7. 
19F NMR (376 MHz, Acetone-D6) δ -121.13 (dd, 3JFH = 12.5, 3JFH  = 8.5 Hz). 
LCMS purity >99% (UV), Ret. time = 22.27 min. 
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5. Library generation towards potential kinase inhibitors 
5.1. Overview  
The focus of this chapter was to evaluate the potential for forming bioactive molecules 
from the bromofluoronitrobenzaldehydes synthesised via nitration in Chapter 3 (Figure 
5.1). To showcase the orthogonal behaviour of the different functional groups in 
compounds 59, 61, and 63 they were elaborated via Pd-catalysed coupling, reduction and 
reductive amination reactions. As a test of hypothesis these compounds were converted 
into EGFR inhibitors related to Gefitinib.  
5.2. Introduction  
During the synthesis of compounds 59, 61, and 63 it was noted that they had potential for 
transformations towards potential kinase inhibitors. A larger review of the action and 
types of kinase inhibitors can be found in the introduction (Chapter 1).  Figure 5.2 shows 
5 examples of different EGFR kinase inhibitors.1–4 The aromatic moieties highlighted in 
blue show some of the functionality incorporated into these molecules. In the case of the 
compounds synthesised in Chapter 3, these contain complementary functionalities e.g. 
halogens and nitro groups. Vandetanib (Figure 5.2) is an example where bromides can be 
incorporated into this family of molecules. Also, one of the early lead compounds in the 
development of Gefitinib contained a bromo group (Chapter 1 Figure 1.6).5 Bromides 
also enable Sonogashira cross-coupling reactions leading to alkyne derivatives, which 
have been included in kinase inhibitors e.g. Erlotinib (Figure 5.2). This made the 
incorporation of the bromo group a multi-purpose addition. The nitro functionality, after 
reduction to an aniline, could facilitate the link to the quinazoline portion of the molecule. 
Figure 5.1. Compounds prepared via nitration. 
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The quinazoline unit of these molecules (highlighted in red, Figure 5.2) serves as a mimic 
for the purine functionality in ATP. These competitive inhibitors interact to form 1 to 3 
hydrogen bonds at the hinge of the purine-binding site.6 The quinazoline groups usually 
incorporate electron donating groups at the 6- and 7-positions, to modulate the pKa of the 
quinazoline or quinolone nitrogen atoms, making them better hydrogen bond acceptors.7 
Kinase inhibitors usually include solubilizing groups, highlighted in green.  
5.2.1. Nitro reduction  
The reduction of aromatic nitro groups can be carried out a number of ways taking into 
account the different functionalities in the molecule and under what conditions they are 
sensitive. An example is outlined in a patent, where they prepared one of the desired 
Figure 5.2. Examples of EGFR kinase inhibitors. 
Scheme 5.1. Platinum catalysis reduction of 5-bromo-4-fluoro-2-nitrobenzaldehyde. 
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compounds, 2-amino-5-bromo-4-fluorobenzaldehyde (95) by a platinum catalysed 
reduction of 5-bromo-4-fluoro-2-nitrobenzaldehyde (61) (Scheme 5.1).8 Most powered 
metal hydrogenation catalysts have an associated hazard of ignition related to their use 
e.g. platinum, palladium, nickel, or the pyrophoric Raney nickel.9 However, most of these 
materials are non-pyrophoric and in fact it is the heat associated with the exothermic 
oxidation of the finely powdered metal that causes ignition of the solvent vapours.  
A modern approach to this transformation is the use of an H-cube™, which is a flow 
reactor that generates hydrogen in situ from water. This enables the use of a large amount 
of different catalyst cartridges, safely at high temperatures.10 The H-cube™ is designed 
to heat cartridges that are packed with a catalyst with filters attached to either end of the 
casing. This design enables high mixing of reactants with catalysts and hydrogen, and 
enables safe handling of pyrophoric catalysts as it limits handling steps e.g. weighing and 
filtering.11 The suggested range of different catalysts for the selective reduction of nitro 
groups includes: 10 % Pd/C, Raney Ni (for the reduction in the presence of benzyl 
groups), 5 % Ru/C or RuO2 (both ruthenium catalysts enable reductions in the presence 
of halides).12 
Scheme 5.2. Example of iron powder reductions.  
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 Another common approach is the use of acids with metal powders e.g. zinc or iron.  
Examples of iron powder reductions are shown in Scheme 5.2. The top example is taken 
from a different patent where they produced the same product 61 using HCl as an acid 
source.13 The middle14 and bottom15 examples used acetic acid with an additional solvent 
i.e. ethanol or ethyl acetate. This methodology showed excellent functional group 
tolerance and short reactions times when heated with acetic acid.  
Examples of similar zinc reductions are shown in Scheme 5.3. The top example16 
achieves reduction using HCl, whereas the bottom example17 uses ammonium chloride 
which enables reduction of more acid sensitive compounds.   
Spencer et al. achieved nitro reduction by a microwave mediated route using 
stoichiometric molybdenum hexacarbonyl and 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) (Scheme 5.4).18,19 The microwave heating facilitates superheating of the ethanol 
Scheme 5.3. Zinc reduction of nitro group. 
Scheme 5.4. Microwave mediated reduction using molybdenum hexacarbonyl. 
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in the reaction mixture to 150 °C, which enables a fast 15-30 minute reaction, compared 
to the 24 hour reaction times of the corresponding conductive heating processes.  
5.2.2. Sonogashira coupling 
The Sonogashira reaction mechanism and some general conditions have been reviewed 
in Chapter 1. However a small review of specific examples will be included within this 
chapter.  
Erdélyi et al. published work on microwave enhanced Sonogashira cross-couplings, 
reducing reaction times to between 5 and 25 minutes (Scheme 5.5).20 Within the work 
they included reactions under room temperature conditions, to illustrate the reduction in 
reaction times.  
Scheme 5.5. Microwave mediated Sonogashira reactions (yields calculated by 1H-NMR). 
atriphenylphosphine was added, blithium chloride was added. 
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Burke et al. synthesised ethynyl MIDA boronate and outlined a selection of Sonogashira 
cross-couplings.21 Some examples of the products prepared via Sonogashira cross-
couplings are shown in Scheme 5.6. Within Burke’s work he outlined Suzuki reactions 
and different functional group inter conversions with these MIDA boronates; also Toste 
et al achieved cyclisomerization forming indoles and benzofurans.22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5.6 Sonogashira cross-couplings prepared with ethynyl MIDA boronate. 
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5.3. Results and discussion  
5.3.1. Nitro reduction  
The initial focus of the work was the reduction of the nitro group. We hoped that use of 
the H-cube flow reactor would facilitate this. Unfortunately this did not give reproducible 
results (Table 5.1).  
Table 5.1. Attempted nitro reduction optimisations using H-Cube™ 
a 
Entry 
(Substrate) 
Cat-card Solvent 
Temperature 
(°C) 
Pressure 
mode (bar) 
Conversiona 
(%) 
1 (59) Pd/C 5% THF/DCMb 50 Full H2 0e  
2 (61) Pt/C 5% THF/DCMb 50 Full H2 19 
3 (61) Pt/C 5% THF/DCMb 100 70 100 d,e 
4 (61) Pt/C 5% EtOAc 100 70 30 
5 (61) RuO2 EtOAc 20 70 100d 
6 (61) RuO2 EtOAc 60 70 70 
7 (61) RuO2 EtOAc 100 70 0f 
8 (61) RuO2c EtOAc 20 70 23e 
aConversions calculated by 1H-NMR spectra,b1:4 ratio of THF DCM,c Repeated best conditions with new 
catalysis cartridge, dresults not reproducible, emixtures of different materials not aromatic, fno benzaldehyde 
peak observed. 
 
A palladium on carbon route was trialled first for the reduction of compound 59 (Table 
5.1, entry 1) and a mixture of different compounds was observed by 1H-NMR spectra. 
 172 
This could potentially be due to palladium reacting with bromide making a complex 
mixture of side products.  
The next attempted conditions were inspired from Scheme 5.1, a literature example of the 
reduction of compound 61 with platinum on carbon.8 Optimisation of these conditions 
achieved 100 % conversion with a high purity, observed for the formation of 2-amino-5-
bromo-4-fluorobenzaldehyde (95) shown in Table 5.1 entry 3. Unfortunately the yields 
under these conditions suffered from inconsistencies. It was noted that the side product 
from these reactions was the 2,1-benzisoxazole (anthranil) analogue (97) shown in 
Scheme 5.7. Formation of 2,1-benzisoxazoles has been observed before when reducing 
nitro groups ortho to aldehydes or ketones.23 
 
Also, solvent incompatibilities with the tubing of the flow reactor caused unexpected 
peaks being observed in the aliphatic region of the 1H-NMR spectra. To remove this 
problem ethyl acetate was chosen as the solvent for future experiments with the H-cube, 
but lower yields were obtained, Table 5.1 entry 4.  
In the ThalesNano quick start guide, it was suggested that ruthenium (IV) oxide catalyst 
cartridge gave positive results when reducing nitro groups in the presence of bromo 
functionalities.12 It suggested running the ruthenium(IV) oxide catalyst at 30 °C at a 
pressure of 70 bar. Whilst maintaining the pressure at 70 bar, a range of different 
temperatures were tested. It was found at higher temperatures the benzaldehyde peak was 
no longer seen in the 1H-NMR spectrum, suggesting reduction to the corresponding 
benzyl alcohol. However lower temperatures yielded an impressive 100 % conversion, 
Scheme 5.7. Side product formed by reduction of compound (yields calculated by 1H-
NMR) 61 with platinum on carbon and X-ray structure.   
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but, as with the platinum on carbon catalyst yields for the reactions were inconsistent and 
irreproducible.  
Due to the lack of reproducibility of the H-cube, the literature method shown in Scheme 
5.1 was trialled on compound 61 (Scheme 5.8). This method gave poor results when 
analysed via crude 1H-NMR spectra. The attempted microwave heated nitro reduction 
with molybdenum hexacarbonyl (Scheme 5.8) also gave poor results, as crude 1H-NMR 
spectra analysis showed a large amount of different aromatic peaks, none of which 
corresponded to the product.   
Adopting a literature iron reduction protocol achieved the reduction of 61, shown in 
Scheme 5.9.24 Iron reduction with HCl to form compound 95, has been achieved in a 
patent before, see top example of Scheme 5.2.13  
Using the iron in acetic acid also produced compound 2-amino-3-bromo-6-
fluorobenzaldehyde (98) in a high yield (Scheme 5.9).  
Scheme 5.8. Attempted nitro reductions of 61. 
Scheme 5.9. Results from iron reduction, on compound 62 and 63. 
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The reduction of compound 4-bromo-2-fluoro-5-nitrobenzaldehyde (59) was not trivial. 
The iron powder in acetic acid reductions that yield compounds 95 and 98 produced an 
inseparable mixture of compounds according to 1H-NMR spectra analysis of the crude 
product, Scheme 5.10.  This led to several different methods being attempted (i.e. iron/ 
hydrochloric acid, zinc/ hydrochloric acid, zinc/ammonium chloride and platinum on 
carbon/ hydrogen), none of which yielded the desired product, Scheme 5.10.   
 
Due to the demanding nature of compound 59 it was decided to continue down the 
planned path and attempt the nitro reduction at a later stage in the synthesis.   
 
 
 
 
 
 
 
 
 
 
Scheme 5.10. Attempted nitro reductions on compound 59. 
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5.3.2. Sonogashira coupling 
The microwave conditions highlighted in Scheme 5.5 were trialled on compound 2b; after 
30 minutes of heating at 80 °C the reactions only showed starting material by LCMS 
analysis.  
Standard conductive heating was attempted next, which yielded the product shown in 
Table 5.2.  
Table 5.2. Compounds synthesised via thermal Sonogashira reactions. 
a 
Entry Starting material Product Yield (%) 
1  
59 99 
66a 
2  
95 100 
45 
3 
98 101 
74 
a reaction ran at rt for 1 hour.  
Table 5.2 entries 1 and 3 showed good yields, better than that of entry 2, which had poor 
yields due to the purification, as the compound could only be purified via reversed phase 
chromatography. The temperature of the reactions needed adjustment in the case of Table 
5.2 entry 1 as it was found that the reactions gave better yields if left for 1 hour and not 
heated above room temperature. This was probably due to the bromide in compound 59 
being more activated because the nitro group was present. 
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Synthesising ethynyl MIDA boronate using Sonogashira cross-couplings similar to those 
shown in Scheme 5.6, was attempted on compounds 59, 95 and 98. Compounds 59 and 
98 both gave the desired the product and in the case of 98 high yields were observed, 
Table 5.3.  
 
Table 5.3. Compounds synthesised Sonogashira reactions with ethynyl MIDA boronate. 
a 
Entry Starting material Product Yield (%) 
1 
 59 102 
38 
2 
98 103 
86 
 
Compound 95 gave positive results according to 1H-NMR spectra, but could not be 
purified, due to poor solubility of the compound in a range of solvents.  
5.3.3. Reductive amination  
Solubilising groups were added to the aromatic core via reductive aminations of the 
aldehyde. Sodium triacetoxyborohydride (STAB) is a mild reducing reagent that can be 
used in a simple one-pot procedure; it is one of the most convenient methods and 
considered the method of choice.25,26 The STAB method was applied to some of the 
compounds that have been discussed previously, either morpholine or tert-butyl 
piperazine-1-carboxylate (1-Boc-piperazine) as the amines, shown in Table 5.4. 
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Table 5.4. Compounds formed by reductive aminations. 
a 
Entry Starting material Product Yield (%) 
1e 
 59 
 
104 
47a 
77b 
2f 
95 
 
105 
83a 
91c 
3f 
95 
 
106 
97a 
4e 
98 107 
82a 
95d 
5e 
98 108 
95a 
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6e 
101 109 
28a 
7e 
101 110 
63a 
a 0.5 mmol scale, b 8 mmol scale, c 3 mmol scale, d 6.3 mmol scale, e 2 eq of STAB, f 2.5 eq of STAB.   
 
Yields throughout Table 5.4 are high with the exception of entries 6 and 7. These 
reactions showed improved yield when reactions were scaled up and in the case of entry 
1 compound 104 was prepared on an 8 mmol scale producing 2.5 g of product.  
At this point the nitro reduction of compound 104 could be achieved using a zinc 
ammonium chloride mixture. Under these conditions the nitro group was successfully 
reduced forming compound 111 without BOC deprotection, Scheme 5.11. This formed 
the missing aniline required for formation of the linker to the quinazoline unit.  
Scheme 5.11. Zinc reductions of compound 104. 
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To show the utility of these compounds a Clauson-Kaas pyrrole synthesis under 
microwave conditions was achieved on compound 107 (Scheme 5.12). To our surprise 
the BOC protecting group withstood these harsh acid conditions and gave the product 112 
in a high yield. Microwave conditions for this pyrrole synthesis have been published and 
have been shown to be quick and high yielding.27,28 This highlights the different chemical 
processes that can be selectively achieved with these compounds.  
 
5.3.4. Reactions with 4-chloro-6,7-dimethoxyquinazoline  
This next step involved linking the 4-chloro-6,7-dimethoxyquinazoline unit via the 
aniline functionality incorporated in the tetrasubstituted aromatic compounds synthesised 
in this Chapter. We chose this quinazoline as a representative privileged kinase inhibitor 
core in order to exemplify the application of this methodology. It was not our intention 
to perform a drug discovery project, since at its onset we were not guaranteed any 
biological feedback. Moreover our target compounds were high molecular weight and 
non-Lipinski like.  
As some of the aromatic compounds synthesised contained a 1-Boc-piperazine moiety, 
methods of linking the quinazoline unit involving acidic conditions were avoided e.g. 
Spencer et. al.29 There are also literature methods that achieve the formations of the linker 
via heating the aniline with the 4-chloro-6,7-dimethoxyquinazoline using microwave 
heating in isopropyl alcohol, or acetonitrile.30,31 Trialling this acetonitrile method gave 
very poor results according to 1H-NMR spectra analysis of the crude reaction mixture.  
It was found that adopting a synthesis from a patent, where by sodium 
bis(trimethylsilyl)amide (NaHMDS) was employed to deprotonate the aniline, yielded 
the desired products.32 Table 5.5 show the compounds synthesised via this methodology. 
Scheme 5.12. Clauson-Kaas pyrrole synthesis under microwave conditions on compound 3e. 
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Table 5.5. Linking of the quinazoline unit. 
a 
Entry Starting material Product 
Yield 
(%) 
1 
 111 
113 
48 
2 
105 
114 
42  
3 
107 115 
72 
 
In the case of compound 114purification by column chromatography did not yield pure 
product and this compound required an additional recrystallization, from a minimum 
amount of ethyl acetate, which led to a lower yield.  
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5.3.5. BOC deprotection and late stage modification to piperazine 
The removal of the BOC protecting group would enable further functionalization of the 
compounds from the newly formed secondary amine of the piperazine. The BOC group 
was successfully removed in good yields using 4 M hydrochloric acid in 1,4-dioxane (Table 5.6).  
Table 5.6. Showing yields for BOC cleavage step. 
 a
Entry Starting material Product 
Yield 
(%) 
1 
 1f 1g 
84 
2 
2f  
2g 
55  
3 
3j  3k 
72 
 
The compounds synthesised in Table 5.7 were then functionalised at the newly 
deprotected secondary amine. These reactions were achieved by adding an acid chloride 
and N,N-diisopropylethylamine (DIPEA) and results are shown in Table 5.7. 
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Table 5.7. Functionalization of the piperazine unit.  
a 
Entry Starting material Product 
Yield 
(%) 
1 
116 
119 
63 
2 
117 
120 
99  
3 
117 
121 
98 
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The modifications where higher yielding with 2g as the both entries 2 and 3 gave yields 
of 99% and 98% respectively.  
5.4. Biological data  
Nine of the compounds synthesised in this Chapter were sent to AstraZeneca for assay 
testing activity in inhibiting EGFR in wild type cells. The results  and starting substrate 
are shown in Table 5.8. 
These results show that the compounds containing a BOC protecting group had low 
activity with the best activity shown by 115, which had an IC50 of 21.5 µM. The 
compounds derived from 59, i.e. 113, 116 and 119, showed the lowest activity of 3 
different precursors. The most active compound was 117, which gave an IC50 of 18.4 nM. 
All of the compounds in series 61 gave good results i.e. all IC50’s were less than 1 µM, 
with the exception of the BOC protected compound 114.  
Unfortunately the percentage hERG inhibition increased as the activity of the compounds 
improved. There are ways in which to design out hERG inhibition e.g. reducing 
lipophilicity, reducing the pKa of the nitrogen atoms, increasing steric constraints around 
nitrogen atoms or decreasing the number of hydrogen bond acceptors.34 These would be 
considered in future work. 
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Table 5.8. EGFR wild type cell assay IC50.33 
aEGFR Ex20 WT HTRF CR GMean IC50 (µM), bhERG Hu CHO IF EPhs SS GD mean, at 10 M.
Compounds synthesised from 61 
 
Compounds synthesised from 63 
 
Compounds synthesised from 59 
 
Compound EGFR IC50a hERG inhibition (%)b Compound EGFR IC50a hERG inhibition (%)b Compound EGFR IC50a hERG inhibition (%)b 
117 
0.0184 61.1 
118 
0.935 44.5 
116 
>21.3 33.7 
121 
0.377 96.5 
115 
21.5 21.5 
113 
27.1 46.4 
120 
0.546 55.6    
119 
>30 43.9 
114 
>30 19.5 
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5.5. Conclusion  
The elaboration of the bromofluoronitrobenzaldehydes synthesised via nitration in 
Chapter 3 (Figure 5.1.) has led to an EGFR kinase inhibitor that has IC50 of 18.4 nM 
(117). This proves the hypothesis that these tetrasubstituted building blocks have the 
potential to be EGFR inhibitors when incorporated into bioactive scaffolds. Although this 
compound did have a high hERG inhibition, this could be designed out of molecules as 
discussed in Section 5.4. 
A vast amount of orthogonal chemistry modifications has been done on compounds 59, 
61 and 63 e.g. nitro reduction, Sonogashira couplings, reductive aminations, Clauson-
Kaas pyrrole, and the linking of these aromatics to 4-chloro-6,7-dimethoxyquinazoline 
unit  forming novel potential kinase inhibitors. This shows how 59, 61 and 63 fit the brief 
of including orthogonal of set by AstraZeneca. This demonstrates how these complex 
building blocks can be manipulated to form novel interesting compounds in a small 
amount of steps. Although some of the perceived simpler manipulations were not as 
trivial as anticipated, e.g. the nitro reduction of 59, many problems were overcome by 
postponing this until a later stage in the synthetic sequence.  Uniquely, these products 
appear to show that a water solubilising piperazine group, as in 116, can possibly be 
incorporated a hydrophobic pocket of a kinase although this would need an X-ray co-
crystal structure to confirm this. 
5.6. Experimental  
Solvents and reagents were purchased from commercial suppliers and used without 
further purification. NMR spectra were recorded on a Varian 500 MHz or 400 MHz 
spectrometer. Chemical shifts are reported in ppm and are referenced to the residual 
solvent peak or to TMS used as an internal standard. LCMSs were ran on a Shimadzu 
LCMS-2020 equipped with a Gemini® 5 µm C18 110 Å column. Percentage purities 
were performed using a 30 minutes method in water/acetonitrile with 0.1% Formic acid 
(5 min at 5%, 5%-95% over 20 min, 5min at 95%) with the UV set to 254 nm. High 
resolution mass spectrometry (HRMS) was done ether internally or by the National Mass 
Spectrometry Facility, Swansea University. A number of the products described below 
are commercially available or known, e.g. in patents. In these cases, 1H, 13C, HRMS and 
% purity data are presented since in many cases these data are not published. 
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2-Amino-5-bromo-4-fluorobenzaldehyde, 95.8 
 
5-Bromo-4-fluoro-2-nitrobenzaldehyde (2.678 g, 10.8 mmol) and iron powder (1.819 g, 
32.4 mmol) were added to a round-bottomed flask, this was purged with argon for 5 min. 
Ethanol (16 mL) followed by acetic acid (16 mL) were added and this mixture was heated 
to 80 °C and monitored via TLC (15 % EtOAc in hexane). After 1 hr the reaction had 
gone to completion, and the mixture was filtered though a Celite pad, this was then 
washed though with ethyl acetate (3 x 10 mL).  Water (50 mL) was added followed by 
sodium hydrogen carbonate (saturated) to adjust to pH 4, this was extracted with ethyl 
acetate (3 x 100 mL), the combined organic layers were washed with brine (3 x 100 mL), 
dried with sodium sulphate. The organic layer was then evaporated under reduced 
pressure on to silica. The silica pad was then loaded on to a silica gel column and purified 
using a gradient of 0 % to 15 % ethyl acetate in hexane to give the title compound as a 
yellow solid.  
 
Yield:  1.571 g (67 %).  
TLC (EtOAc: hexane 15 %) Rf = 0.33. 
FTMS APCI (m/z) found 217.9616, calcd for [C7H5
79Br1F1N1O1H]
+ 217.9611. 
1H NMR (500 MHz, chloroform-d) δ 9.75 (s, 1H), 7.64 (d, 4JFH = 7.5 Hz, 1H), 6.42 (d, 
3JFH = 10.5 Hz, 1H), 6.30 (s, 2H). 
13C NMR (126 MHz, chloroform-d) δ 191.7, 163.4 (d, 1JFC = 255.2 Hz), 151.2 (d, 3JFC = 
12.6 Hz), 140.7 (d, 3JFC = 4.4 Hz), 117.4, 103.3 (d, 
2JFC = 25.8 Hz), 95.3 (d, 
2JFC = 23.1 
Hz). 
19F NMR (376 MHz, chloroform-d) δ -97.63 (dd, J = 10.5, 7.5 Hz). 
LCMS purity >99% (UV), Ret. time = 18.83 min. 
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2-Amino-3-bromo-6-fluorobenzaldehyde, 98. 
 
 
3-Bromo-6-fluoro-2-nitrobenzaldehyde (7.44 g, 30 mmol) and iron powder (5.02 g, 90 
mmol) were added to a round-bottomed flask, this was purged with argon for 5 min. 
Ethanol (30 mL) followed by acetic acid (30 mL) were added and this mixture was heated 
to 80 °C and monitored via TLC (15 % EtOAc in hexane). After 1 hr the reaction had 
gone to completion, and the mixture was filtered through a Celite pad, this was then 
washed though with ethyl acetate (3 x 30 mL).  Water (150 mL) was added followed by 
sodium hydrogen carbonate (saturated) to adjust to pH 4, this was extracted with ethyl 
acetate (3 x 100 mL), the combined organic layers were washed with brine (3 x 300 mL), 
dried with sodium sulphate. The organic layer was then evaporated under reduced 
pressure on to silica. This silica pad was then loaded on to a silica gel column and purified 
using a gradient of 0 % to 15 % ethyl acetate in hexane to give the title compound as a 
yellow solid. 
 
Yield:  5.40 g (83 %).  
TLC (EtOAc: hexane 15 %) Rf = 0.61. 
FTMS APCI (m/z) found 219.9593, calcd for [C7H5
81Br 1F1N1O1H]
+ 219.9591. 
1H NMR (500 MHz, acetone-D6) δ 10.23 (s, 1H), 7.71 (dd, 3JHH = 8.5, 4JFH = 6.0 Hz, 
1H), 7.32 (s, 2H), 6.43 (dd, 3JFH = 11.0, 
3JHH = 8.5 Hz, 1H).  
13C NMR (126 MHz, acetone-D6) δ 188.9 (d, 3JFC = 12.5 Hz), 166.7 (d, 1JFC = 254.7 Hz), 
149.4 (d, 3JFC = 4.8 Hz), 140.1 (d, 
3JFC = 11.9 Hz), 109.1 (d, 
3JFC = 10.7 Hz), 104.9 (d, 
4JFC = 3.4 Hz), 103.4 (d, 
2JFC = 22.9 Hz).  
19F NMR (376 MHz, chloroform-D) δ -123.05 (dd, J = 11.0, 6.0 Hz). 
LCMS purity >99% (UV), Ret. time = 19.68 min. 
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2-Fluoro-5-nitro-4-((trimethylsilyl)ethynyl)benzaldehyde, 99. 
 
 
4-Bromo-2-fluoro-5-nitrobenzaldehyde (2.480 g, 8.0 mmol), copper iodide (181 mg, 1.0 
mmol) and bis(triphenylphosphine)palladium(II) dichloride (351 mg, 0.5 mmol) were 
added to a round bottomed flask, this was placed under vacuum and then purged with 
argon and cycled 3 times. DMF (dry, 24 mL), triethylamine (dry, 4.28 mL, 30.0 mmol) 
were added followed by the drop wise addition of trimethylsilylacetylene (1.34 mL, 12.0 
mmol). This mixture was stirred at rt for 1h. The bulk of the DMF was evaporated under 
reduced pressure, then diethyl ether (100 mL) was added to the mixture, this was then 
filtered though a pad of Celite, which was then washed with more diethyl ether (3 x 20 
mL). Water (150 mL) was added and the organic layer separated and the aqueous layer 
was extracted with diethyl ether (2 x 50 mL). The combined organic layers were washed 
with brine (5 x 150 mL), dried with magnesium sulphate and evaporated under reduced 
pressure on to silica. This crude was then loaded on to a silica gel column which was ran 
at a gradient of 0 % - 15 % diethyl ether in hexane, to give the title compound as a yellow 
solid.  
 
Yield: 1.736 g (66%).  
TLC (Diethyl ether: hexane 10%) Rf = 0.40. 
FTMS (m/z) found 266.0638, calcd for [C12H12FNO3SiH]
+ 266.0643. 
1H NMR (500 MHz, chloroform-D) δ 10.31 (s, 1H), 8.56 (d, 4JFH = 6.5 Hz, 1H), 7.46 (d, 
3JFH = 10.0 Hz, 1H), 0.30 (d, J = 1.0 Hz, 9H). 
13C NMR (100 MHz, chloroform-D) δ 184.3 (d, 3JFC = 5.5 Hz), 165.1 (d, 1JFC = 267.0 
Hz), 146.9, 126.1, 126.0 (d, 3JFC = 4.5 Hz), 123.6 (d, 
2JFC = 11.0 Hz), 123.2 (d, 
4JFC = 
24.0 Hz), 111.2, 97.8, -0.5. 
19F NMR (376 MHz, chloroform-D) δ -114.40 (dd, J = 10.0, 6.5 Hz). 
LCMS purity >99 % (UV), Ret. time = 23.46 min. 
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2-Amino-4-fluoro-5-((trimethylsilyl)ethynyl)benzaldehyde, 100. 
 
2-Amino-5-bromo-4-fluorobenzaldehyde (218 mg, 1.00 mmol), copper iodide (18 mg, 
0.10 mmol) and bis(triphenylphosphine)palladium(II) dichloride (35 mg, 0.05 mmol) 
were added to a MPS tube, this was placed under vacuum and purged with argon and 
cycled 3 times. DMF (dry 3 mL), triethylamine (dry, 417 μL, 3.00 mmol) were added 
followed by the drop wise addition of trimethylsilylacetylene (170 μL, 1.20 mmol). This 
mixture was heated to 80 °C for 4 hr. The reaction mixture was cooled to rt and diethyl 
ether (20 mL) was added to the mixture, this was then filtered through a pad of Celite, 
which was then washed with more diethyl ether (3 x 5 mL). Water (50 mL) was added 
and the organic layer separated and the aqueous layer was extracted with diethyl ether (2 
x 50 mL). The combined organic layers were washed with brine (5 x 50 mL), dried with 
sodium sulphate and evaporated under reduced pressure. The crude material was 
dissolved in the minimum amount of DMSO and loaded on to a reverse phase flash 
chromatography column, the column was ran at 100% water (0.1% formic acid modifier) 
for 1-3 column volumes i.e. until the UV trace normalised from the DMSO. The column 
was then run at a gradient of 45% to 95% acetonitrile (0.1% formic acid) in water (0.1% 
formic acid). The fractions containing product were then lyophilized to the title 
compound as a yellow solid.    
 
Yield: 105 mg (45%).  
FTMS (m/z) found 236.0903, calcd for [C12H14ONFSiH]
+ 236.0901. 
1H NMR (500 MHz, chloroform-D) δ 9.75 (s, 1H), 7.64 (d, 4JFH = 7.5 Hz, 1H), 6.40 (bs, 
2H), 6.31 (d, 3JFH = 11.0 Hz, 1H), 0.25 (s, 9H). 
13C NMR (126 MHz, chloroform-D) δ 192.2, 167.0 (d, 1JFC = 259.5 Hz), 151.9 (d, 3JFC = 
13.5 Hz), 142.8 (d, 3JFC = 5.5 Hz), 116.1, 102.0 (d, 
2JFC = 25.0 Hz), 101.4 (d, 
2JFC = 18.5 
Hz), 97.9 (d, 2JFC = 2.5 Hz), 97.4, 0.1. 
19F NMR (376 MHz, chloroform-D) δ -100.02 (appt, J = 9.5 Hz). 
LCMS purity >99 % (UV), Ret. time = 23.09 min. 
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2-Amino-6-fluoro-3-((trimethylsilyl)ethynyl)benzaldehyde, 101. 
 
2-Amino-3-bromo-6-fluorobenzaldehyde (1.144 g, 8.00 mmol), copper iodide (145 mg, 
0.80 mmol) and bis(triphenylphosphine)palladium(II) dichloride (281 mg, 0.4 mmol) 
were added to a round bottomed flask, this was placed under vacuum and then purged 
with argon and cycled 3 times. DMF (dry 24 mL), triethylamine (dry, 3.34 mL, 24.00 
mmol) were added followed by the drop wise addition of trimethylsilylacetylene (1.34 
mL, 9.6 mmol). This mixture was heated to 80 °C for 4 h. The reaction mixture was 
cooled to rt and the diethyl ether (150 mL) was added to the mixture, this was then filtered 
through a pad of Celite, which was then washed with more diethyl ether (3 x 15 mL). 
Water (150 mL) was added and the organic layer separated and the aqueous layer was 
extracted with diethyl ether (2 x 50 mL). The combined organic layers were washed with 
brine (5 x 150 mL), dried with sodium sulphate and evaporated under reduced pressure 
on to silica. This crude was then loaded on to a silica gel column which was ran at a 
gradient of 0 % - 10 % diethyl ether in hexane, to give the title compound as a green solid.  
 
Yield: 1.398 g (74%).  
TLC (Diethyl ether: hexane 10 %) Rf = 0.70. 
FTMS (m/z) found 236.0904, calcd for [C12H14ONFSiH]
+ 236.0901. 
1H NMR (500 MHz, chloroform-D) δ 10.28 (s, 1H), 7.43 (dd, 3JHH = 8.5, 4JFH = 6.0 Hz, 
1H), 6.28 (dd, 3JFH = 10.5, 
3JHH = 8.5 Hz, 1H), 0.27 (s, 9H). 
13C NMR (126 MHz, chloroform-D) δ 188.8 (d, 3JFC = 12.0 Hz), 166.6 (d, 1JFC = 259.5 
Hz), 152.3 (d, 3JFC = 5.0 Hz), 139.7 (d, 
2JFC = 12.5 Hz), 107.6 (d, 
3JFC = 10.5 Hz), 105.7 
(d, 4JFC = 3.5 Hz), 102.0 (d, 
2JFC = 22.0 Hz), 101.6 (d, 
5JFC = 1.5 Hz), 99.2, 0.2. 
19F NMR (376 MHz, chloroform-D) δ -119.33 (dd, J = 11.0, 6.0 Hz). 
LCMS purity >99% (UV), Ret. time = 24.74 min. 
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2-Fluoro-4-((6-methyl-4,8-dioxo-1,3,6,2-dioxazaborocan-2-yl)ethynyl)-5-n, 102. 
4-Bromo-2-fluoro-5-nitrobenzaldehyde (143 mg, 0.575 mmol), copper iodide (9 mg, 0.05 
mmol), bis(triphenylphosphine)palladium(II) dichloride (18 mg, 0.025 mmol) and 
ethynylboronic acid MIDA ester (90 mg, 0.5 mmol) were added to a round bottomed 
flask, this was placed under vacuum and then purged with argon 3 times. DMF (dry, 1.5 
mL), triethylamine (dry, 209 μL, 1.5 mmol) were added this mixture was stirred at rt over 
night. The DMF was evaporated under reduced pressure heptane was added and 
evaporated under reduced pressure (3 x 5 mL) to azeotropically remove any residual 
DMF. The residues were dissolved in acetone (15 mL) and evaporated under reduced 
pressure on to silica. This crude powder was then loaded on to a silica gel column which 
was ran at a gradient of 30% - 40% acetonitrile in DCM, to give title compound as a 
yellow solid. 
 
Yield: mg 67 (38%).  
TLC (MeCN:DCM 30%) Rf = 0.78. 
FTMS (m/z) found 349.0638, calcd for [C14H10BFN2O7H]
+ 349.0638. 
1H NMR (500 MHz, acetonitrile-D3) δ 10.25 (s, 1H), 8.51 (d, 4JFH = 6.5 Hz, 1H), 7.70 
(d, 3JFH = 10.0 Hz, 1H), 4.11 (d, J = 17.0 Hz, 2H), 3.98 (d, J = 17.0 Hz, 2H), 3.18 (s, 3H). 
13C NMR (126 MHz, acetonitrile-D3) δ 185.4 (d, 3JFC = 4.5 Hz), 167.5, 164.7 (d, 1JFC = 
266.0 Hz), 146.5, 126.2 (d, 3JFC = 4.5 Hz), 124.8 (d, 
2JFC = 12.0 Hz), 124.2 (d, 
3JFC = 11.0 
Hz), 123.5 (d, 2JFC = 25.0 Hz), 61.7, 48.1. 
19F NMR (376 MHz, acetonitrile-D3) δ -114.33 (dd, J = 10.0, 6.5 Hz). 
11B NMR (128 MHz, acetonitrile-D3) δ 6.18. 
LCMS purity >99% (UV), Ret. time = 23.46 min. 
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2-Amino-6-fluoro-3-((6-methyl-4,8-dioxo-1,3,6,2-dioxazaborocan-2-
yl)ethynyl)benzaldehyde, 103. 
 
 
2-Amino-3-bromo-6-fluorobenzaldehyde (429 mg, 1.97 mmol), copper iodide (31 mg, 
0.17 mmol), bis(triphenylphosphine)palladium(II) dichloride (60 mg, 0.09 mmol) and 
ethynylboronic acid MIDA ester (310 mg, 1.71 mmol) were added to a round bottomed 
flask, this was placed under vacuum and then purged with argon and cycled 3 times. DMF 
(dry 6 mL), triethylamine (dry, 751 μL, 5.13 mmol) were added this mixture was stirred 
at rt overnight. The DMF was evaporated under reduced pressure, heptane was added and 
evaporated under reduced pressure (3 x 5 mL) to azeotropically remove any residual 
DMF. The residue was dissolved in acetone (15 mL) and evaporated under reduced 
pressure on to silica. This crude powder was then loaded on to a silica gel column which 
was ran at a gradient of 30% - 40% acetonitrile in DCM, to give the title compound as a 
white solid. 
 
Yield: 470 mg (86%).  
TLC (MeCN:DCM 30%) Rf = 0.69. 
FTMS (m/z) found 319.0900, calcd for [C14H12BFN2O5H]
+ 319.0896. 
1H NMR (500 MHz, acetonitrile-d3) δ 10.24 (s, 1H), 7.53 (dd, 3JHH = 8.5, 4JFH = 6.0 Hz, 
1H), 7.04 (bs, 2H), 6.38 (dd, 3JFH = 11.5, 
4JHH = 8.5 Hz, 1H), 4.04 (d, J = 17.0 Hz, 2H), 
3.93 (d, J = 17.0 Hz, 2H), 3.09 (s, 3H). 
13C NMR (100 MHz, acetonitrile-D3) δ 188.7 (d, 3JFC = 12.0 Hz), 167.7, 166.6 (d, 1JFC = 
257.5 Hz), 152.2 (d, 3JFC = 5.5 Hz), 140.2 (d, 
2JFC = 12.5 Hz), 107.2 (d, 
3JFC = 10.5 Hz), 
105.1 (d, 4JFC = 3.5 Hz), 101.6 (d, 
2JFC  = 22.5 Hz), 94.0, 61.6, 48.0. 
19F NMR (376 MHz, acetonitrile-D3) δ -120.70 (dd, J = 11.5, 6.0 Hz). 
11B NMR (128 MHz, acetonitrile-D3) δ 6.50. 
LCMS purity >99% (UV), Ret. time = 16.41 min. 
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General procedure for reductive aminations.  
A benzaldehyde derivative (1 eq), sodium triacetoxyborohydride (2-2.5 eq) and a 
secondary amine (1.1 eq) were added to a round-bottomed flask and purged with argon. 
This was dissolved in THF (5 mLmmol-1), acetic acid (1 eq) was added to the resulting 
stirred mixture and then left at rt overnight. Once there was no starting material observed 
via TLC water was added to quench. This was then extracted with ethyl acetate (3 times) 
then combined organic layers were washed with brine (3 times), the organic layer was 
dried (Na2SO4). Alternatively on scales less than 1 mmol, hydrophobic phase separators 
were used with DCM extractions (3 times). The organic layer was then evaporated under 
reduced pressure on to silica. This silica pad was then loaded on to a silica gel column 
and purified using a gradient of ethyl acetate in hexane.  
 
tert-Butyl 4-(4-bromo-2-fluoro-5-nitrobenzyl)piperazine-1-carboxylate, 104. 
 
 
The general reductive amination procedure was used on a 0.5 mmol and 8 mmol scale, 
with 1-Boc-piperazine and 2 eq of sodium triacetoxyborohydride. The crude material was 
purified by column chromatography using a 0% to 20% gradient of EtOAc in hexane, 
giving the title compound as a orange solid. 
 
Yield: 98 mg (0.5 mmol scale, 47%) 2.579 g (8.0 mmol scale, 77%). 
TLC (EtOAc: hexane 20%) Rf = 0.20. 
HRMS-ESI (m/z) found 418.0766, calcd for [C16H21
79BrFN3O4H]
+ 418.0772. 
1H NMR (500 MHz, chloroform-D) δ 8.06 (d, 4JFH = 6.5 Hz, 1H), 7.43 (d, 3JFH = 8.5 Hz, 
1H), 3.56 (s, 2H), 3.46 -3.41 (m, 4H), 2.46 -2.40 (m, 4H), 1.45 (s, 9H). 
13C NMR (126 MHz, chloroform-D) δ 162.2 (d, 1JFC = 259.0 Hz), 154.8, 146.3, 128.5 (d, 
3JFC = 6.5 Hz), 126.6 (d, 
2JFC = 16.5 Hz), 122.3 (d, 
2JFC = 27.0 Hz), 114.5 (d, 
3JFC = 10.5 
Hz), 80.0, 54.4, 53.0, 43.7, 28.6. 
19F NMR (376 MHz, chloroform-D) δ -108.27 (appt, J = 7.5 Hz). 
LCMS purity >99%  (UV), Ret. time = 15.09 min. 
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tert-Butyl 4-(2-amino-5-bromo-4-fluorobenzyl)piperazine-1-carboxylate, 105. 
 
 
 
The general reductive amination procedure was used on a 0.5 mmol scale, with 1-Boc-
piperazine 2.5 eq of sodium triacetoxyborohydride. The crude material was purified by 
column chromatography using a 0% to 20% gradient of EtOAc in hexane, giving the title 
compound as a yellow solid. 
 
Yield: mg 161 mg (0.5 mmol scale, 83%) 1.048 g (2.95 mmol scale, 91%). 
TLC (EtOAc: hexane 20%) Rf = 0.26. 
HRMS-ESI (m/z) found 388.1017, calcd for [C16H23
79BrFN3O2H]
+ 388.1030. 
1H NMR (500 MHz, chloroform-D) δ 7.08 (d, 4JFH = 7.5 Hz, 1H), 6.40 (d, 3JFH = 10.0 
Hz, 1H), 4.87 (s, 2H), 3.43 (s, 2H), 3.42- 3.37 (m, 4H), 2.39- 2.31 (m, 4H), 1.45 (s, 9H). 
13C NMR (126 MHz, chloroform-D) δ 159.2 (d, 1JFC = 244.0 Hz), 154.7, 148.0 (d, 3JFC = 
10.0 Hz), 134.3 (d, 3JFC = 2.0 Hz), 119.2 (d, 
4JFC = 3.0 Hz), 103.3 (d, 
2JFC = 25.0 Hz), 
94.6 (d, 2JFC = 21.5 Hz), 79.8, 61.0, 52.5, 43.7, 28.5. 
19F NMR (376 MHz, chloroform-D) δ -109.56 (dd, J = 10.0, 7.5 Hz). 
LCMS purity >99% (UV), Ret. time = 12.81 min. 
 
4-Bromo-5-fluoro-2-(morpholinomethyl)aniline, 106. 
 
 
The general reductive amination procedure was used on a 0.5 mmol scale, with 
morpholine and 2.5 eq of sodium triacetoxyborohydride. The crude material was purified 
by column chromatography using a 0% to 20% gradient of EtOAc in hexane, giving the 
title compound as a yellow solid. 
 
 195 
Yield: mg 140 mg (97%). 
TLC (EtOAc: hexane 20%) Rf = 0.30. 
HRMS-ESI (m/z) found 289.0355, calcd for [C11H14
79BrFN2OH]
+ 289.0346 
1H NMR (500 MHz, chloroform-D) δ 7.08 (d, 4JFH = 7.5 Hz, 1H), 6.38 (d, 3JFH = 10.5 
Hz, 1H), 4.90 (s, 2H), 3.69–3.62 (m, 4H), 3.41 (s, 2H), 2.44-2.32 (m, 4H). 
13C NMR (126 MHz, chloroform-D) δ 159.2 (d, 1JFC = 244.0 Hz), 148.0 (d, 3JFC = 10.0 
Hz), 134.3 (d, 3JFC = 2.0 Hz), 119.1 (d, 
4JFC = 3.0 Hz), 103.2 (d, 
2JFC = 25.0 Hz), 94.6 (d, 
2JFC = 21.0 Hz), 67.0, 61.3, 53.2. 
19F NMR (376 MHz, chloroform-D) δ -109.58 – -109.67 (m). 
LCMS purity >99%  (UV), Ret. time = 9.38 min. 
 
tert-Butyl 4-(2-amino-3-bromo-6-fluorobenzyl)piperazine-1-carboxylate, 107. 
 
 
The general reductive amination procedure was used on either a 0.5 mmol or a 6.3 mmol 
scale, with 1-Boc-piperazine and 2 eq of sodium triacetoxyborohydride. The crude 
material was columned using a 0% 10% gradient of EtOAc in hexane to give the title 
compound as a white crystalline solid. 
 
Yield:  160 mg (0.5 mmol scale, 82%) 2.336 g (6.3 mmol scale, 95%).  
TLC (EtOAc: hexane 20%) Rf = 0.52. 
HRMS-ESI (m/z) found 388.1017, calcd for [C16H23
79BrFN3O2H]
+ 388.1030. 
1H NMR (500 MHz, acetone-D6) δ 7.35 (dd, 3JHH = 9.0, 4JFH = 6.0 Hz, 1H), 6.38 (pt, 3JHH 
,3JFH = 9.0 Hz, 1H), 5.62 (s, 2H), 3.59 (m, 2H), 3.37 (m, 4H), 2.40 (t, J = 5.0 Hz, 4H), 
1.43 (s, 9H).  
13C NMR (126 MHz, acetone-D6) δ 162.1 (d, 1JFC = 241.5 Hz), 155.0, 147.7 (d, 3JFC = 
6.5 Hz), 132.8 (d, 3JFC = 11.0 Hz), 110.4 (d, 
2JFC = 17.5 Hz), 105.2 (d, 
2JFC = 25.5 Hz), 
104.3 (d, 4JFC = 3.0 Hz), 79.7, 53.2, 52.9, 44.5 (d, 
3JFC = 4.5 Hz), 28.6.  
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19F NMR (376 MHz, acetone-D6) δ -121.00--121.09 (m). 
LCMS purity > 92% (UV), Ret. time = 13.93 min. 
 
6-Bromo-3-fluoro-2-(morpholinomethyl)aniline, 108. 
 
 
The general reductive amination procedure was used on a 0.5 mmol scale, with 
morpholine and 2 eq of sodium triacetoxyborohydride. The crude material purified by 
column chromatography using a 0%-20% gradient of EtOAc in hexane, giving the title 
compound as a yellow solid. 
 
Yield: 137 mg (95%).  
TLC (EtOAc: hexane 20%) Rf = 0.50. 
HRMS-ESI (m/z) found 289.0351, calcd for [C11H14
79Br FN2OH]
+ 289.0346. 
1H NMR (500 MHz, acetone-D6) δ 7.25 (dd, 3JHH 9.0, 4JFH = 5.5 Hz, 1H), 6.29 (pt, 3JHH 
,3JFH = 9.0 Hz, 1H), 5.55 (s, 2H), 3.57 – 3.51 (m, 4H), 3.49 (d, 4JFH = 2.0 Hz, 2H), 2.36 – 
2.30 (m, 4H). 
13C NMR (126 MHz, acetone-D6) δ 162.4 (d, 1JFC = 241.5 Hz), 147.9 (d, 3JFC = 6.5 Hz), 
132.9 (d, 3JFC = 10.5 Hz), 110.5 (d, 
2JFC = 17.5 Hz), 105.5 (d, 
2JFC = 26.0 Hz), 104.5 (d, 
4JFC = 2.5 Hz), 67.7, 54.1, 53.5 (d, 
3JFC = 4.0 Hz). 
19F NMR (376 MHz, acetone-D6) δ -121.22 – -121.32 (m). 
LCMS purity >99%  (UV), Ret. time = 14.11 min. 
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tert-Butyl 4-(2-amino-6-fluoro-3-((trimethylsilyl)ethynyl)benzyl)piperazine-1-
carboxylate, 109. 
 
The general reductive amination procedure was used on a 0.5 mmol scale, with 1-Boc-
piperazine 2 eq of sodium triacetoxyborohydride. The crude material was subjected to 
column chromatography using a gradient of 0% to 10% EtOAc in hexane, giving the title 
compound as an orange solid. 
 
Yield: 56 mg (28%). 
TLC (EtOAc: hexane 20%) Rf = 0.63. 
HRMS-ESI (m/z) found 406.2307, calcd for [C21H32BrFN3O2SiH]
+ 406.2321. 
1H NMR (500 MHz, chloroform-D) δ 7.18 (dd, 3JHH = 8.5, 4JFH = 6.0 Hz, 1H), 6.32 (pt, 
3JHH ,
3JFH = 9.0 Hz, 1H), 5.50 (s, 2H), 3.56 (d, 
4JFH = 1.5 Hz, 2H), 3.46-3.35 (m, 4H), 
2.44-2.34 (m, 4H), 1.44 (s, 9H), 0.25 (s, 9H). 
13C NMR (126 MHz, chloroform-D) δ 162.2 (d, 1JFC = 246.5 Hz), 154.8, 151.1 (d, 3JFC = 
7.0 Hz), 132.5 (d, 3JFC = 11.0 Hz), 108.0 (d, 
2JFC = 17.0 Hz), 104.3 (d, 
4JFC = 2.5 Hz), 
104.2 (d, 2JFC = 25.0 Hz), 101.4, 99.5 (d, 
5JFC = 25.0 Hz), 79.9, 52.5, 52.2 (d, 
3JFC = 4.0 
Hz), 43.8, 28.5, 0.3. 
19F NMR (376 MHz, chloroform-D) δ -115.18 – -115.76 (m). 
LCMS purity >99% (UV), Ret. time = 18.45 min. 
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3-Fluoro-2-(morpholinomethyl)-6-((trimethylsilyl)ethynyl)aniline, 110. 
 
 
The general reductive amination procedure was used on a 0.5 mmol scale, with 
morpholine and 2 eq of sodium triacetoxyborohydride. The crude material was purified 
by column chromatography using a 0% to 10% gradient of EtOAc in hexane, giving the 
title compound as an orange solid. 
 
Yield: 96 mg (63%). 
TLC (EtOAc: hexane 20%) Rf = 0.59. 
HRMS-ESI (m/z) found 307.1625, calcd for [C16H22BrFN2OSiH]
+ 307.1636. 
1H NMR (500 MHz, chloroform-D) δ 7.18 (dd, 3JHH = 8.55, 4JFH = 6.0 Hz, 1H), 6.33 (t, 
3JHH ,
3JFH = 9.0 Hz, 1H), 5.54 (s, 2H), 3.67 (appt, J = 4.5 Hz, 4H), 3.56 (d, J = 1.5 Hz, 
2H), 2.48 - 2.39 (m, 4H), 0.26 (d, J = 0.8 Hz, 9H). 
13C NMR (126 MHz, chloroform-D) δ 162.3 (d, 1JFC = 246.5 Hz), 151.1 (d, 3JFC = 7.5 
Hz), 132.4 (d, 3JFC = 11.0 Hz), 107.8 (d, 
2JFC = 17.0 Hz), 104.2 (d, 
2JFC = 25.0 Hz), 104.2 
(d, 4JFC = 3.0 Hz), 101.5, 99.4 (d, 
5JFC = 1.5 Hz), 67.2, 53.1, 52.5 (d, 
3JFC = 4.0 Hz), 0.3. 
19F NMR (376 MHz, chloroform-D) δ -115.25 – -115.60 (m). 
LCMS purity >99% (UV), Ret. time = 13.75 min. 
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tert-Butyl 4-(5-amino-4-bromo-2-fluorobenzyl)piperazine-1-carboxylate, 111. 
 
 
tert-Butyl 4-(4-bromo-2-fluoro-5-nitrobenzyl)piperazine-1-carboxylate (1.254 mg, 3 
mmol) was dissolved in methanol (11 mL). To this mixture zinc powder (1.950 mg, 30 
mmol) was added followed by saturated ammonium chloride (11 mL). This mixture was 
allowed to stir at rt for 14 h before it was filtered though a bed of celite, this was then was 
though with ethyl acetate (3 x 10 mL). This mixture was then extracted with ethyl acetate 
(3 x 30 mL), the combined organic layers were then washed with brine (2 x 20 mL) dried 
with sodium sulphate and evaporated onto silica. This silica pad was then loaded onto a 
silica gel column and was purified using ethyl acetate: hexane 50%. This gave title 
compound as a light yellow solid.  
 
Yield: 546 mg (47%). 
TLC (EtOAc: hexane 50%) Rf = 0.30. 
HRMS-ESI (m/z) found 388.1017, calcd for [C16H23
79BrFN3O2H]
+ 388.1030. 
1H NMR (500 MHz, chloroform-D) δ 7.13 (d, 3JFH = 9.0 Hz, 1H), 6.80 (d, 4JFH = 6.5 Hz, 
1H), 3.91 (s, 2H), 3.46 (s, 2H), 3.45 – 3.39 (m, 4H), 2.45 – 2.36 (m, 5H), 1.45 (s, 9H).  
13C NMR (126 MHz, chloroform-D) δ 154.9, 154.1 (d, 1JFC = 240.5 Hz), 140.6 (d, 4JFC = 
2.5 Hz), 125.0 (d, 2JFC = 16.0 Hz), 119.2 (d, 
2JFC = 26.5 Hz), 117.3 (d, 
3JFC = 4.0 Hz), 
107.5 (d, 3JFC = 10.0 Hz), 79.8, 55.2, 52.9, 43.8, 28.6. 
19F NMR (376 MHz, Chloroform-D) δ -129.75 – -129.83 (m). 
LCMS purity >99%  (UV), Ret. time = 11.19 min. 
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tert-Butyl 4-(3-bromo-6-fluoro-2-(1H-pyrrol-1-yl)benzyl)piperazine-1-carboxylate, 
112. 
 
tert-Butyl 4-(2-amino-3-bromo-6-fluorobenzyl)piperazine-1-carboxylate (58 mg, 0.15 
mmol), 2,5-Dimethoxytetrahydrofuran (22 mg, 0.17 mmol) and acetic acid (1.5 mL) were 
added to a 10 mL microwave vial. This was loaded in to the microwave and heated at 115 
°C for 15 min. The cooled reaction mixture was transferred to round-bottomed; ethyl 
acetate was used to transfer washing from the microwave vial and evaporated under 
reduced pressure. The residues were dissolved in DCM (3 mL ) then saturated sodium 
hydrogen carbonate was added (5 mL), a hydrophobic phase separators was used with 
DCM extractions (3 x 3 mL). The combined organic layer was then evaporated under 
reduced pressure on to silica. This silica pad was then loaded on to a silica gel column 
and purified using a gradient of 10 % - 20% ethyl acetate in hexane, to the give title 
compound as a white solid.  
 
Yield: 42 mg (64%).  
TLC (EtOAc:Hexane 20%) Rf = 0.54. 
HRMS-ESI (m/z) found 338.0663, calcd for product without BOC [C15H18N3F
79BrH]+ 
338.0663.  
1H NMR (500 MHz, chloroform-D) δ 7.58 (dd, 3JHH = 9.0, 4JFH = 5.5 Hz, 1H), 7.04 (appt, 
3JHH ,
3JFH = 9.0 Hz, 1H), 6.72 (t, J = 2.0 Hz, 2H), 6.30 (t, = 2.0 Hz, 2H), 3.33-3.29 (m, 
4H), 3.22 (d, 4JFH = 2.0 Hz, 2H), 2.29-2.21 (m, 4H), 1.43 (s, 9H). 
13C NMR (126 MHz, chloroform-D) δ 160.8 (d, 1JFC = 249.0 Hz), 154.8, 142.3 (d, 3JFC = 
6.0 Hz), 132.7 (d, 3JFC = 9.5 Hz), 126.7 (d, 
2JFC = 16.5 Hz), 122.7, 118.3 (d, 
4JFC = 3.5 
Hz), 116.8 (d, 2JFC = 24.5 Hz), 108.9, 79.7, 52.7, 51.7, 43.9, 28.6. 
19F NMR (376 MHz, chloroform-D) δ -114.53 – -114.85 (m). 
LCMS purity >99% (UV), Ret. time = 16.86 min. 
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tert-Butyl 4-(4-bromo-5-((6,7-dimethoxyquinazolin-4-yl)amino)-2-fluorobenzyl)-
piperazine-1-carboxylate, 113. 
 
tert-Butyl 4-(5-amino-4-bromo-2-fluorobenzyl)piperazine-1-carboxylate (533 mg, 1.37 
mmol) and 4-chloro-6,7-dimethoxyquinazoline (341 mg, 1.51 mmol) were added to a 
round bottomed flask, this was placed under vacuum and then purged with argon 3 times. 
DMF (dry 15 mL) was added, this mixture was cooled to 0 °C, then sodium 
bis(trimethylsilyl)amide (1M, 6.00 mL) was added drop wise over 5 min. The mixture 
was allowed to stir at 0 °C for 30 min, then the mixture was stirred for further 30 min at 
rt. The bulk of the DMF was evaporated under reduced pressure, and then ethyl acetate 
(30 mL) was added to the mixture. This organic layer was washed with water (50 mL) 
this water layer was extracted with ethyl acetate (2 x 30 mL), the combined organic layer 
was washed with brine (5 x 30 mL) dried with magnesium sulphate and evaporated under 
reduced pressure on to silica. This crude was then loaded on to a silica gel column which 
was ran at a gradient of 5% - 20% methanol in dichloromethane, this also needed 
recrystallization from the minimum amount of hot ethyl acetate, to the give title 
compound as a white solid.  
 
Yield:  378 mg (48%).  
TLC (MeOH:DCM 10%) Rf = 0.68. 
HRMS-ESI (m/z) found 576.1616, calcd for [C26H31
79BrFN5O4H]
+ 576.1616. 
1H NMR (500 MHz, chloroform-D) δ 8.68 (s, 1H), 8.63 (d, 4JFH = 7.0 Hz, 1H), 7.51 (s, 
1H), 7.35 (d, 3JFH = 8.5 Hz, 1H), 7.29 (s, 1H), 7.08 (s, 1H), 4.06 (s, 3H), 4.05 (s, 3H), 
3.63 (d, 4JFH = 1.5 Hz, 2H), 3.49 – 3.42 (m, 4H), 2.53 – 2.45 (m, 4H), 1.45 (s, 9H). 
13C NMR (126 MHz, chloroform-D) δ 157.0 (d, 1JFC = 248.0 Hz), 155.9, 155.2, 154.9, 
153.6, 150.1, 147.9, 133.0, 125.48 (d, 3JFC = 3.0 Hz), 125.2 (d, 
2JFC = 15.5 Hz), 119.3 (d, 
2JFC = 27.0 Hz), 113.5 (d, 
3JFC = 10.0 Hz), 109.5, 108.4, 99.0, 79.8, 56.5, 56.4, 55.3, 52.8, 
28.6. One carbon missing from piperazine carbamate.  
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19F NMR (376 MHz, chloroform-D) δ -120.70 – -121.00 (m). 
LCMS purity >99% (UV), Ret. time = 9.94 min. 
 
tert-Butyl4-(5-bromo-2-((6,7-dimethoxyquinazolin-4-yl)amino)-4-fluorobenzyl)-
piperazine-1-carboxylate, 114. 
 
 
tert-Butyl 4-(2-amino-5-bromo-4-fluorobenzyl)piperazine-1-carboxylate (388 mg, 1.00 
mmol) and 4-chloro-6,7-dimethoxyquinazoline (225 mg, 1.10 mmol) were added to a 
round bottomed flask, this was placed under vacuum and then purged with argon 3 times. 
DMF (dry 16 mL) was added, this mixture was cooled to 0 °C, then sodium 
bis(trimethylsilyl)amide (1M, 2.00 mL) was added drop wise over 5 min. The mixture 
was allowed to stir at 0 °C for 30 min, then the mixture was stirred for further 30 min at 
rt. The bulk of the DMF was evaporated under reduced pressure, and then ethyl acetate 
(25 mL) was added to the mixture. This organic layer was washed with water (50 mL) 
this water layer was extracted with ethyl acetate (2 x 25 mL), the combined organic layer 
was washed with brine (5 x 50 mL) dried with sulphate and evaporated under reduced 
pressure on to silica. This crude was then loaded on to a silica gel column which was ran 
at a gradient of 90% - 100% ethyl acetate in hexane, to give the title compound as a light 
orange solid.  
 
Yield:  245 mg (42%).  
TLC (EtOAc 100%) Rf = 0.45. 
HRMS-ESI (m/z) found 576.1626, calcd for [C26H31
79BrFN5O4H]
+ 576.1616. 
1H NMR (399 MHz, chloroform-D) δ 10.04 (s, 1H), 8.70 (s, 1H), 8.43 (d, 3JFH  = 11.0 
Hz, 1H), 7.33 (d, 4JFH  = 7.5 Hz, 1H), 7.29 (s, 1H), 7.12 (s, 1H), 3.68 (s, 2H), 3.61-3.50 
(m, 4H), 2.58-2.48 (m, 4H), 1.47 (s, 9H). 
13C NMR (100 MHz, chloroform-D) δ 158.9 (d, 1JFC = 245.0 Hz), 156.1, 155.7, 154.7, 
153.7, 150.0, 148.5, 140.2 (d, 3JFC = 10.5 Hz), 134.3 (d, 
4JFC = 2.0 Hz), 122.9 (d, 
3JFC = 
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3.5 Hz), 110.6 (d, 2JFC = 28.0 Hz), 110.1, 108.5, 101.9, 101.4 (d, 
2JFC = 21.5 Hz), 80.5, 
61.6, 57.5, 56.4, 52.8, 43.6, 28.5. 
19F NMR (376 MHz, chloroform-D) δ -106.28 --106.41 (m). 
LCMS purity >99% (UV), Ret. time = 10.59 min. 
 
tert-Butyl 4-(3-bromo-2-((6,7-dimethoxyquinazolin-4-yl)amino)-6-fluorobenzyl)-
piperazine-1-carboxylate, 115. 
 
tert-Butyl 4-(2-amino-3-bromo-6-fluorobenzyl)piperazine-1-carboxylate (1.164 g, 3.00 
mmol) and 4-chloro-6,7-dimethoxyquinazoline (0.743 g, 3.3 mmol) were added to a 
round bottomed flask, this was placed under vacuum and then purged with argon 3 times. 
DMF (dry 48 mL) was added, this mixture was cooled to 0 °C, then sodium 
bis(trimethylsilyl)amide (1M, 6.00 mL) was added drop wise over 5 min. The mixture 
was allowed to stir at 0 °C for 30 min, then the mixture was stirred for further 30 min at 
rt. The bulk of the DMF was evaporated under reduced pressure, and then ethyl acetate 
(75 mL) was added to the mixture. This organic layer was washed with water (100 mL) 
this water layer was extracted with ethyl acetate (2 x 75 mL) the combined organic layer 
was washed with brine (5 x 100 mL) dried with sulphate and evaporated under reduced 
pressure on to silica. This crude was then loaded on to a silica gel column which was ran 
at a gradient of 90% - 100% ethyl acetate in hexane, to give the title compound as a light 
yellow solid.  
 
Yield:  1.235 mg (72%). 
TLC (EtOAc 100%) Rf = 0.32.  
HRMS-ESI (m/z) found 576.1613, calcd for [C25H31
79BrFN5O4H]
+ 576.1616. 
1H NMR (399 MHz, DMSO-D6) δ 8.20 (s, 1H), 7.78 (s, 1H), 7.68 (dd, 3JHH = 9.0, 4JFH = 
5.5 Hz, 1H), 7.19 (s, 1H), 7.10 (appt, 3JFH, 
3JHH = 9.0 Hz, 1H), 3.96 (s, 3H), 3.95 (s, 3H), 
3.52 (s, 2H), 3.09-3.02 (m, 4H), 2.26-2.20 (m, 4H), 1.37 (s, 9H). 
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13C NMR (126 MHz, chloroform-D) δ 160.6 (d, 1JFC = 247.5 Hz), 156.5, 155.2, 154.4, 
153.7, 149.8, 147.7, 140.5, 133.64 (d, 3JFC = 9.5 Hz), 120.8 (d, 
2JFC = 15.5 Hz), 116.8, 
113.9 (d, 2JFC = 24.5 Hz), 110.0, 107.9, 100.1, 80.2, 56.4, 56.3, 52.8, 52.5, 43.7, 28.3. 
19F NMR (376 MHz, DMSO-D6) δ -116.09 – -116.24 (m).  
LCMS purity 94% (UV), Ret. time = 10.6 min. 
 
N-(2-Bromo-4-fluoro-5-(piperazin-1-ylmethyl)phenyl)-6,7-dimethoxyquinazolin-4-
amine, 116. 
 
 
tert-Butyl4-(4-bromo-5-((6,7-dimethoxyquinazolin-4-yl)amino)-2-fluorobenzyl)-
piperazine-1-carboxylate (99 mg, 0.17 mmol) was added to a round bottomed flask then 
hydrogen chloride solution in dioxane (4M, 1.4 mL) was added. This mixture was stirred 
for 15 min and the sonicated for a 15 min. This mixture was the evaporated under reduced 
pressure, the residues where then dissolved in methanol (4 mL) and the minimum amount 
of water was added to aid to dissolve the residues. This solutions was then loaded onto a 
SCX column, the column was then washed with methanol (20 mL) and then acetonitrile 
(20 mL). This was then eluted with ammonia in methanol (2 M) then was then evaporated 
under reduced pressure to give the title compound as a white solid.  
 
Yield:  130mg (55%).  
HRMS-ESI (m/z) found 476.1082, calcd for [C21H23
79BrFN5O2H]
+ 476.1092. 
1H NMR (500 MHz, methanol-D4) δ 8.27 (s, 1H), 7.69 (s, 1H), 7.62 (d, 4JFH = 7.0 Hz, 
1H), 7.52 (d, 3JFH = 9.0 Hz, 1H), 7.17 (s, 1H), 4.01 (s, 3H), 4.00 (s, 3H), 3.59 (s, 2H), 
2.87 (t, J = 5.0 Hz, 4H), 2.54 (s, 4H). 
13C NMR (126 MHz, methanol-D4) δ 159.3 (d, 1JFC = 249.5 Hz), 158.2, 155.5, 152.4, 
149.9, 146.2, 133.6 (d, 3JFC = 4.0 Hz), 131.9, 124.6 (d, 
2JFC = 16.1 Hz), 121.1 (d, 
3JFC = 
7.0 Hz), 119.6 (d, 2JFC = 27.0 Hz), 108.8, 105.8, 101.2, 55.5, 55.2, 54.6, 52.7, 44.7.  
19F NMR (376 MHz, methanol-D4) δ -109.74 – -109.81 (m). 
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Elemental analysis CHN (%) found C: 45.97, H: 4.30, N: 12.02, calcd for 
C21H23BrFN5O2-HCl-0.6CCl2H2: 46.02, H: 4.51, N: 12.42. 
 
N-(4-Bromo-5-fluoro-2-(piperazin-1-ylmethyl)phenyl)-6,7-dimethoxyquinazolin-4-
amine, 117. 
 
tert-Butyl4-(5-bromo-2-((6,7-dimethoxyquinazolin-4-yl)amino)-4-fluorobenzyl)-
piperazine-1-carboxylate (288 mg, 0.5 mmol) was added to a round bottomed flask then 
hydrogen chloride solution in dioxane (4M, 4 mL) was added. This mixture was stirred 
for 15 min and the sonicated for a 15 min. This mixture was the evaporated under reduced 
pressure, the residues where then, methanol (5 mL) and the minimum amount of water 
was added to aid to dissolve the residues. This solutions was then loaded onto a SCX 
column, the column was then washed with methanol (20 mL) and then acetonitrile (20 
mL). This was then eluted with ammonia in methanol (2 M) which was then evaporated 
under reduced pressure to give title the compound as a white solid.  
 
Yield:  199 mg (84%).  
HRMS-ESI (m/z) found 476.1091, calcd for [C21H23
79BrFN5O2H]
+ 476.1092. 
1H NMR (500 MHz, methanol-D4) δ 8.49 (s, 1H), 8.29 (d, 3JFH = 11.0 Hz, 1H), 7.53 (d, 
4JFH = 7.5 Hz, 1H), 7.33 (s, 1H), 7.19 (s, 1H), 4.01 (s, 3H), 4.00 (s, 3H), 3.68 (s, 2H), 2.93 
– 2.86 (m, 4H), 2.58 – 2.48 (m, 4H). 
13C NMR (126 MHz, methanol-D4) δ 159.7 (d, 1JFC = 243.5 Hz), 157.9, 157.6, 154.0, 
151.6, 148.4, 141.0 (d, 3JFC = 10.5 Hz), 135.5 (d, 
4JFC = 1.5 Hz), 126.8 (d, 
3JFC = 3.0 Hz), 
112.3 (d, 2JFC = 27.5 Hz), 110.9, 107.9, 104.0, 102.9 (d, 
2JFC = 21.5 Hz), 61.7, 58.2, 56.7, 
54.2, 46.3. 
19F NMR (376 MHz, methanol-D4) δ -119.49 – -119.64 (m). 
LCMS purity >99% (UV), Ret. time = 9.06 min. 
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N-(6-Bromo-3-fluoro-2-(piperazin-1-ylmethyl)phenyl)-6,7-dimethoxyquinazolin-4-
amine, 118. 
 
tert-Butyl4-(3-bromo-2-((6,7-dimethoxyquinazolin-4-yl)amino)-6-fluorobenzyl)-
piperazine-1-carboxylate (99 mg, 0.17 mmol) was added to a round bottomed flask then 
hydrogen chloride solution in dioxane (4M, 1.4 mL) was added. This mixture was stirred 
for 15 min and then sonicated for a 15 min. This mixture was the evaporated under 
reduced pressure, the residues where then dissolved in methanol (4 mL) and the minimum 
amount of water was added to aid to dissolve the residues. This solutions was and then 
loaded onto a SCX column, the column was then washed with methanol (20 mL) and then 
acetonitrile (20 mL). The product was then eluted with ammonia in methanol (2 M) and 
this was then evaporated under reduced pressure to give title compound as a white solid.  
 
Yield:  80 mg (99%).  
HRMS-ESI (m/z) found 476.1087, calcd for [C25H31
79BrFN5O4H]
+ 476.1092. 
1H NMR (399 MHz, methanol-d4) δ 8.24 (s, 1H), 7.72 – 7.64 (m, 2H), 7.19 (s, 1H), 7.09 
(t, J = 9.0 Hz, 1H), 4.02 (s, 3H), 4.00 (s, 3H), 3.71 – 3.40 (m, 1H), 2.77 – 2.66 (m, 4H), 
2.46 – 2.37 (m, 4H). 
13C NMR (100 MHz, methanol-d4) δ 161.1 (d, J = 246.5 Hz), 157.5, 155.6, 152.0, 150.1, 
146.1, 139.8, 132.9 (d, J = 9.5 Hz), 124.6 (d, J = 16.0 Hz), 118.6, 115.0 (d, J = 25.0 Hz), 
109.3, 106.2, 101.6, 55.7, 55.3, 52.0, 51.8, 44.4. 
19F NMR (376 MHz, chloroform-d) δ -105.68. 
LCMS purity >99% (UV), Ret. time = 12.26 min. 
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N-(2-bromo-4-fluoro-5-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)-6,7-
dimethoxyquinazolin-4-amine, 119. 
 
 
N-(2-Bromo-4-fluoro-5-(piperazin-1-ylmethyl)phenyl)-6,7-dimethoxyquinazolin-4-
amin (29 mg, 0.06 mmol) was added to a round bottomed flask, then dichloromethane 
(dry, 0.5 mL) followed by N,N-diisopropylethylamine  was added (21 μL, 0.122 mmol). 
To this stirred mixture methanesulfonyl chloride (5 μL, 0.066 mmol) was added. After 1 
h of stirring at room temperature the reaction had gone to completion, dichloromethane 
(5 mL) was added followed by water (5 mL). This mixture was then added to a phase 
separator, the aqueous layer was washed with dichloromethane (2 x 5 mL). The combined 
organic washes were evaporated under reduced pressure. No further purification was 
required giving the title compound as a white solid. 
 
Yield:  21 mg (63%).  
HRMS-ESI (m/z) found 554.0864, calcd for [C22H26
79BrFN5O4SH]
+ 554.0867. 
1H NMR (500 MHz, chloroform-D) δ 9.92 (s, 1H), 8.71 (s, 1H), 8.54 (d, 3JFH = 11.0 Hz, 
1H), 7.36 (d, 4JFH = 7.5 Hz, 1H), 7.32 (s, 1H), 7.20 (s, 1H), 4.04 (s, 3H), 3.99 (s, 3H), 
3.74 (s, 2H), 3.45 – 3.34 (m, 4H), 2.82 (s, 3H), 2.77 – 2.66 (m, 4H). 
13C NMR (126 MHz, chloroform-D) δ 159.0 (d, 1JFC = 246.0 Hz), 156.0, 153.7, 149.8, 
148.4, 140.0, 134.2, 122.1, 109.8, 108.6, 104.0, 60.9, 58.4, 56.3, 52.3, 45.3, 35.4. Three 
carbons missing as the compound had low solubility in low boiling point NMR solvents.  
19F NMR (376 MHz, methanol-d4) δ -118.78 – -118.83 (m). 
LCMS purity 90 % (UV), Ret. time = 9.19 min. 
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N-(4-bromo-5-fluoro-2-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl)-6,7-
dimethoxyquinazolin-4-amine, 120. 
 
 
N-(4-Bromo-5-fluoro-2-(piperazin-1-ylmethyl)phenyl)-6,7-dimethoxyquinazolin-4-
amine (29 mg, 0.06 mmol) was added to a round bottomed flask, then dichloromethane 
(dry, 0.5 mL) followed by N,N-diisopropylethylamine  was added (21 μL, 0.122 mmol). 
To this stirred mixture methanesulfonyl chloride (5 μL, 0.066 mmol) was added. After 1 
hr of stirring at room temperature the reaction had gone to completion, dichloromethane 
(5 mL) was added followed by water (5 mL). This mixture was then added to a phase 
separator, the aqueous layer was extractedwith dichloromethane (2 x 5 mL). The 
combined organic were evaporated under reduced pressure. No further purification was 
required giving the title compound as a white solid. 
 
Yield:  33 mg (99%).  
HRMS-ESI (m/z) found 554.0868, calcd for [C22H26
79BrFN5O4SH]
+ 554.0867. 
1H NMR (500 MHz, chloroform-D) δ 8.64 (s, 1H), 8.54 (d, 4JFH = 7.0 Hz, 1H), 7.84 (s, 
1H), 7.38 (d, 4JFH = 8.5 Hz, 1H), 7.31 (s, 1H), 7.18 (s, 1H), 4.08 (s, 3H), 4.05 (s, 3H), 
3.68 (d, J = 1.5 Hz, 2H), 3.31 – 3.25 (m, 4H), 2.78 (s, 3H), 2.71 – 2.64 (m, 4H). 
13C NMR (126 MHz, chloroform-D) δ 156.9.8 (d, J = 256.5 Hz), 155.3, 152.6, 150.1, 
132.8, 125.7, 124.4, 119.5, 119.2, 114.2, 109.1, 107.3, 99.2, 88.3, 56.4, 56.3, 54.8, 52.1, 
45.8, 34.4. 
19F NMR (376 MHz, chloroform-D) δ -105.60 – -105.77 (m).  
LCMS purity 90% (UV), Ret. time = 10.93 min. 
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1-(4-(5-bromo-2-((6,7-dimethoxyquinazolin-4-yl)amino)-4-fluorobenzyl)piperazin-
1-yl)ethanone, 121. 
 
 
N-(4-Bromo-5-fluoro-2-(piperazin-1-ylmethyl)phenyl)-6,7-dimethoxyquinazolin-4-
amine (29 mg, 0.061mmol) was added to a round bottomed flask, then dichloromethane 
(dry, 0.5 mL) followed by N,N-diisopropylethylamine (21 μL, 0.122 mmol) were added. 
To this stirred mixture acetyl chloride  (5 μL, 0.067 mmol) was added, this reaction was 
monitored via TLC (10% methanol in dichloromethane). After 1 hr of stirring at room 
temperature the reaction had gone to completion, dichloromethane (5 mL) was added 
followed by water (5 mL). This mixture was then added to a phase separator, the aqueous 
layer was extracted with dichloromethane (2 x 5 mL). The combined organic extracts 
were evaporated under reduced pressure on to silica. This crude was then loaded on to a 
silica gel column which was ran with 100 % dichloromethane to give the title compound 
as a white solid. 
 
Yield:  31 mg (98%).  
TLC (MeOH: DCM 10%) Rf = 0.62. 
HRMS-ESI (m/z) found 518.1190, calcd for [C23H25
79BrFN5O3H]
+ 518.1198. 
1H NMR (500 MHz, chloroform-D) δ 9.88 (s, 1H), 8.68 (s, 1H), 8.47 (d, 3JFH = 11.5 Hz, 
1H), 7.32 (d, 3JFH = 7.5 Hz, 1H), 7.28 (s, 1H), 7.10 (s, 1H), 4.02 (s, 3H), 3.97 (s, 3H), 
3.78 – 3.70 (m, 2H), 3.68 (s, 2H), 3.58 – 3.52 (m, 2H), 2.62 – 2.51 (m, 4H), 2.09 (s, 3H). 
13C NMR (126 MHz, chloroform-D) δ 169.0, 159.0 (d, 1JFC = 245.5 Hz), 156.1, 155.9, 
153.7, 150.0, 148.5, 140.2 (d, 3JFC = 10.5 Hz), 134.3, 122.6 (d, 
3JFC = 3.5 Hz), 110.6 (d, 
2JFC = 28.0 Hz), 110.0, 108.6, 102.3, 101.4 (d, 
2JFC = 22.0 Hz), 61.4, 57.7, 56.4, 53.0, 
52.9, 46.10, 41.3, 21.3. 
19F NMR (376 MHz, methanol-d4) δ -117.81 – -118.02 (m). 
LCMS purity 96% (UV), Ret. time = 9.57 min. 
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6. Conclusions and future work. 
6.1. Conclusions  
Tetrasubstituted aromatics have been outlined in Chapter 1 to be key synthons in 
medicinal chemistry. AstraZeneca funded this CASE award into the synthesis of new 
tetrasubstituted aromatic scaffolds. They outlined a specific set of key objectives at the 
start this project: 
 Synthesised tetrasubstituted aromatics must contain 4 different orthogonal groups. 
 Synthesised tetrasubstituted aromatics must haver either a 1,2,3,4 or a 1,2,4,5-
substitution pattern. 
 Methods of preparation must be scalable.  
 
Chapter 2 highlights the development of a new rapid microwave-mediated synthesis 
leading to a library of MIDA boronates, prepared from their parent boronic acids. This 
work meets the project objectives, as methods are scalable as they can be performed on 
multigram scales using cheap starting materials. These reactions in most cases gave high 
yields, using low solvent volumes and high tolerance to an array of different functional 
groups. Moreover, this method meets many of the requirements of green chemistry since 
it employs low energy, rapid routes and environmentally friendly solvents. 
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Chapter 3 first discusses the synthesis of new tetrasubstituted building blocks. This was 
achieved via bromination or nitration of compounds described and synthesised in the 
previous chapter; some of these compounds are shown in Figure 6.1. Twelve 
tetrasubstituted aromatics were synthesised, 10 of which were novel. The bulk of these 
compounds use trisubstituted MIDA boronates which were formed in Chapter 2. We 
found that MIDA boronates could be nitrated utilising classical methods and in fact the 
MIDA functionality provided a good handle to aid solubilisation in sulphuric acid. This 
was also true in the case of bromination, and mixed classical chemistry with 
contemporary iterative palladium cross-coupling methodology. This gave the desired 
compounds that contained four different orthogonal functionalities as outlined in the 
objectives. These methods were also scalable, using cheap and simple reagents. 
 
Figure 6.1 Compounds synthesised by nitration or bromination with the 
new functional group highlighted in blue.  
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Chapter 4 highlights the brominated MIDA boronates, many of which are described in 
Figure 6.1 can be used in iterative Suzuki cross-coupling reactions. These iterative cross-
couplings validated that these compounds contain orthogonal groups, meeting the project 
brief and show how complex polyaromatic compounds with tetrasubstituted cores can be 
synthesised in a simple procedure. There are two different types of cross-couplings shown 
in Scheme 6.1 anhydrous and aqueous, this is to enable the iterative methodology. A total 
of 7 compounds were synthesised via the anhydrous and 4 by the aqueous cross-coupling 
methodology.  
 
Chapter 5 consists of the elaboration on the bromo-fluoro-nitro-benzaldehydes 
synthesised via nitration in Chapter 3. Multiple modifications on these three different 
bromo-fluoro-nitro-benzaldehyde scaffolds where achieved i.e. nitro reduction, 
trifluoromethylation, Sonogashira couplings, reductive aminations, Clauson-Kaas 
pyrrole synthesis and the reaction of polysubstituted amines with 4-chloro-6,7-
dimethoxyquinazoline. Scheme 6.2 shows how the 4-chloro-6,7-dimethoxyquinazoline  
was used to afford novel compounds that have potential as kinase inhibitors. 
Scheme 6.1 Some examples of cross-couplings discussed in Chapter 4. 
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Nine of these potential kinase inhibitors were submitted to AstraZeneca for EGFR wild 
type cell assay. The best compound had an impressive IC50 of 18 nM, but unfortunately 
gave a large hERG inhibition. The assays were performed after all of the chemical 
synthesis had ceased. No further development to improve on these first compounds could 
be done. 
A vast amount of orthogonal chemistry modifications has been achieved in chapters 4 
and 5 on tetrasubstituted aryls synthesized in chapter 3. All of this work was maintaining 
attention towards the original brief and this was key to this work. This demonstrates how 
these complex tetrasubstituted building blocks can be manipulated to forming novel 
interesting compounds.  
 
 
 
 
 
 
Scheme 6.2. Potential kinase inhibitors synthesised from bromo-fluoro-nitro-
benzaldehydes. 
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6.2. Future work 
A number of studies merit further investigation these including, 
 Improvement the methodology of the MIDA boronate deprotection aqueous Suzuki 
cross-couplings step in Chapter 4, to improve the yields.  
 Link the quinazoline unit to different scaffold synthesised via reductive amination 
and Sonogashira reactions, in Chapter 5. This will be done with the series of 
compounds synthesised from compound 62 (Scheme 6.3) as they gave the most 
active compounds in the assays. The morpholine compound would hopefully lower 
the hERG inhibition  
 
 Commence a study developing the lead compounds from the AstraZeneca EGFR wild 
type cell assay, aiming to reduce their hERG inhibition.  
 Look at alternative “ATP” like scaffolds other than quinazoline to address Lipinski 
and other drug like limitations of the prototypical EGFR inhibitors synthesized.    
 
Scheme 6.3. Scaffolds 62, 95. 100 and 106 are key compounds for investigation after 
addition of the quinazoline. 
